Bacterial compositions for treatment of bipolar disorder or symptoms thereof

Abstract

There is provided bacterial compositions for treatment of bipolar disorder or symptoms thereof and methods of treating bipolar disorders or symptoms there of using the same. The compositions comprise a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides.

Description

BACTERIAL COMPOSITIONS FOR TREATMENT OF BIPOLAR DISORDER OR SYMPTOMS THEREOF This application claims the benefit of priority from U.S. Provisional Application No. 63 / 613,222 filed December 21, 2023. The disclosures of all of the above applications are incorporated by reference herein in their entireties.SEQUENCE LISTINGThe instant application contains a sequence listing which has been submitted electronically in xml format and is hereby incorporated by reference in its entirety. Said xml copy, created on December 18, 2024, is named 4421-104PCT sequence listing and is 204 kilobytes in size.  Field of the InventionThe present invention pertains to the field of psychiatric disorders and more particularly, bacterial compositions for treatment of bipolar disorder or symptoms thereof. Background OF THE INVENTIONBipolar disorder (BD) is characterized by recurring episodes of mania and depression. The depressive phase of BD can be refractory to traditional treatment highlighting a need for alternative therapeutic options. Studies have implicated dysregulation of the gut microbiome in neuropsychiatric disorders. Specific alterations in gut microbiome composition have been identified in individuals with BD and correlate with disease severity. Recent studies suggest fecal microbiota transplantation (FMT) is a feasible biotherapeutic option for the treatment of the depressive bipolar state. Variation in fecal microbiome populations in donor samples and microbial engraftment within recipients may result in clinical outcome variability. There exists a need for a method of improving gut microbiome in subjects with BD depression without the variability of traditional FMT. This background information is provided for the purpose of making known information believed by the applicant to be of possible relevance to the present invention. No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention. Summary of the invention An object of the present invention is to provide bacterial composition for treatment of bipolar disorder (BD) or symptoms thereof.  In accordance with an aspect of the invention, there is provided a method of treating bipolar disorder (BD) or a symptom associated with BD in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides. In some embodiments, the methods of the invention treats the depressive phase of BD.  In accordance with an aspect of the invention, there is provided a method of treating bipolar disorder (BD) or a symptom associated with BD in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria that comprises or consists of Agathobacterrectalis, Alistipes communis,Alistipesputredinis, Anaerotignumfaecicola,Bacteroides caccae, Bacteroides salyersiea, Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa(previously Clostridium fessum), Bariatricus comes(previously Coprococcus comes),Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Faecalibacteriumprausnitzii, Odoribactersplanchnicus,Parabaceroidesmerdae, Parabacteroides distasonis, and Sutterellamerdavium (S. parvirubra). . In some embodiments, the methods of the invention treats the depressive phase of BD In accordance with an aspect of the invention, there is provided a method of treating bipolar disorder (BD) or a symptom associated with BD in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria that comprises or consists of Agathobacterrectalis, Anaerotignumfaecicola,Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa(previously Clostridium fessum), Bariatricus comes(previously Coprococcus comes),Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus, Odoribactersplanchnicus,Parabaceroidesmerdae, and Parabacteroides distasonis. In some embodiments, the methods of the invention treats the depressive phase of BD In accordance with an aspect of the invention, there is provided a method of treating bipolar disorder (BD) or a symptom associated with BD in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria that comprises or consists of Agathobacterrectalis, Alistipes communis,Anaerotignumfaecicola, Bacteroides salyersiea,Bifidobacterium bifidum,Butyricimonasparavirosa, Clostridium fessum, Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis. In some embodiments, the methods of the invention treats the depressive phase of BD. In accordance with an aspect of the invention, there is provided a method of treating bipolar disorder (BD) or a symptom associated with BD in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria that comprises or consists of Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides salyersiea, Bifidobacterium bifidum,Butyricimonasparavirosa,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis. In some embodiments, the methods of the invention treat the depressive phase of BD. In accordance with an aspect of the invention, there is provided a method of treating bipolar disorder (BD) or a symptom associated with BD in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides. In some embodiments, the methods of the invention treat the depressive phase of BD. In accordance with an aspect of the invention, there is provided a method of treating bipolar disorder (BD) or a symptom associated with BD in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria, wherein the composition comprises or consists of Agathobacterrectalis, Alistipes communis, Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiae, Bariatricus comes, Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum, Butyricimonasparavirosa, Butyricimonasvirosa, Dysosmobacterwelbionis, Eubacterium_Iramulus, Faecalibacteriumprausnitzii, Odoribactersplanchnicus, Otooleafessa, Parabacteroides distasonis, and Parabacteroides merdae. In some embodiments, the methods of the invention treat the depressive phase of BD. In accordance with an aspect of the invention, there is provided a composition for treating bipolar disorder (BD) or a symptom associated with BD in a subject, the composition comprising a community of fecal bacteria that comprises or consists of Agathobacterrectalis, Alistipes communis,Alistipesputredinis, Anaerotignumfaecicola,Bacteroides caccae, Bacteroides salyersiea, Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa(previously Clostridium fessum), Bariatricus comes(previouslyCoprococcus comes),Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Faecalibacteriumprausnitzii, Odoribactersplanchnicus,Parabaceroidesmerdae, Parabacteroides distasonis, and Sutterellamerdavium (S. parvirubra).  In accordance with an aspect of the invention, there is provided a composition for treating bipolar disorder (BD) or a symptom associated with BD in a subject, the composition comprises or consists of Agathobacterrectalis, Alistipes communis, Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiae, Bariatricus comes, Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum, Butyricimonasparavirosa, Butyricimonasvirosa, Dysosmobacterwelbionis, Eubacterium_Iramulus, Faecalibacteriumprausnitzii, Odoribactersplanchnicus, Otooleafessa, Parabacteroides distasonis, and Parabacteroides merdae. In accordance with an aspect of the invention, there is provided a composition for treating bipolar disorder (BD) or a symptom associated with BD in a subject, the composition comprising a community of fecal bacteria that comprises or consists of Agathobacterrectalis, Anaerotignumfaecicola,Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa(previously Clostridium fessum), Bariatricus comes(previouslyCoprococcus comes),Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus, Odoribactersplanchnicus,Parabaceroidesmerdae, and Parabacteroides distasonis. In accordance with an aspect of the invention, there is provided a method of treating the depressive phase of bipolar disorder in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria, wherein the community of fecal bacteria comprises bacteria from the genusAgathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides. In accordance with an aspect of the invention, there is provided a composition for treating bipolar disorder (BD) or a symptom associated with BD in a subject, the composition comprising a community of fecal bacteria that comprises or consists of Agathobacterrectalis, Alistipes communis,Anaerotignumfaecicola, Bacteroides salyersiea,Bifidobacterium bifidum,Butyricimonasparavirosa,Otooleafessa(previously Clostridium fessum), Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis.In some embodiments, the methods of the invention treat the depressive phase of BD. In accordance with an aspect of the invention, there is provided a composition for treating bipolar disorder (BD) or a symptom associated with BD in a subject, the composition comprising a community of fecal bacteria that comprises or consists of Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides salyersiea, Bifidobacterium bifidum,Butyricimonasparavirosa,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis.In some embodiments, the methods of the invention treat the depressive phase of BD. In accordance with some embodiments of the methods and compositions provided herein specific strains of fecal bacteria of the species disclosed herein which are isolated from healthy individuals are used to displace the predominant strain of that species in a subject with BD. Brief description of the figures These and other features of the invention will become more apparent in the following detailed description in which reference is made to the appended drawings. FIG. 1 illustrates the participant flow diagram. FIG. 2 illustrates the baseline distribution of Montgomery–Åsberg Depression Rating Scale (MADRS) scores. FIG. 3 illustrates the impact of fecal microbiota transplant (FMT) on MADRS scores Visit 1 through Visit 15. FIG. 4 illustrates quadratic, polynomial model analysis run with time since intervention and time squared as continuous predictors of MADRS. FIG. 5 illustrates Sheehan disability scale results. FIG. 6illustrates State-Trait Anxiety Inventory results. FIG. 7 illustrates short-read analysis pipeline FIG. 8 illustrates assembly based metagenomic analysis. FIG. 9details the limitation of Metaphlan and metagenomic assembled genomes (MAGS) for looking for strain specific engraftment. DETAILED DESCRIPTION OF THE INVENTIONDefinitionsUnless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. As used herein, the term “fecal microbiota” or “fecal microbiota preparation” refers to a community of microbes present in or prepared from a subject's feces. As used herein, the term “fecal bacteria” refers to bacteria commonly found in human or animal feces. As used herein, “therapeutically effective amount” refers to an amount of a composition which is effective in treating the named disease, disorder or condition. As used herein, the terms “non-pathogenic” in reference to a bacterium or any other organism or entity includes any such organism or entity that is not capable of causing a disease, disorder or condition of a host organism containing the organism or entity. As used herein, “colony forming units” (cfu) refers to an estimate of the number of viable microorganism cells in a given sample. The number of cfu can be assessed by counting the number of colonies on an agar plate as in standard methods for determining the number of viable bacterial cells in a sample. As used herein, “viable” means possessing the ability to multiply.  As used herein, “bipolar disorder” or “BD” includes both type I and type II bipolar disorder according to the Mini International Neuropsychiatric Interview (MINI) and characterized in part by recurring episodes of mania or hypomania and depression.  As used herein, “MADRS” refers to “Montgomery–Åsberg Depression Rating Scale”.  As used herein, “YNRS” refers to “Young Mania Rating Scale”. As used herein, “FMT” refers to “fecal microbiota transplant”. As used herein, “STAI” refers to “State-Trait Anxiety Index”. As used herein, “WHOQOL” and “WHOQOL-Bref” refer to World Health Organization Quality of Life and World Health Organization Quality of Life Brief, respectively. As used herein, “SDS” refers to “Sheehan Disability Scale”. As used herein, “TSES” refers to “Toronto Side Effects Scale”. As used herein, “CGI” refers to “Clinical Global Impressions” rating scale.  The compositions and methods provided herein are aimed at achieving a detectable improvement in bipolar disorder (BD) including Type I (BD-I) or Type II (BD-II) or symptoms thereof including without limitation symptoms of mania or hypomania or symptoms of depression or other symptoms including without limitation anxious distress, melancholy, psychosis.  Methods are known in the art for assessing bipolar disorder (BD) symptoms and their impact on a person’s quality of life including the Montgomery–Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale, State-Trait Anxiety Index, World Health Organization Quality of Life and Sheehan Disability Scale. The Montgomery–Åsberg Depression Rating Scale (MADRS) is a diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders including bipolar disorder (BD). The MADRS questionnaire includes questions on apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts with each yielding a score. Higher MADRS score indicate more severe depression. Accordingly, in some embodiments, use of the compositions and methods of the invention result in a reduction in MADRS score. In some embodiments, the reduction in MADRS is sufficient to decrease the severity of depression from severe to moderate, and moderate to mild. The Young Mania Rating Scale (YMRS) is a multiple-choice diagnostic questionnaire used to measure the presence and severity of mania and associated symptoms. Higher scores indicate higher severity. Accordingly, in some embodiments, use of the compositions and the methods of the invention result in a reduction in YMRS score. In some embodiments, there is no symptoms of mania following use of the methods of the invention. The State-Trait Anxiety Index measures two types of anxiety – state anxiety and trait anxiety with higher scores positively correlating with higher levels of anxiety. Accordingly, in some embodiments, use of the compositions and the methods of the invention result in a reduction in STAI score. The World Health Organization Quality of Life is a self report measure useful for measuring outcomes with adults with a psychosocial disability with higher scores indicative of a better quality of life. Accordingly, in some embodiments, use of the compositions and the methods of the invention result in an increase WHOQOL or WHOQOL-Bref score. The Sheehan Disability Scale provides a measure of disability and functional impairment that is a composite of three self-rated items designed to measure the extent to which three major domains in the patient’s life are functionally impaired by psychiatric or medical symptoms. Higher scores indicative of a higher level of impairment. Accordingly, in some embodiments, use of the compositions and the methods of the invention result in a decrease of the SDS score. In one aspect, use of the composition or methods achieves at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in BD severity after 2 or more weeks of treatment as compared to before initiating the treatment, where the BD severity is assessed by a method described above.  In one aspect, treatment achieves at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in in BD severity after 4 or more weeks of treatment as compared to before initiating the treatment, where the BD severity is assessed by a method described above.  In one aspect, treatment achieves at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in in BD severity after 6 or more weeks of treatment as compared to before initiating the treatment, where the BD severity is assessed by a method described above.  In one aspect, treatment achieves at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in in BD severity after 8 or more weeks of treatment as compared to before initiating the treatment, where the BD severity is assessed by a method described above.  In one aspect, treatment achieves at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in in BD severity after 10 or more weeks of treatment as compared to before initiating the treatment, where the BD severity is assessed by a method described above.  In one aspect, treatment achieves at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in in BD severity after 15 or more weeks of treatment as compared to before initiating the treatment, where the BD severity is assessed by a method described above.  In one aspect, treatment achieves at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in in BD severity after 20 or more weeks of treatment as compared to before initiating the treatment, where the BD severity is assessed by a method described above.  Compositions: There are provided compositions comprising a community of isolated non-pathogenic fecal bacteria. In some embodiments, the community of isolated fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides. Optionally, the community of isolated fecal bacteria include Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides salyersiea, Bifidobacterium bifidum,Butyricimonasparavirosa,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis. In some embodiments, the community of isolated fecal bacteria further comprises Alistipes communis. In still further embodiments, the community of fecal bacteria further comprisesOtooleafessa (previously Clostridium fessum). In some embodiments, the community of fecal bacteria further comprises one or more of Bacteroides caccae, Bifidobacterium pseudocatenulatum,Butyricimonasvirosa,Bariatricus comes(previously Coprococcus comes),and Parabaceroidesmerdae. In other embodiments, the community of fecal bacteria comprise Agathobacterrectalis, Alistipes communis,Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa, Otooleafessa(previously Clostridium fessum), Bariatricus comes(previously Coprococcus comes),Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Faecalibacteriumprausnitzii, Odoribactersplanchnicus,Parabaceroidesmerdae, Parabacteroides distasonis, and Sutterellamerdavium (S. parvirubra).  In other embodiments, the community of fecal bacteria consist of Agathobacterrectalis, Alistipes communis,Alistipesputredinis, Anaerotignumfaecicola,Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa(previously Clostridium fessum), Bariatricus comes(previously Coprococcus comes),Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Faecalibacteriumprausnitzii, Odoribactersplanchnicus,Parabaceroidesmerdae, Parabacteroides distasonis, and Sutterellamerdavium (S. parvirubra).  In still other embodiments, the community of fecal bacteria consist of Agathobacterrectalis, Anaerotignumfaecicola,Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa(previously Clostridium fessum), Bariatricus comes(previously Coprococcus comes),Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus, Odoribactersplanchnicus,Parabaceroidesmerdae, and Parabacteroides distasonis. In still other embodiments, the community of fecal bacteria consist of Agathobacterrectalis, Alistipes communis,Anaerotignumfaecicola, Bacteroides salyersiea,Bifidobacterium bifidum,Butyricimonasparavirosa,Otooleafessa(previously Clostridium fessum), Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis. In still other embodiments, the community of fecal bacteria consist of Agathobacterrectalis, Alistipes communis, Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiae, Bariatricus comes, Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum, Butyricimonasparavirosa, Butyricimonasvirosa, Dysosmobacterwelbionis, Eubacterium_Iramulus, Faecalibacteriumprausnitzii, Odoribactersplanchnicus, Otooleafessa, Parabacteroides distasonis, and Parabacteroides merdae. In still other embodiments, the community of fecal bacteria consist of Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides salyersiea, Bifidobacterium bifidum,Butyricimonasparavirosa,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis. In still other embodiments, one or more probiotic lactic acid bacteria are added to the community of fecal bacteria. Optionally, one or more strains of each bacterial species are present in the community of fecal bacteria. In other embodiments, a single strain of each bacteria is present in the community of fecal bacteria. In accordance with some embodiments, the specific strains of each bacterial species disclosed herein are strains isolated from healthy individuals. In some embodiments, individual members of the community of fecal bacteria are growth separately and the same number of CFU for each species is provided. In other embodiments, the CFU for each species is based on the ratio found in a healthy gut. In some embodiments, the effective dose of community of fecal bacteria comprises at least about 105,106,107,108,109, 1010, 1011, 1012, or 1013 cfu . Optionally, each bacteria in the community of fecal bacteria is provided at a maximum doses of about 105,106,107,108,109, 1010, 1011, 1012, or 1013 cfu.  The effective dose of each fecal bacteria present in the community of fecal bacteria may be the same or different.  The individual bacteria or the community of bacteria may be provided as dried, powdered or lyophilized form. The compositions may include other components such as inert diluents; carriers, adjuvants, wetting agents, emulsifying and suspending agents; and sweetening, flavoring, and perfuming agents and optionally with an appropriate carrier or stabilizer.  The compositions may be provided as a solid form, optionally oral form. Solid forms include tablets, capsules, pills, troches or lozenges, cachets, pellets, powders, or granules or incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. The compositions may be provided in liquid form including emulsions, solutions, suspensions, and syrups. In some embodiments, the compositions are formulated for oral delivery. In such embodiments, the compositions may be encapsulated as enteric-coated and / or acid-resistant capsules. These capsules may take the form of enteric-coated and / or acid-resistant microcapsules. Alternatively, the composition for oral delivery may further comprise further an acid suppressant, an antacid, an H2 antagonist, a proton pump inhibitor or a combination thereof. In some embodiments, the composition is formulated as a food item or food supplement. In other embodiments, the composition is formulated for delivery by enema, or via rectal suppository. In other embodiments, the composition is formulated for delivery by upper endoscopy, nasogastric / nasoduodenal tube or colonoscopy. In some embodiments, the composition further comprises bacterial metabolites and / or bacterial derived products. In some embodiments, the composition further comprises a prebiotic such as a fiber supplement. METHODS There are provided methods of treating bipolar disorder (BD) or a symptom associated with BD in a subject. The methods comprise administering to the subject one or more doses of compositions of the invention. Optionally, two or more doses of compositions of the invention are administered.  In one aspect, the method further comprises subjecting a subject to a bowel cleanse prior to administration of the first dose of the composition. Appropriate bowel cleanses are known in the art and include polyethylene glycol laxative solution. In one aspect, the method further comprises administering an antibiotic to a subject prior to administering the composition. Optionally, after administration of the antibiotic the method further comprises a bowel cleanse. Appropriate antibiotics are known in the art. The composition can be administered by various routes. Routes of administration include but are not limited to upper gastrointestinal tract administration, optionally orally, by enteroscopy, nasogastric tube, nasoduodenal tube or upper endoscopy and lower gastrointestinal tract administration, optionally by colonoscopy, by enema, or via rectal suppository.  In some embodiments where the composition is administered orally, the method further comprises administration of an acid suppressant, an antacid, an H2 antagonist, a proton pump inhibitor or a combination thereof. In some embodiments, a first dose of a composition of the invention is administered by a first route of administration and a second dose of the composition is administered contemporaneously via a second route of administration. In some embodiments, the mixed route dosing combines upper gastrointestinal tract administration, optionally orally, by capsules, enteroscopy, nasogastric tube, nasoduodenal tube or upper endoscopy and lower gastrointestinal tract administration, optionally by colonoscopy, by enema, or via rectal suppository. In one aspect, the present disclosure provides a method for treating BD in a subject in need thereof, where the method comprises administering to the subject a single dose of the composition described herein. In one aspect, the present disclosure provides a method for treating BD in a subject in need thereof, where the method comprises administering daily to the subject a dose of the composition described herein. In one aspect, the composition is administered to a subject in need thereof at least once daily for at least two consecutive days. In one aspect, the composition is administered at least once daily for at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive days. In another aspect, the composition is administered at least once daily for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive weeks. In one aspect, the composition is administered at least once daily for at most 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive days or weeks. In another aspect, the composition is administered at least once daily for at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive weeks or months. In a further aspect, the composition is administered at least once for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive months or years, chronically for a subject's entire life span, or an indefinite period of time. In one aspect, the composition is administered to a subject in need thereof at least twice daily for at least two consecutive days. In one aspect, the composition is administered at least twice daily for at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive days. In another aspect, the composition is administered at least twice daily for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive weeks. In one aspect, the composition is administered at least twice daily for at most 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive days or week. In another aspect, the composition is administered at least twice daily for at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive weeks or months. In a further aspect, the composition is administered at least twice for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive months or years, chronically for a subject's entire life span, or an indefinite period of time. In another aspect, the composition is administered at least once weekly for at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive weeks or months. In a further aspect, the composition is administered at least once weekly for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive months or years, chronically for a subject's entire life span, or an indefinite period of time. In another aspect, the composition is administered at least once monthly for at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive months. In a further aspect, the composition is administered at least once monthly for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive months or years, chronically for a subject's entire life span, or an indefinite period of time. In another aspect, the composition is administered at least once every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, chronically for a subject's entire life span, or an indefinite period of time. In some embodiments, the methods of the invention are used in combination with other treatments for BD including first-line treatments. To gain a better understanding of the invention described herein, the following examples are set forth. It will be understood that these examples are intended to describe illustrative embodiments of the invention and are not intended to limit the scope of the invention in any way.EXAMPLES EXAMPLE 1:Fecal Microbiota Transplantation in A Population With Bipolar Disorder (BD) During Depressive Episodes METHODS Study design and participants This study was a phase 2 / 3, double-blind, randomized controlled trial (RCT). Patients with bipolar disorder (BD) on stable, first-line treatment were randomized to receive either (1) allogenic fecal microbiota transplantation (FMT) from a healthy donor or (2) autologous FMT with their own feces. FMT was manufactured into an enema and administered via colonoscopy by a trained gastroenterologist after bowel cleansing. Participants were then followed for 24 weeks for assessment of primary and secondary study outcomes.  Adults 18 - 65 years of age, who had a Mini-International Neuropsychiatric Interview (MINI)1 confirmed diagnosis of BD (type I or II) on a stable first-line treatment for BD depression as defined in the Canadian Network for Mood an Anxiety Treatment (CANMAT) 2018 guidelines2 at an adequate dose for ≥ 8 weeks prior to study entry, who were currently experiencing a depressive episode were recruited. A participant met inclusion criteria if their current episode was characterized by a Montgomery–Asberg Depression Rating Scale (MADRS)3 score at screening and baseline of ≥ 12. Exclusion criteria included a Young Mania Rating Scale (YMRS)4 score of ≥ 12 at screening; DSM-IV criteria5 for substance abuse within the last 6 months or lifetime dependency; active suicidal ideation, an active eating disorder; schizophrenia or schizoaffective disorder; chronic gastrointestinal diseases; conditions causing immunosuppression; a significant bleeding disorder; a history of incomplete colonoscopy; pregnancy, regular used of non-steroidal anti-inflammatory drugs, antibiotics, or iron supplements within 3 months prior to study entry; prebiotics or probiotics for medical purposes or antibiotics use within 3 months prior to study entry. The healthy donors who provided the allogenic FMT were recruited as part of the Microbial Therapeutics Outcome Program (MTOP) at the University of Toronto.6 Potential donors were excluded if they had a psychiatric disorder according to the MINI1 or a family history in first-degree relatives of psychiatric illness, a personal or family history of autoimmune disease, smoked (cigarette, marijuana, other); use recreational drugs; regularly consumed 2 or more alcoholic beverages daily; and regularly used iron supplements in the 3 months prior to donation; had a history or symptoms suggestive of underlying gastrointestinal disease; infection or colonization with transmissible agents; active malignancy, or any cancer within the last 5 years, excluding basal cell carcinoma of the skin; had risk factors for prion-related disease, including family history of Creutzfeld-Jacob Disease, corneal or dural transplant, or receipt of human-derived pituitary growth factor; a history or high-risk status for recent acquisition of HIV, Hepatitis B, or Hepatitis C or sexually transmitted illnesses; immunosuppression; history or physical findings of chronic liver disease or cholestasis; evidence of active encephalitis or meningitis; evidence of active systemic viral, bacterial or fungal infection; receipt of live vaccine in preceding 30 days; receipt of blood transfusion from a country other than Canada in preceding 6 months; history of dementia or degenerative neurological disorders of unknown etiology; recent bite from an animal that may have rabies within the past 6 months; antibiotic use in the 6 months preceding donation; probiotic use for medicinal purposes in the 3 months prior to donation; use of cholestyramine within 3 months of donation; known and current history of blood in stools; and travel outside Canada or the USA in the past 6 months.  Randomisation and masking Participants were randomly allocated (1:1) to groups receiving either the allogenic FMT or autologous FMT. Randomization occurred according to a blocked randomization list (4 patients per block), generated in SAS proc PLAN by an individual not involved in conducting or analyzing the study. Both the participant and study team, except for the lab technologist, were blinded to group interventions. The allocation list was maintained in sequentially numbered envelopes with the group assignments. The lab technologist maintained allocation concealment and prepared fecal filtrates for each participant but was not involved in any other aspect of the study. The team member performing the FMT received the designated fecal filtrate labeled only with the participants’ numbers.  Procedures The active phase of the study involved administration of 1 dose of either autologous or allogenic FMT product delivered via colonoscopy. Prior to colonoscopy, three falcon tubes of frozen fecal filtrate, corresponding to a total of 150 g of feces was thawed, diluted to a total volume of 300 mL with 0.9 N NaCl and packaged into 6 × 50 mL syringes for colonoscopy. The evening prior to colonoscopy, participants took 4L of polyethylene glycol laxative solution. Colonoscopy was be performed by an experienced gastroenterologist with fecal filtrate in one syringe deposited in the terminal ileum and five in the cecum.  A MADRS score, a 10-item questionnaire use to measure the severity of depressive episodes in patients with mood disorders, was determined by trained research staff at baseline, and every two weeks after dosing for a total of 24 weeks of follow-up. Secondary outcome measures were also measured at the same time points, as was concomitant medications use and anthropometric measurements (waist-to-hip ratio, and body mass index (BMI)). The secondary outcome measures included the YMRS4, an 11 items clinician-administered interview scale used to assess manic symptoms; the State Trait Anxiety Index (STAI)7 , a commonly used measure of anxiety used to diagnose anxiety and to distinguish it from depressive syndromes; the Clinical Global Impressions (CGI) rating scales8, commonly used to measure symptom severity and treatment response in studies of patients with mental disorders; and the Sheehan Disability Scale (SDS)9, a brief self-report tool developed to assess functional impairment in work / school, social life, and home life or family responsibilities domains. The World Health Organization Brief Quality of Life Scale (WHOQOL-BREF)10 , a quality of life assessment designed to be applicable cross-culturally, was also administered.  Food intake was recorded for 3 days (2 weekdays and 1 weekend day), and the completed forms collected during visit 2 (base- line), visit 9 (12 weeks), and visit 15 (24 weeks). To minimize confounding effects, participants were asked to maintain their usual diet and exercise level. Participants also itemize their food intake using a validated form developed by the Fred Hutchinson Cancer Research Center11. A symptom diary to record adverse events was also provided and reviewed at every subsequent study visit. In addition, the Toronto Side Effects Scale (TSES)12, a 32-item instrument designed to establish incidence, frequency, and severity of CNS, gastrointestinal, and sexual side effects was administered.  Recipients also receive instructions and two kits for collecting two stool samples at home which were collected at 3 and 6 months to assess fecal microbiome composition pre- and post-FMT. Outcomes The primary outcome was reduction in MADRS score from baseline to the end of follow-up. If participants received the allogenic and follow-up data was available , they were assessed for the primary endpoint. In the same population of participants we also assessed response, defined as > 50% reduction in MADRS scores from baseline and remission, defined as a MADRS score of < 9. We also assessed changes in YMRS, STAI, CGI, WHOQOL, and SDS. Side-effects were monitored by the TSES. Dietary data was analyzed using NUTRITIONIST PRO diet analysis software (Axxya Systems) to assess intake of macro-and micronutrients.  Microbiome Analysis Microbiome analysis was carried out by shotgun metagenomics using established protocols23, 24). Replicates, reagent blanks, and positive control samples (standardize stool aliquots) will be included in each set of DNA extractions and subsequent enrichment and sequencing reactions. Metagenomic sequencing libraries were constructed using NEBNext Ultra DNA Library kits with modifications to reduce reaction volume and reagent costs as described23. Library QC, normalization and Illumina NovaSeq (2x150 paired end reads) was carried out the at the Farncombe Genomic Facility. The samples had an average depth of ~40x106 reads per sample. This raw data then underwent a two-step quality enhancement process. Firstly, Low-quality reads and sequencing primers removed using fastp25. Following this, we employed BWA to decontaminate the data by mapping and removing any human DNA sequences present. These combined steps resulted in an average depth of ~38.7 x106 reads per sample, marking a reduction of approximately 4.2% from the initial raw data. The processed metagenomic reads were analysed using humann326, 27 and metaphlan427 to identify genes / pathways / species enriched in responders of the treatment group. Donor metagenomic data was assembled into contigs using the metaSPADEs28 and binned into metagenomic assembled genomes (MAGs) using metaBat229. All assembled contigs independent of binning were annotated using bakta30.  The microbiome analysis emphasized donor MAGs and genes that were engrafted in responders in the treatment group (i.e. absent at baseline but present at 15 weeks) as the primary criteria for selection. Secondar considerations was given to species or strains enriched in responders.  Statistical Analysis No formal sample size calculation was been carried out18 a review by Hertzog suggests a range of 20 to 40 participants to allow for sufficient variability in acceptability assessment of an intervention19. We therefore aimed for an enrollment of 45 participants.  For the initial primary analysis, a mixed design, two-way repeated measures ANOVA was used to compare the MADRS scores of the allogenic and autologous groups and measure change from baseline through visit 15. Given the smaller sample size and lower power calculation, the hypothesis testing of the ANOVA was followed by a quadratic polynomial regression to identify a pattern over time in order to assess the feasibility of a future trial. Time since intervention and time squared were both used a predictors of MADRS scores.  The secondary outcomes included the WHOQOL, STAI and SDS. All were assessed for changed over time and with a comparison between allogenic and autologous groups. For tolerability comparison, the prevalence and proportion of participants reporting side-effects and adverse events were calculated and compared with Wilcoxon rank-sum test, Pearson’s chi-square test, and Fisher’s exact test. The trial is registered with ClinicalTrials.gov, number NCT03279224. Results 75 participants with BD were screened for enrollment, of whom 31 (41.3%) were ineligible or declined to participate prior to randomization or intervention allocation. An additional 9 participants withdrew or were deemed ineligible prior to randomization. 35 participants were randomly assigned to receive the study interventions, (17 [49%] allogenic FMT and 18 [51%] autologous FMT). In the allogenic group, one participant withdrew prior to treatment allocation and one withdrew after receiving FMT but prior to providing a follow-up visit. Of those receiving the intervention and a minimum one follow-up visit (n=15), one participant was excluded at visit 7 (week 8) (secondary to antibiotic use), one was lost to follow-up after visit 4 (week two) and another after visit 11 (week 16) while another was unblinded due to a medical reason unrelated to the study at visit 14 (week 22). In the autologous group, one participant withdrew prior to treatment allocation. Of those receiving the intervention and a minimum one follow-up visit (n=17), another withdrew after visit 5 (week 4) secondary to personal reasons. 27 participants completed the entire follow-up period. All participants whom received the intervention and had at minimum one data point ( n=32) were included in the final analysis, using LOCF. (FIG. 1) The baseline distribution of MADRS scores was approximately bell shaped and allowed parametric statistics based on the central limit theorem (FIG. 2).  Baseline statistics further confirmed that randomization successfully produced balance groups.  Table 1Baseline Statistics Overall sample,mean (95% CI)Group 1,mean (95% CI)Group 2,mean (95% CI)MADRS22.2 (20.7 – 23.7)21.6 (19.0 – 24.1)22.6 (20.9 – 24.4)YMRS1.2 (0.42 – 1.95)1.33 (0 – 2.8)1.1 (0.3 – 1.8)STAI (state)50.75 (47.2 – 54.3)48.8 (43.4 – 54.2)52.5 (47.8 – 57.1)STAI (trait)57.7 (53.4 – 61.9)56.3 (47.7 – 64.8)58.9 (56.2 – 61.6)Sheehan (social)5.2 (4.0 – 6.3)6.3 (4.7 – 7.8)4.2 (2.6 – 5.7)Sheehan (family)4.8 (3.9 – 5.8)5.1 (3.4 – 6.8)4.6 (3.6 – 5.6)Sheehan (days lost)1.4 (0.63 – 2.1)1.7 (0.5 – 2.9)1.1 (0.2 – 2.1)Sheehan (days unproductive)3.5 (2.7 – 4.3)3.5 (2.3 – 4.7)3.5 (2.3 – 4.6) Analysis was conducted using IBM SPSS Statistics, version 28.0.1.1. The initial statistical analysis was performed using a mixed design, two-way repeated measures ANOVA. The test compared the mean MADRS scores of the allogenic and autologous groups, including slopes of change (interaction of treatment by time in the repeated-measures design). The statistical analysis compared fixed effects change in MADRS scores between groups, and also from Visit 1 through Visit 15 for both groups. An independent-samples t-test found no significant difference at Visit 2 (baseline) for the allogenic (M = 21.6, SD = 4.87) compared to the autologous group (M = 22.65, SD = 3.46), t(30) = -.71, p = .49, d = -.251, 95% CI [-4.07, 1.98]. A second independent samples t-test found no significant difference at Visit 15 (end of study) for the allogenic (M = 6.2, SD = 7.2) compared to the autologous group (M = 8.5, SD = 6.7), t(30) = -.946, p = .35, d = -.335, 95% CI [-7.4, 2.7]. Despite a lack of difference at each time, MADRS means decreased from baseline to end of study for both the allogenic (-15.4 points, 95% CI = 11.8, 19.0) and autologous (-14.1 points, 95% CI = 10.1, 18.1) groups. A mixed design two-way repeated measures ANOVA indicted a difference over time for both the treatment and autologous groups F(1, 30) = 104.5, p < .001, , but no interaction (slope of change) for treatment-by-time F(1, 30) = .994, p = .327, . Both groups’ scores decreased from Visit 2 to 15, indicating that the allogenic was effective, with a statistically large effect size. The main effect of group was not statistically significant F(1, 30) = .57, p = .46,  The mean for the allogenic group drops below the autologous group at Visit 7 and remains lower for all final visits. Table 2 presents group means and differences from Visit 7 through Visit 15. At Visit 7, the allogenic group (M = 11.2, SD = 7.51) is 1.86 points lower than the autologous group (M = 13.06, SD = 13.06), 95% CI [-7.76, 4.05]. The largest consistent differences in means, with the allogenic group’s scores being lower, occurred in the final four visits (Visit 12-Visit 15). Table 2   Means and Differences for Visits 7-15(N = 33)   VisitGroup 1Group 2Difference in Means95% Lower Limit95% Upper Limitp-valueMmTSDMSD711.27.513.18.7-1.9-7.84.0.538 9.16.912.710.1-3.6-9.92.7.26910.79.011.411.3-0.7-8.16.8.85109.78.210.29.6-0.5-7.06.0.88118.06.79.58.2-1.5-7.03.9.57128.08.311.58.6-3.5-9.72.6.25137.37.310.96.7-3.7-8.71.4.15146.06.88.97.1-2.9-7.92.2.26156.27.28.56.7-2.3-7.42.7.35         Based on the results of the linear model, a quadratic, polynomial model was run with time since intervention and time squared as continuous predictors of MADRS. The pattern of MADRS scores over time fit a pattern of regression to the mean. To explore whether the polynomial mixed model provides a better fit than the linear model, the AIC and BIC were estimated for the linear (2211.181 & 2226.485 respectively) and polynomial (2206.316 & 2225.446, respectively). Consistent with the visual impression the polynomial model had a better fit. The patterns of the polynomial quadratic models suggest that only the allogenic group may have continued reduction, whereas the autologous group may regress to the mean. Time in the allogenic group predicted MADRS, , accounting for more explanation of variance compared to the autologous group, . Neither adjustments with time-varying indicators of medication or LOCF imputation altered the results. The results suggested that the allogenic group continued to experience improvement over time, while the autologous group did not. However, given the limited sample size, the change over time did not achieve statistical significance (as reported above).  The smaller sample size also suggested that hypothesis testing, as the primary analysis, was not supported. Post hoc power calculation for MADRS score at trial end point indicated power of 25% to detect a 50% reduction in MADRS score. Rather, the study aligned more closely with a pilot feasibility trial, giving preliminary information about the magnitude of effect and the distribution of outcome measures. The model of response to treatment identified a pattern of symptoms that suggested that the allogenic group responded better to treatment than the autologous group. The pilot data confirmed the feasibility of a future trial study. Secondary outcomes World Health Organization Quality of Life The WHOQOL instrument was used to measure quality of life in the four domains of physical health, psychological, social relationships, and environment. Higher scores denote higher quality of life. All four domains showed statistically significant improvement from Visit 2 through Visit 15. No differences between allogenic or autologous groups were found in any of the four domains (p = .40; p =.45; p =.53; p = .06). The allogenic group improved more between Visit 2 and Visit 15 in the social relationships and environment domains, whereas the autologous group showed more improvement in the physical and psychological domains (see Table 3).  Table 3World Health Organization Quality of Life Means by Group AllogenicAutologousDomainVisit 2Visit 15 Visit 2Visit 15 MSDMSDDifference 95% CIMSDMSDDifference 95% CIPhysical47.212.054.412.97.2 (-1.56, 16.0)46.012.054.314.18.3 (1.5, 15.1)Psychological39.511.746.311.56.7 (.72, 12.8)40.511.449.415.38.9 (2.2, 15.6)Social Relationships39.227.654.622.015.4 (5.6, 25.2)46.823.157.419.510.6 (-1.9, 23.2)Environment54.717.265.616.310.9 (3.0, 18.7)68.914.575.218.26.2 (-1.8, 14.2) Sheehan Disability Scale  The SDS means scores decreased in each group. Visit 2 means stood at 19.8 (SD = 8.7) for the allogenic group and 16.0 (SD = 8.0) for the autologous group. At Visit 15, the allogenic mean was 5.8 (SD = 8.8) and autologous mean was 4.7 (SD = 9.5). The means did not statistically differ at Visit 15, t(29) = .343, p = .73, d = .124, 95% CI [-5.6, 7.9]. However, the allogenic group decreased by 13.9 (95% CI = 6.9, 21.3) and the autologous group decreased by 11.4 (95% CI = 5.9, 16.8).  State-Trait Anxiety Inventory  A mixed design two-way repeated measures ANOVA did not find a difference over time in state anxiety for either the treatment or autologous group, F(12, 360) = 1.62, p = .084, , and no interaction (slope of change) for treatment-by-time F(12, 360) = 1.16, p = .31, . There was also not a difference between groups, F(1, 30) = 1.43, p = .24, . Analysis on the trait anxiety did find a statistical difference for over time, F(12, 360) = 4.05, p < .001, . The treatment group’s mean dropped from 56.3 (SE = 3.04) at Visit 2 to 43.3 (SE = 3.4) at Visit 15. The autologous group dropped from 58.9 (SE = 2.9) at Visit 2 to 48.9 (SE = 3.2) at Visit 15. However, both the interaction F(12, 360) = 1.2, p = .28, , and groups F(1, 30) = .358, p = .55, , did not reach statistical significance.  Discussion There was a significant improvement over the course of 24 weeks, with a mixed design two-way repeated measures ANOVA indicting a difference over time for both the allogenic and autologous groups F(1, 30) = 104.5, p < .001, .  The mean for the allogenic group drops below the autologous group at visit 6 (week 6), indicating a gradual separation of groups. At Visit 7, the allogenic group (M = 11.2, SD = 7.51) is 1.86 points lower than the autologous group (M = 13.06, SD = 13.06), 95% CI [-7.76, 4.05]. The largest consistent differences in means, with the allogenic group’s scores being lower, occurred in the final four visits (Visit 12-Visit 15). Given this is a feasibility study, the lack of significance is to be expected. We have, however, carefully modeled the outcome data, and the analysis shows a different pattern of improvement over time, with the suggestion that the allogenic group continues to improve over time whereas the autologous group does not. In terms of feasibility, we are seeing a pattern that suggests effectiveness of the treatment and leads to an expectation that the effects would become significant if there were larger sample sizes or longer follow-up. This pattern also makes biological sense. Both groups’ scores decreased from Visit 2 to 15, indicating that the intervention was effective, with a statistically large effect size but although the MADRS means decreased from baseline to end of study for both the allogenic (-15.4 points, 95% CI = 11.8, 19.0) and autologous (-14.1 points, 95% CI = 10.1, 18.1) groups, this may be because the autologous arm was not a pure placebo, in that both it, and the autologous arm, received 4L of polyethylene glycol laxative solution 24 hours before the FMT. Given the efficacy outcome of the trial was to assess if altering potentially illness causing bacteria caused symptom improvement, it makes sense that the administration of a medical grade colonic cleanse, which has been shown to significantly alter the gut microbiome,20 would have an effect. The results indicate a rapid improvement immediately after the cleanse is administered between visit 2 (baseline) and visit 4, 2 weeks after the cleanse was given. This is consistent with the known effects of a bowel cleanse, which acts immediately to significantly change bowel flora which at the 2-3 week mark begins to repopulate20. Studies have indicated changes are still evident at the 4 week mark and beyond, with a gradual return to baseline beginning to occur21. It is interesting that the graduate pattern of change we noted on our microbial analysis comparing responders and non-responders across groups is consistent with other work regarding changes associated with the patterns linked to a bowel cleanse21 and those related to microbial changes linked to depression and inflammation22.  Example 2: DefiningTherapeuticConsortiafromFecal Microbial Transplant of Example 1 MicrobiomeAnalysis: Deep metagenomic data generated from donor and patient samples of Example 1(pre-treatment, 9- and 15- weeks post FMT) using established protocols generating > 50x106 2 x 150 paired-end reads on an Illumina NovaSeq. Low-quality reads and sequencing primers were removed using fastp and reads of human DNA were removed with DeconSeq. The analysis was carried out using two different approaches: 1) short read analysis (FIG. 7) and 2) a metagenomic assembly approach (FIG. 8). Short read analysis of microbiome data is computationally less demanding and can provide data on taxonomy (metaphlan4) and functional composition (humann4).  The primary methodological approach was based on identifying strains or genes that are engrafted in responders following FMT- that is strains of genes present in the donor that are absent at baseline in the subjects but present at 9 or 15 weeks (with an emphasis on 15 weeks). This starts by assembling the donor metagenomic data onto contigs, followed by binning contigs not ‘strain specific bins’. High-quality metagenomic assembled genomes (MAGs) and high quality that do not meet the stringent requires for a MAG constituted a donor MAG / BIN Database containing 573 genomes. These were annotated and assigned taxonomy using gtdb-tk. To predicted engraftment, the short reads from each subject for baseline and 9 week and 15 week post FMT were mapped to this database. A donor MAG / BI is engrafted if it is absent at baseline and present post-FMT. Alternatively, all the genes in the assembled contigs were functionally annotated and a Donor Gene Database (1023235 genes) constructed. Using the same short read mapping strategy of subject reads to this database, a donor gene is engrafted if it is absent at baseline and present post-FMT. These two methods are complementary but the gene based mapping is more sensitive and this has been taken consideration in defining our therapeutic community. The rationale for these two approaches is summarized in FIG. 9. False positives were reduced by assessing evidence that many genes from a particular species are predicted as engrafted. This approach also means the consortia based on specific strainsof the species selected.  Additional considerations include the presence of antibiotic resistance and virulence genes.  RationalDesignofConsortia: Using the strategy outlined in FIG. 8 a list of candidate organisms with evidence of engraftment post FMT was selected. Data from the analysis in FIG 7 was considered supporting evidence. This list contained 25 species. Evidence of an association of these species with psychiatric comorbidities in the literature (2 species were eliminated because of positive correlation with psychiatric comorbidities) was assessed. A deep metabolic pathway analysis to ensure the consortia covered core metabolic pathways associated with a healthy gut was completed. Some strains with weaker engraftment data and fewer metabolic pathways were removed. This results in a final list of 20 species that make up Consortium 1.  Consortia1(20species)1.Agathobacterrectalis2.Alistipescommunis3.Alistipesputredinis4.Anaerotignumfaecicola5.Bacteroidescaccae6.Bacteroidessalyersiea7.Bifidobacteriumbifidum8.Bifidobacteriumpseudocatenulatum9.Butyricimonasparavirosa10.Butyricimonasvirosa11.Otooleafessa(previously Clostridium_Qfessum)12.Bariatricus comes(previously Coprococcuscomes)13.Dialistersuccinatiphilus14.Dysosmobacterwelbionas15.Eubacterium_Iramulus16.Faecalibacteriumprausnitzii17.Odoribactersplanchnicus18.Parabaceroidesmerdae19.Parabacteroidesdistasonis20.Sutterellamerdavium / S.parvirubra Consortium2(16 species)Alistipes(#1, #4) and Sutterella(#20) were removed since some data suggest positive correlation with psychiatric comorbidities although the literature is conflicting on this. The data for these strains does justify their inclusion in the larger consortium. Faecalibacteriumprausnitzii(#16) is well recognized as a beneficial microbe; however, it is genetically very diverse (and will probably be reclassified into several species). Moreover, the subjects own strains are likely to recover post FMT. Consortium3(12 strains) To reduce the size of the community, only one species of each genus was retained with the species with the least engrafted genes removed. This removes Alistipesputredinis(#3), Bacteroidescaccae(#5), Butyricimonasvirosa(#6) and Parabaceroidesmerdae(#18). Faecalibacteriumprausnitzii (#16) is remove as described above. In addition, Bariatricus comes(previously Coprococcuscomes)(#12) was removed as it is on the low end of engrafted genes and metabolic products of interest that this produces are covered by other species. Consortium4(10 strains)Alistipes(#1, #4) and Sutterella(#20), Faecalibacteriumprausnitzii (#16) removed as described for Consortium 2. Butyricimonasvirosa(#6), Parabaceroidesmerdae(#18), and Bariatricus comes(previously Coprococcus comes)(#12) are removed as described in Consortium 3. Otooleafessa(previously Clostridium_Qfessum)(#11) has also been removed. This community still contains a core set of species that cover key metabolic processes (short chain fatty acid and D-lactate production, complex carbohydrate metabolism and bile acid modification). Consortium 5 (18 strains)Agathobacterrectalis, Alistipes communis, Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiae, Bariatricus comes, Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum, Butyricimonasparavirosa, Butyricimonasvirosa, Dysosmobacterwelbionis, Eubacterium_Iramulus, Faecalibacteriumprausnitzii, Odoribactersplanchnicus, Otooleafessa, Parabacteroides distasonis, and Parabacteroides merdae. Identification of Engrafted StrainsStrain definition was defined using the Genome Database Taxonomy (GTDB) toolkit (gtdb-tk version 2.4.0) which uses complementary methods to assign taxonomy. For each whole genome sequence , the complementary methods predicted the same taxonomy and no warnings (indicative of incomplete or contaminated genomes were reported.   Closest Genomeuser_genomeSpeciesReferenceANIAFGC563AgathobacterrectalisGCF_000020605.197.750.761GC1077Alistipes communisGCF_006542665.198.640.822GC1016AlistipesputredinisGCF_000154465.199.130.872GC1987AnaerotignumfaecicolaGCF_003865035.198.050.797GC203Bacteroides caccaeGCF_002222615.298.970.875GC2270Bacteroides salyersiaeGCF_000381365.199.130.883GC2120Bariatricus comesGCF_025149785.198.350.749GC2386Bifidobacterium bifidumGCF_001025135.198.880.923GC3144Bifidobacterium pseudocatenulatumGCF_001025215.198.070.879GC466ButyricimonasparavirosaGCF_011927845.199.770.936GC957ButyricimonasvirosaGCF_025148635.198.030.772GC623DysosmobacterwelbionisGCF_005121165.398.970.813GC2786Eubacterium_IramulusGCF_000469345.197.590.729GC163FaecalibacteriumprausnitziiGCF_003324185.196.240.804GC1179OdoribactersplanchnicusGCF_000190535.199.330.904GC2916OtooleafessaGCF_003024715.197.570.787GC1219Parabacteroides distasonisGCF_000012845.198.80.863GC695Parabacteroides merdaeGCF_025151215.198.920.852 The similarity to the closest reference genome was measured by average nucleotide identity (ANI) and aligned fraction (AF)5. ANI from only the orthologous regions so is a measure of sequence identify to only the regions shared between the two genomes. An ANI of greater than 95% is the cutoff for species identification. AF is a measured of how much of the reference genome is covered by the query genome. Bacterial genomes of the same species shared a common core genome as well as an accessory genome which includes genes found in some but not all genomes. The AF is a proxy for the portion of the total reference genome shared with the query genome. As shown Table 1 both ANI and AF differ significantly between the Strains and the closest reference genome. To generate phylogenetic trees to assign taxonomy, gtdbtk uses 120 bacterial proteins which are phylogenetically informative markers. These are concatenated for multiple sequence alignments (MSAs). These provide unique genetic signatures of the Strains.  Concatenate protein sequences are provided below for each strain: STRAIN: GC1016 (SEQ ID NO:1)RAVFKTISLLDIQVKQTTENDIAEALRADEFKNGPEQPRKFFPIFTIRAAVAKIITIEQYIYKDEIIWDKALQKLKIAKKVLYYEVIDSEQLHFTNLEASRCFDIKVVLAALEVEASVMTG-LKE-EERIAEKLRRTKLVFPDLQRALEVKIFKLTHHVVQGKVLFKV------GDLFVVSPVLDSDSVGIETCIEFR---DDLTVAAI------KAYIATGMHERDAFNAEAEFEEELIYFVQKKAMIGLRLSDVHRLAT-YLDRGALTAILWAAT-LIVMLARYIDFE-ISALKTVEEEETNGAGMTSKSKELTALISSAVCKLFFKDGSKQDK---IVLVEDLNMRNGLGKVYVKSDTITDTSVTRMAQIFGLIKAHKSERQTVARAHHKRKRNT--TSALSLDKLKHNVAGNKLQVVTYCSARLEMNFLDDSFIETVNAEYGAAVVGLLDPRQHRERWILGLAREIFESPGVWYPDIVGEAVNRDSLTEGKFMGAIKEIVHALSILIAKAVQPLKTHSRRSLKQAELRTPPGFLAADMCIEFYVIQFKAKLHREVSFDLLADNDGGEGSKCKILKDVLVKQQVELIKDEIVVAIIVEIRPADVAKAVLGAPLVLQATKGRIGLKDESMVRLKLIMKLAGTVIGRNLKGDALVKHAEMYVHIWSKNLVVRKARDAEIFEAEVRGVTVRVSFSAKIYVSFEMLQHAKVDSY-------------------------------------------EYIELPTVSTYVVHYRASARELVGSEIILKNKTIISAVMAVSNKEEWIAVVLKASTDCEINNRNKIRADGGFLNLGAEKNDKEKTLLSDIVYTDRIIRTEDYLTGACSVIPGAADLAFNDREERLLIKKGKIVLDKGAICSIVCDSQVIAEEVRVEIMYVDVFEFEELNAFIIDPISKNNIIDREKVETLLDVV-AEAEGLARLFKYDQGRYRAPDFENNVLDEDVTSIYGTSLIDEEILDLKPFHFSP-SSKKLQAEAYILDFG-DKEEELPKLATFLLL-VTYTAEAFMMVVMEAKGCERDIKTIQANMALLTEEYAVKIVASEILMFF-IED-DWNRKDQRVLALVCGFSVPFPFAKVGLPCATEYYVVQALGTIIKINDVNVKYNIPGKATKLKRDAQEANVEGIFTLAAGDKLHINVIVPVLSAQEAFQITGISAWGKKAKFLEFTGITLERILFKD-ELPLDMEEIIQQKLKAVIRQTDLKNLKGKFELLATSKNMIKPVEILCLITVLT-HLLIVSAGLPLASASAICVKTMSDLESAFKFKINLVRSVQTDDGLL--KLEHFDEMEQPAFLSGIAFFITFATKIDPLIIVT-LFAIIEWLDEFYRTAHRMSGMRLVTIIQYMYTAILRSNTHKIVLTEHPSCNVRLNVKSILVAVQCYKHDVHYSVMTLHFSIDPVNYVMFKIMGFEI-EHEAETGYENHEIVDVVRFWFKPQTVLYQLQQFFQIPIFIQGLVLTELISERRAHIAKERRSGSQERNVLSDIVQNIEKRDDRFLLLRLEGVVFDIERLS--PLDIEVEETEYYKTADRQVIKIGKYLIELSFYPALNYTSFMWDLGKQRLEGQLLFIEESVGSRVALP-PYGMQKAIETLAAKGVTLVIPTVIRSTSLPY-EGHLKFCVEAFENVDGGIGIKEFSFQAAQAERAAEKLLGALARQNILEVTKDRLQHLLSVLYLN-A-FRAGNRNVVGSLIYDIEKYTKENLFEVILLHYTLVVVAYALI-------------------------------------------VDPDVIRATVTLALTTHVELKEAGEERKYMECASLSGLAL-DETPVVVRMIMVESKDHSPIASLIHINESLHSDNSILLWLKWVINPVLVGRSIIIKMDTNILAGLTTSRCIIEYE-IKADELVLPTEPSEDFDRCVIGVLNAEKKA-MIVLIAISTGSFAENGGSI-NEEIVLLFIQMWGYKGYSWLTTVLMIELVGIVSTKLSYVTITLTLNLFAKNKCWYKLVYFDVMELYQKSDEKKLRFGYLTLRPYCRNVRVKDYQQVWRMFTATVGGFTQLEWRYDYLAILGSIIQTYPGLEVLLPKAGLVWQWEVHDNMDTSNWIRLARIISQSAQLMVAPEKTRAGR-SVFIEAEMLRVESRIGEFAIVDMIKFYNDLEVVGVCAVGVAKVAYKIFIPVINRIAYILAALRYEKREADTKVAMSDAEIIANSQEDKKVRMHRIGFKIVLSPIVEIGVIKKGFKEVVDYSSSTPAKWKEIILQISITEERATADEGEAKFLDIKTMEIFSGACVTNSDMTNFKLLALITRGYGAYPNKRLRELELCG-LGQI--FTNKDFVSKKHESVELSNPIERVGSQLQNEREVDRMMTVRPLAKLIIRFDT-NMLELLFVAAFGRSAESIEVDEELL-LKRTLFRKKSICVEVVIQYHVKIITYLNKVSARFEETHLMRVGKNTTEIGMEPADMGDFTKYAKFIYINRSTVVASESGVTATAILTNNPDIHYLATLDPSSPRARIALADFPAPVLALF--DELKDDVLTLANHTLPDIKSILTLQVLLVGIDTRLMIGIASGVEYLTRAGIFSYRLPTNCMFELVLITIGTKEESMSLRATDRLSLTKITILLTLLKYPGIFADRNVKLKVGYDLVIRDIDIIIFNTRLAGVIHQAIIVDKKQNLIAQKVLTNVIIDAHKVAAVQQFDKLPRLNASVLLTAISATMRSQFIVEKGSVLFVHVSRLRSEDFLTWTCIILLASIIAVQPSGMAANFQVMGRQTSLTMVIVVLSLAT-YRNKRISQLEKVTVSVPPGDRKMLVEPFGEIPSFIEAELVPQIEFDKYVQNAAVAPEVFVANNLALIFGEPNRMLKKLLGATT-IILVVKTKYDKNVAVAISRQRLKAFSPMGAEMLIIEPVKFK-KDKDRMRKAVQVDR-KDNV-DATIEVSQVQISEGGQLNTLYLYVKESYLHKVTWPTFAQLTVVMVSLIAIVIAMFIMAIIYLGGFGSILMFQRMLYTLMIEGNRMAPAANVKAIRPVQYRHQNILIWGKLKLTTAIQLKTKQIGALATGAEGAECLVVITVYGGKARAAAYLAKMSTIMGSQAKKIAVKSVFTCDYVAAAVCAILRPKKQKVGKATGRYQENLCNIRLCCVNYSVVLGSAQPNILVKEQVTAVYSEIVKLMFGGLRPPTGEVVKAKGSPLVKIARSAGMAKILPARFLKIYTIFDLDWKIKSITVMEPKISVRKTADAMERPVVRKVFGRGVKNTGYAQKRFMNARGMTQIKNLNKDMNPKEI------------------------------------------VLRDPTRMRVDIRVIYEASEKLIAEAEVKEVDRIPAARKRSNIIKGTLCRKEKDTAYTTTRAGLKDATRQLWELSGGWERSREHDVVIIWMAEEVMIISTTSNVIHKAVEAENMTETLEQDMKTVIAVVTVSQVILRKSYTPVCIIVKMDTTGFTDKLEAVKTGMNLKLKPKSTGTAKSSLFMPRNLKPLAKTDAAGISVLNAKVSEAAAHGNAGQVAQQAVEGNIKATPAPQGIEEHVPGKQAAVFAKSGELLVRAEFHSLMALVRLRLVTGRGNYIWVAEFYQYAKTFEIGVIFLHSDILRRAIISDIQEFHAAALAVIEAWTLDDARASALFYDGPMYQVA-TPTIQAGILATNLSPTHEFNLIPKLIFLSGLLL------------------------------------------QKTRGRMGYKAAIREQWKPAEVKNEGVPVTIAEGVPLVQLQPTKAPKYKALIVRKANVHVRCPEKEDVEKGTNRGVHIAIVFLLVIFTEKSSKKRVDGVTVVVGAEEQAGVILPSLNMRAG-KFIRESADIAAHEKVLIREGVVAHYTTVGPVASIKATRDFQKFKMLYIDRHPYCGVSYFICRFEMHSQEKATVASINIISDVPEADIENNLRGENLYHDCAGLVFAIEEIIDPLLLDKKVEDPGLKREQKMERVYAVELVSYITKAIELAALQIMRETIFIIEHNTMSSEAVQAVIINVGLEYDNRVVGADARNETLPDTTPDIVRLGTEI---VQIGVPAVDKQFRQTVSIVQQEKSSQPRGVDVRCAMMTSINV---------DFLFTILYTWVEIVNAVSSIPKTIAKSGTDIVAAIKRHADIVEPPEGSQESGVIEKYIVRIFEVVVTK-KKPDVDLNEKSMDQPSTMLEAQDDNIEALIIDALTTVAIRVVEYGKIVRVITTNFLEINTTNSTDAENIEARIGLEAIRIDVRRLECIAAPLLSVVAEGYFLEVCLAALIEKDNGKLHEQKSDLRKRFLNLKLLKGIAVGVARLIAQSAPILAIGTNYKRTFDIETREIDTEIG-FFHNLLNAALQLLSRSTTGLA--SIAGGEALLNYDQTGTIELFLLLPDLALTADAEEFILYLE-NDDGRSALVLVVFIGERLEAGSTNERVPADSYFDHVKMKLFELGGDLEAKSNDIPRKEIKALEVRYTEERVGGVELITLNMVRAEDANEDLCGTTTPLPDISGRAFYPNCSRLIVIVALLKKLDAQDQLVADNRLEPELKSELGKIVMLS-VCELEYGTGSMYWSVHFLGLITGLMSDLEYRSSKLGYIAVDDYTGGDLTYHFTREEGLSKISFHV-RDKRILESGKMLSTVSVSGKLEQFWETTLRGNDNKFCAPELTPIALEVDLAIAIIRTTRDFRLVTNFLGESTLKSAFRVLLNGLTAYANITPIPPQKACRAIDKEGSGHFKRMETDFSEEDVISKVHQRQSPGMELKKKVKMAYSVTITNDISSARSKNPYQTAAKYLVKPAESIEMICRGPVTVNSVLVSVRSHLLNVFILMYHDPVAGKDKVQVAKPIKAAIQAVVIAGSLSASSILQIGTAAFDLGPDSLLLVKSRLEIAAITLSLHVGELGVSKRPLVASATALPVARMVFTAVFFFGNFFL-EAVKYSLKSPFVVYKLKQQAVPIDKAAKLVDLCRPVYMME- STRAIN: GC1077 (SEQ ID NO:2)RAVFKTIALLDIQVKQTTENDIAEALRADEMKAGPEQPRKFFPIFTIRAAVAKIITIEQYIYKDEIIWNKALKELKIAKKVLYFEVINNEQLHFTDLEAQRCFEIKVVFGALEAEASVMTTAVKER--PIAEKLRRTKLIMPDMDRALAVGIFSLTHHVVQRKVLFKV--------------------------------------------IALDKAAIASMHERDMFNAEAEFEEELIYFVQKKAMIGLRLSDVHRLGTDYLDRRAVTRVLWAAT-LIVMLARYVDFE-LSILKTVEEEERNGAGFTSKSKELTALVSSAVCKLFFKDGSKQDKKQAIILIEDLNMRNSLCKTYVKSDSIVDTSVTTMAQIFGIIKAHKSKRQTVTRAHHKRKRN---SSALSLDKLKHNIAGNKLQVVDYCSARLEMNYLDDAFIETVNAIYGATVVGLLDPRQHREK-VLGLAREIFESPGIYYTDIV-DAVSVGLPTEGKFMGAMKDIVHAMSILIAKALQPLKTHQRRSLKQAELRTPPGFLAADMCIEFYVIQFKAKLHRVVSFDLLADNDGGEGSKCKILKDVLVKQQVELIKDEITVAIIVEIRPADVAGAVLGAPLVLQATKGRIRLQDA-MVQLKLVMKLAGTVIGSNVKGDADVKHAEALMHIWSKRLVVRKARDADIFEASLQGVTVRVSFGAKIYVSFDMLKQSKVDSYE------------------------------------------EYLELPAVSTYVTHFRSTTRELVGSEIILKNKTIISAVMAVSNKEEFVAVVLKASVDCEINNRNKLRSDGGFLNLGAEKNDREKTLLSDVIYTDRIIRTEDYLTGACSVVPGAADLAFRDEEERLLVKKGKIVLDGGAICSVVCDSQVIDEEVRVEVMYMDVFSFEELNAFIVDPISKNNIVDREKTETLLDVVGAEAEGLARLFKYDVGRYKAPDFENNVLDQDVTSIYGTALCDEGVLGLRELHFSD-LSSKLTANAYILDFG-ERDEELPKLETFLLL-LSHTAEAFMTVV---KGCERDIKSITANMVLMREEYAVKLVADEILMFFLIQE-EWNRKDQRVLALVCGFSVPFPFAKVALANAQEFYVTWVLGTILKMNDVNVKYNIPGKATKLKRDAQEANTEGIFTLAAGDKVHINVIVPVLSAQEAFQITGLVKWGKKANFLEFTGLTLERILFKD-EMPMDMEEIIQQKIKVVIRQTDLKNLKGKFELLATMKNMIKPVEILCLVVVLV-HLLVVSAGLPLSAASAICVKTMSDLESAFRFKINLIRTIQADDALL--KLAHFDEMEQPAYLSGIAFFITFATRIDPLLIVT-LIRIVEMLSELYRTAHRMGGRRLVTIIEFMYTAILRTNTKRIILTERASCNVDLNVKSILVAVQCYGHEVHYSVMTLHYSIEPVNYVLFKIMDFEV-AHEAETGFENKEMLEKVQFWFQPQTVLYQLQQFFHIPIFIQGASLTELPSERRAHAAKEHSQGNHDRNVLSDITQNIERRDDKFLLLRLEGVAFDIVKLSRKPLDIEVEETNYYKTAERQVIRVGKYLIELSFFPALNYTSFLWDLGKQRLVGQLLFIEESVGEKVALPGPYGMQKAIDTAAAKGVTLVIPTVIRSVSLLY-EGHLRFCVDAFENVGGGIGVKEFTFQAAQAEKKAQTLLGALARQNILEVTKDRLQHLLSVLYLN-V-FKAGARNVVGSDIYDIEKYTKENLFPVILLHYTLVVVAYALIVAKYVIDAPLVYMFALRDLDVNKQAFERIEQFQKAIFIGLTEVVDPDVVRATVTLALTTHVELKEAGQERQYIECASLSGVALDSEEPVVVRMIFVESKENSPIASLIHVNESLHSDNSVLLWLKWVINPVLVGKSIIIKMDTAILAGLTTSRCIIEYEIIKAEELVLPTEPSEDFDRCVVGVLNAEKKN-LVVLVAISTGSFVAKSGSLIREEVVLLFIQMWGYKGYAWFTSVLMIELVGIVSTKFSYVTITLALNLFAKNRCWYKLVYYDVMELYQKSDEKKLRFGYLVLRPYCRNVRVKDYQQVWRMFTAAIGGFTQLEWRFDYLAILGSIIPTYPGLEVVLPKAGLVWEWEIHDNMHLHEWIRIVRVIEQAARPMVAPEKARRAA-TVFIEAEMLRVESRIGEFAIVDLIKFYNDLEVVGVCALGVARAAYTIFIPILNRYAYVLASLRYEKREADTKVAMSDAEVIANAQDDKKVRMHRIGFKIVLSPIVEIGVIKKGFREVVDYSSSTPAKWKEIILQISITEERATADEGEVKFLDARTMELFSEICVTDSDMTNFALLTLVTRGYGAYPDERLRELDTRG-VDQI--FTNRDFVSKKEEAVELSNPVERVGSRLQNEREVDRLMTVRPLSKLIFRFD--NMLELMFRAAFGRSAESIEIDDELLSLKRTLFRRRSICVEVVIQYHVKIVTYLNKVSARFEETHLLRVGKNTTEIGTDPADMGDFTKYAKFVYVNRSTVVASVSGGTAAIIITNEQDIHYLTAQGPSTPRAQLQIAGFGPPVLALF-TTELKEDVLTLANHTLPDIKSILTLQVLLVGIATRLMINIAGGVEFLTRAAVFTYRLPTNCMLALVLVTIGVREAAMSLRATDRLSLQKITILLTLLNYPGIFADRN-KLKVGYDLVIRDIDIIIFNTRLVGVVHQAIIVDKKQNLIAQKVLTNVLIDAHKVAAVQQFDKLP-LNAAVLLSAISATMRSQFVECKGSVLFIRVSRLRSEDFLTWTCIVVLASVIVVQPG-MAANFQVMGRDAALAMVIVVLSLAT-YRNKRISQLEKVTISVPPGERKMLVEPFGEVPSFIEAELVPQVEFDKYVQNALLAPEVFVANNLALIFGEPNRVVKKILGTTT-IILVVKTKYDKNVAVAIAKDRLKSFSPMGAELLIIEPVKFKMKDKNRMDQAVQVQR-KDNV-DATIEVSQVAISEGGQMNELYLYIKESYLEKVSWPTFAQLTVVMVSLIALVVVMFLMG-IYLGGFGSILMFQRFAFTLMIEGNRMTG-ANVKQIRPVQHRHQNILIWGKLKLTTAIQLKTKQIGALATGAEGAECLVVITVYGGKARAAAYLAKMATIMGSQAKKIAVKSVFTCDYVAAAICAVTKPRKQKVGKYTGRYAENLCNIRLRCVNYSVVLESSQPNILVKEQVTAVYSEIVKLMFGGQRPPTGEVVKAKGSPLVKIARSAGMAKILPLRFLKIYSIFDLDWKIKSITVTEPKISVRKSSDAMERPVVRKVFGRGVKNTGYAQKRFTNARGMTEIKNINKDMNPKEI------------------------------------------VLRDPTRMRVDIRVIYEASEKLIAEAEVKEVDRIAAARKRSNIVRGTLCRKEKETPYTTTRAGLKDAQRQLWELSGGWERSREHDAVIIWMAEEVLIISTTSNVIHKAIEEENMTETLQQDMKTVIAVVTVSQIILRKGYTPVCIVVDLEVTGFTDKVEAVKTGFNLKLKPKATGYSKSSLFMPRNLKALAKDESAGVSVLNTKVSEAAAHGIAGQVPEQAVEGNMKAEPAPQGIEEHVPGKAAKVYAKSGEILVRAEFHSLMALVPLRLVTGRVNYIWVGLFYQYARTFEIAVLFLHSDVLRRAVISDIAERHAAALAVIEAWTLDDARAAALFYDGPMYEVA-TASVAAGILACNVSPTDEFDLIPKLLFIMGLLL------------------------------------------QKTRGRMGYKATIREQWKPAEVKNEGVPVTIAEGVPMIQLQPTKAPKYKALIIRKANVHVRCPEKEDVEKGTNRAVHVPIFYLLVIFTEKSSKKQADGVTIVVGAEEQAGIILPSLNMRAG-KFIRENADIAAHEKILINEGVVAHYTTVSPVASIKATRDFQKFKSLYIERHPFCGAGYFICAFDIHSQEKATVSSINIISDVPPADIENNARGENLYHDLAGLVFAIEEIIEPLLLDKKVEDPGLKREQKMERVYAVELVTYITRAIELAQLQIMRETIFIIESGTMSSEAVEAVIINVGLEYGDRVAGAQARNETLPATTPDIVRLGSRI---VQIGVPAVDKQFRQTVSVVQQEKSSQPRGVEIECAMMTSINK---------DFLFVVQYTWIEIAYATSEIPKTISKSGVDLV-AIKRHADIVEPPEGSQESGVIEKYIVRIFEAVVTK-QKPDVDLSEKSMDPPSTMLEAQDDNIEALIIDSLTTVAIKVVEYGKLVRVITTNFLEINTTNSTDAENIEARIGLEAIRIDVRRLECIAAPLLSVVAEGYFLEVCIAALIEKDNGKLHEQKSDLRKRFLNLKLLGGIQVGVAGLIAQSAPILAIGTNFKRTFDVETKEEDTEIG-FFHNLLNAALDMLSRSAQGLLSN-IAGGNVLLLEDQ-QTIE-FVVLPILALEADASELVLFVE-DDDGDSALVLVVFIGERLEAGSTGERVPRESYFDHVQMKLFELSGDLEAKSNDIPRKEIKMLEVRYTNERVGGVELITLNMVKADDANEDLCGTSTPPPDVSGRAFYPNCSRLIVIVALLKKLDAQDALVADAQLETEARSELGKIVLLLGVCDTEYGTGSMYWRIHFLGLITGVMSELEFRSSKLGYIAVDDYTGADLGTHFSREEGLSKISFHV-RDKRVLETGKLLSTVSISGTLDDFWETTLRGHDNKFCSPRLTPIALEVVLDVVIIRTTKDFRLVTNFLGDSTLSSAFRVLLNGLTAFPNITPIPPQKACKAIDKESSGHFKRMETDFSEEDVISKVHQRQSPGMELKKKVKMAFSVTLTNEISSARSKNPYQTAAKYLVKPAESIETICRGPVTVNSVLVSVRSHLLNVFILMYHDPVAGKDKIQVAKPIKAAIMAVVIAGSLSAAAILQIGTAAFDLGPDSLLLVRARLEIAAITISLHVGELGVSKRPLVASACALPVARMVFQAVFFFGSFFL-EAVKYSLKSPFIVYKLKQQALAVEKATKLVELCRPIYMME- STRAIN: GC1179 (SEQ ID NO:3)RAVYSTIPLLPTIVKQLVGQDIAELLRANEDRAGPERPKRFFPIFTIRAVVIKIMTIEKYIYKERIIYHKALRELMLKEQVLYYEVIDNEQIHISDLAQERCFGIKIQLRALDLEDAVMETALKERKDELSEKLRRTRLLIPNFERSLEVEIFQFPLQVCQHKVIFKVEPVLTHHFLVELDNIFDALGVNIQTCIELR---DDLTVSAL-LDIDCQKADVAQNHLRELLDNRAEYEEELVYYVEKEAMIGLTLSRLHGLGA-FLDRLAVTAIFRVAS-LIVLLMRYLDLVEVARYRTVDKEEGNGAGFARKNKEMTALIGNGLCRPKYKDGSKQEK-VRLVLAEDLNMGNSMAKVFVKSDSIADTSVTRTADIFNIIKAHKSERQTATREHAKRKRM-V-TAELALDKLKKNIAANKLAVINFCDDYLAVNYLDDSFIDTVNSMFSTFVCSLLDDVERKEILVLLLAKEMFESPGVYVSDVFNEAIGLGYATKGLLVGVVKEFIHSLAILIPKALIPLKNNSRRSLGQAELSEPPGNINAETCIELYVIQFKVKVHREIEFDLLVDNDGGEGKTAKVLKDVIIKEKIELIKEEIVVALVIDVKPADKAGAVINAPLVLQATKGKIKLQNE------------------------------------------RKARDSEMFEKETEGLTVRVSLSAKIYVSFEMLEKIRVDSY-IARISEPELGELLLYDVLLNSIYTVKFLLLVAGNDYIEFSRSEYLEAPAVSTYVIHQRFNERTVIASEAIIKSKTVIKAVMQLTNKEEYNATIAKASVDCEVYNRTKLRKEGPFLNYAAEKKDKDRSLLSDIIYTDEMIRTEDYLTGPCAIVPGAADLAFNDKKERLLINKAHIVIDKNCFCSVICTSHILDEEPHIEVVYGDVFDYEDFNAFINVPISKNNIVDREKMETLLNVVGKEAEGLNKLFKFEASRHRQDDFENNVLDDSATSIYGVSLFDDDPAELAEIHFS-PHSKELVLESIIMEIGEIEEEAHYRVATKLVL--KAEREQLFNVF---KGCEKDILKAKANIALLSAEYGINIAADDMLLFYFIAD-EWNRKDEHVLAMVTGFGIPFPFLKVGVTQVNEQFVVRRIGFILTIDDINVKYRIPGIATKTKREAEAAETSGIFNILAGDKVHVNVITPVLSQQEVFKITGIEAWGRKAKHLQFEGLKLERILFR-R-YPMEAGEIISQKIKVVVRQTDLKELQGRFDLLIAAKIVVKAVEMLIRIFVFA-HLLVVSAVVPNSSASAVCVRTMDTIESAFSLKINYVKKIIVNDQFN-QKLDRFDEMEKPAFLASIAFFITFAKKLDPCIIVS-LLHFVEMLHPMYRTAHKLGGKQLITIITYMYTAILRKNTQRIVL-EHENCKVELNVNSLLIAVQCYEAETHYSVMTLHFSIDSVDYVLFKIMGFKV-YHAVETAMENKEFLAQIQFLFEPVTILYQLQQFFHIAMFVRGITLTDFSTTRRCYSAKERNADDDARHVLDDIIQNIEKMTIKFLILRLEGIKFEIERLST-SLKLEVVATDYYKTAAVVVIKIGKYVIELSQFPPYNYTSFLWDLGKQRLVGQLLFLDASVNEFIALP-PYGLAKPIETAAEKKITLVVPVVIQSTSLPY-EGHLKFCIDAFENIGGGLGIKAFSFFASQAEAGSEKEIGALAKQNILGVSKDRLQHLLSVLFLN-VMVQEGGRDVVGSQALDLERFTKEQLSQVLLLNYTLVVVMIVLV------------------------------------------LLDPDVIKATVTM-YVTTLDAIDAGEEPANLECASLIGVAMESEQPVVIHMILVESAENTPICSLIHMKNSLHADNSLLVWLKWVVNPVLVGKSIIIKLDVLILSGLTPNQVVVEFD-IAADEFVLPTEPSEDFDRCVIKVLNAEQKK-LVLVIAISTGSFVKAEGEL-REQIVLLFIQMWGYKGLGLFTTGLMIELVGIVNTKFAFVTITFKLNLYQKNKCWFKLVYLDVMEMYQSSDEKKMKFGFLLLLPYCRNVRVKEYQRVMRMFTVPVQGNTRLEWRFDLMAVLALIIATFPGLEVLLPKDQLVWDREVQMTMGAVEWIRLAKVVEQSTERFVPADKAKDQ-TTLFIEAEMLRLESRIAEFAIMDLIEFYNDLEVVGVVATEVAQQCYEVFVRVLDRIAYILTQLLYEKKEADTKIAFSDTAVIANAQEEEKMKRHRIGFQIVLTPMIEIGVIKKGYNEVVDYSSNTPPRWKQMLFVVNVTAEKGTADSAEVSYIDIKTLEVFSDVLITNSDITNYLLLVLLSDGFSSYPDNRIKWIQE---HEQIGIFTQTDYVSKKRENVEMSNPVEKTCAKLQNEREFDRIRTAHPLARLVIKLRESDKVEFLYGATFERSAESMEFKYELLSFSRTLLKKRSICVEIIIQYHVHIVTYIKVITAKIDEGRIV-TGSQVTEIGNERGEFADFTEYAFFIYPCQSTVTASDTTAKAAAIITK-NDIHFLEELDESEARAKIELMAFDQPILAMFTSTEIKEDVLTLSNGTLEDIKSIITLNILLVGIDTRLMIKIAGGVEYLSKAEIFKHRFPCNCLIEHVLITLGVKDSEMTLRTTDELSLNKIVILKTLLEYAGIFANRNVKMKTGFELYLRDMDLIIFNSRLEGVIHAAIIVGKKQNLIAQKVLTNVLIDAHKVAAVQQFDKLPRLNASVLFPIISQQLSSQFVEAKGSVLFITFGRLRSDDFLC-TISVLFICVIIVQSGGLASSFQIMGRKTTLTLGMMILCVATFYRKKAVSQLEKIQIFVPTGPPMRLVNPVGEVPNFIEEDVVPQVEFDKYIQNVILAPEVFTANNFALIFGEPNRLVKKIIANTT-ILLIVKNKYEKTVAVAIARERLKTYGPMGAELLIIEPVKFKMDDRDRLKQAVQVDRTKDQM-EATIEVSTVEISESGQMNEIYV-------------------------------------ITLGGFGSVLVQRRYIHVLMVEGTRIV-GANVKKIRPVQHRHQNILIWGKLKLTTAIQLKTKQIGALATGAENAEAQYVIEVYGDKAKAANYLAKMTTIMGSQAKKIAVKYVFTSDFVCASVAAILRPKRQKIGKYTGIFKEVLCNIRLRTCNAAVVLDSRNPNILVKENVTAVWNEIIKLAFSGEQPSTGEAIHAKGSPLVKIARTAGLTKILPLRFLKVFKIFDLKWKIKSVTVTEPKISIRHSSAATERPKVRKVFGRKVKNTGYARKSFQNARGLSKMLHMNKDMNPEKVEYALDTLIDKEKVNEVKFSAAAATSRDPVEQQKRREMPRATI----PSQMRVDVRMTFEAAEKLIASKDIKEVDGLPAARKRSNVIKDTLTTLEKETKYTTTRAGLKSATPQLYELAGGWERSRQNDVVIVMMAEEIMIDNTSSNVIRQAIAADNMTETLENNMKTVIVVIEVSKVLLRKSFTPECIIVNLDTTGHSAVVEAVKNGLNLHLKPCSTGTSKSSIFMPRNINAVEDDDAAGLNLLDSAISIAAAHGNAGKVPDEAVEGNMKHTPAPQGIKEHVPGKKEKVYAKSGILKVRIQFAAIIALSSIRLVTENGTGIRLAVFQTYARTFDIRLLYLHSDVLRRATISPIEHVHAAALAVLEAWVLDKARYACLFYAGPMRQVA-INSVGGCIIATNLLPQLEFDNIPNLLLMGALLILSQISAAYSTRQKFDINKLAGVVAALVQLEYIECLLALLLG-QRTRGRMGFKAKIRQQWKPAEVKNEGVPVTIADGVPYVKLQPTKEDRYTALIIRKANVHIRCPDKVDVEKGMARGVHVAIFFLIVVFTESKTKKREENITLVIGKEEQAGSILPSLVMRAG-KYIRESVQIEEMQGTLMDNGVVSDYDIIEPISDMLMKWQDMGYAKM------------------------------------------NTHFGKNLYNNEAGLEFTLEVLIEPARIGKIIEDSGLKREQKMDRVYSVELESYITKAIELALLQILHEAIFIIESDVMSSEAVEEIIVNPELDFDTRVVGCQARTEAMGRTTSFVVRYGDEL---VQIAVPAVDKQFRQQVGITQQEKSSEPRALDVKAKMMTSITD-------QMDYLMAYMITWLDISKAKHSIPKTISKSKADAV-AIRRNMDILEPEEGDQEKGVVEKFVVYIFEVVINKEKDPEVDLQEKSLNPPSAKLEAEDENIEALIIDSLTTCSLRVVEYGKLIQVITNAFLEINTINSTDAEPVEARIGLEAIRIDVRRLACITSPLLSIITEGDFLEVCMSAIIEKDLGKLHEQKVEFKKRFLNLELLKGIEAGITNLIASSNPIINFSTNYKRTFEIETKEVDVQIG-IFNNLLYAALDLVSRSENGLA--IIAGGVTFIFPNQKVTLEFHVITLGIYIKDYAGRLVVLFEPESEGKYGVVLLSYIEESIRAGSTNERVPQVNYFDHKKMKLFELGGDLEAKSNDIPRSEIKALEVRYTKDRVDGVELITKNKHKSDDATEELVGTTTSPSNVSVRAFYPNCSKLIVIVALLKKLDAQDKLVANGKLAQDCQMELAKFAMLL-VCDFFYGTGSVYWKIHLCGLISGILSDLKFRSSKHQYTATDDYTNGDLGTNFSREEGLSKISFHV-HDKRIL-TGKILSSVSISGKFDEFWECTLLGHDNKFLSPQLTPIAMKIKLEFA-IRESKDFNMATNFLKDSTLISAFRVMLNDLAAYKNITPVPPQKVCKALEKEKQGHFKRLEVTLEGTAITSKVHARLCPGMDEKK--KQAHSISLTNQISSARSKNPYQMAAKFMAKPNESIEAICRGPITVNTVKVAVRAHLLHVFVLLYHSAVVAEDKIQVAKPIRAALEAVIVAGSLSAAALLQIGTAAFDLGPDSLLLIKAKLRVATITLALHLGELSVSKGPLIATAAAYPIARMVFQAIFIFGNFFL-QAVKFSLKNPFIVYKLKKSAVDFEKAMQLVGVARQVYMLEL STRAIN: GC1219 (SEQ ID NO:4)RAVFSTIELSSIIVKQLVEQDISEALRANEDREGPARPKRFFPIYTLRAAVVNLITIDKYIFKVQIIYDKALKELKVKEDILYYDTIGQETLNFTDLESKRCFEVKVVLKALEIEDAVMQVALKDTLQEYNESLRRTKLLLPDFERNVEVDIFQFTEFICQFKVIHKVEEKLASSYLVDVGNIEDNDAVSIDDCLELR--DVDLEVGAI-LDVDCAKAAVASGHEREAFEKVEEYEEEMIYYVEKEAMIGLKLSRVHRLGADFLDRQAINAVFRAAI-LIVMLMRYCDFR-VSELRTVSPEEANGAGYVLKSKELTALIGNGLCRPKYKDGSKQEK--KLVLIEDLNMDNSMAKIYVKSDTIKATSVSTTADIFNIIKAHKSIRQTNARLRAKRKRA---ENAFSLDKLKKNIAGNKLAVISYCSDKLEVNYLDDSFIDTVNATFHTDTIGLLDPGIEEER-LLIIARELFESPGFMMEDLFDRAVSYNLRGSGRFMGVVKDIIHNLCIKIAKALKPLKTHSRRSLQDAELKEQPGNLNAAMCIELYVIQFKAKLHHSVEFDLLVDNNGGEGKVCEVVKDVLVKRLIKLIKDEIKVALVIEVKPADKADAVINAPLVLQATKGRIGLQREKVLLLMLIMRIAGTVIGANRMGDAIITLGERMNRIWADNMTLRKEKESDIFQQGHGVVSVRVSLSARAYLSFDLISNDRIDSY-IAKVTPPALGDCLLAEAVYGSIYPVKFVVIVAGYDYIDFKR-EYIELPTISTYGIYERAEIRELVPSEVILTAKTILKAVMAVAQKEDFTATILKASVDCEVNNRTKIGAAGPFINLAADRRDRERTMISNIVYTDSIIRTEDYLTGAAAVVPGAADLAYKEKQERLLVKRGKIVVDQGAICQVICNTQVLDDKPSIDIMYGTLFAFENLNAFINEPISKNNIVDREKQETFLDVV-KQAQGLSRLFKYEASRYGRPDFENNVVDGDATSIFGTALTDPPPLDLRDIHFSP-HSKALLVENIVLDYGEIVEEEVGRMELMLLLFLKNENFRFVELAMAMKGCEKEIQAKEANIRVKTQDYCNKIENDEMILFLDVEE-DWNRKENHVLTMLTGFGIPFPFLKVAVFHGEQFFVVRIIGFLKEVDDVTVKYRIPGVASKLKRDAQAEGTSGIFTVAKGDKVHVNVILPVLSAQEVFTLKAIENWGRKAKQLEFKPVTLERILFR-R-YPIEQGEIVQQKQKVVVRQTDLKGLEGKFELLANQRIIMKAVELLLRIVVLT-HLIIVTCAIPASAASALCERSMSDVGSAYEFKINYVKKEQINNQGT--KLDHFMEMPSPALMRSIVFFITFARKIDILMIVS-LIRFVEMLSPYYRTAHKMGGKQLVVIIQYLYTVILRKNTRKIFLCEHENCDVRLNLDSLLIAVQCFKAEVLYSVMTLHFSIDSVDYVMFKIMGFNV-EHEMETALENKQYIDKIIFWFVPYNVLYRLQQFFHIPMLLNGIVVSQFQTSRRAYSAKESRNSDETRHVLDDIIQNIEKRTVKFLILRLEGITFEIEKLSHSSLDLEVAKTDYYKTAAAMAVKMGKYCIELSNYPPLNYTMFMWDLGKQRVEGQILFLDDSVGEAIALP-PYGLQKSINDISAKGITLVVPAVIKSTSLPY-EDHLTFCVDAGENVEGGLGAKPFSFLEIQAHVATQTVIGALADQNILEITKDRLEHLLSVLYLN-A-VSSGGLDVVGSDHLDIEKYNKEQLAEVLLLQYTLVVVSLVLVVVKYPREARLVYTIEMKG-DIVKRLFEAIAQFRYGLFIHIADIYNPDLFKATVTFYLTTKVEVCEAGEEKSDLECASLIGLCPETEQPVVVQMILVESKENQPIAGLIDMNESLHANNSLMLWLKWVVNPVLVGRSIIIKLDVNIQESLTPTLVVVEFDLIAADEFVMPTEPSEDFDRCGIGVINAEKKN-LIITLAISTGSFVQSKGEL-DEEITLLCVIMWGYKGYALFTAGLMIELVGIVNTKFAFVTMTFQLNLCNKNKCWWKLVYYDVMDIYQSSDEKKTKFGFLLLVPYCRDVRVHDYQQVMRMFMAEVGDMTQLEWRFDLLAVLALILPTYPHLPVLLPKAQLVWQWDVHDDMALRDWIRLAKVLSQAITNMVAADKTKQT--TCFIESDMLRIESRFAKFAIMDLIKYYNDLEVVGVVAVEVAKLCYKVFVKVLHRVSYVLSQLRYEKREADTKVTMSDTAVIANAQEEERVQRMRIGFQIVLSPMTQIGVIKKGFFQVVMYATTTPARWKELLIVIGITEEKANADSAEVKFIDLKTLELFSKFVLKNSPLDNQQWLALLIDGFGSYPNIRIRWVSFKG-G-QI--FTKDDFVSKKEQKVEMSNPQPRVAARLQNEKELPRIRTAHPLSQLVLAFKGENMLEFLYQAAFGRSAESLEFNEELL-LSRTLLRKKCICVEIVIQFHVRIVTFIRRIVARIEEGRII-SGPQTTEIGKESGDFADFTYYAMFIYPCNSTVHASDTSAKAAVIITKDSDIHFLDDQGPSEPRVQIELLSFKELVLALYRTEELKEDVLTLSNGTLKDIKSILTLNTLLVGIAACLILQIAGGVEYLSRGGVFKIRFPMNCMIKLALITIGVRDTEMSLRISNELSLQRISILATLLQYPGIFADRNVKLKVGYDFLLRDIDILIFNSRLDGVVHAAIIVGKKQNLIAQKVLTSVIIDAHKVAAVQQFDKLPKLQATVLLGVLSQKICSQFIEAKGSVLFLTKSRLRSPQFLT-VISILLASIIIVQSGGLASGFQIMGRKTTLSLTVIVLSIIT-YRNRKVSQLEKTTVYVAPGPPLRLVDQYGEVPSFIEEELVPQVEFDKYIQNGLVAPEVFVANNLALIFGEPNRLFKKLLGQTT-IILVVKNKYERNVAVAIARERLKTFGPMGAEILIISPVKFK-ADNDRLKKAVQIE--KDAV-DATIEVSTVDISEAGEMNTTYVYIKESYLYKVSWPTRAELAVVMFSLIAALIVVFVMFFITLGAFGSVLVQKRYLSTLMIEGVRVVQWANVKNIRPVQHRHQNILIWGTLKLTTSIQLKTKQIAALATGAENAEALVVIEVYGGKAKAASYLAKMATIMGSQAKKISVKHVFTSDYVAAEICAMLRPKKQKTGKYTGNFKEVLGNIRLRTVNYSIVMDASHPNILVKENVTAVWGEIVKLAFGGQRPHTGEVITAKGSPLVKIARDAGVAKQLPKRFLKTFEIFSLKWKIKSVTVTEPKISIRKTSDAMERPVVRRIYGRKVKNTGYARKRFQNARGLSRMAHINKDVNPEKIEHAMNPMIDGEKVNQIKFSATAATTRDPVEKQRRREMSRVTLKLNNPTRMRVDIRMVFEAAEKLIAEQEVSSVDTMPAGRKRSNTIKGTLTTKEKESKYTTARAKLKDAQAQLFELSGSWDQARENDVVLVFMAEDIMIDSKSSNVIAIAIEDENMTESLENTMKTVIAVIETAKVLLRKNFTPVCIIVNWDLTGETDKLRVVKNGLNMYLKPESTGTSKSSIFMPRNINAIEKGNEAGISVLNSAVSEAAAHGNAGKVVKNAVEGNVKHTPAPQGIKEHVAGKLEKVYSKSGEVLVKAEFHAILALSDTRLVTGRIESVKVNVFHVLAKTFDIFV-FVHSDILKRSTISAIQPVHSASIAILEALSLDEAYMACLFYDGPMYQLA-VSSVADGMIANKIIATLEFDNIPSLLLVMSLLLISQISAALSTRKSFSANKLTQLLDTLTQLAYIEARLLLLTA-QKTRGRMGFKSKIRQQWKPAEVKNEGVPVTLIEGVPFIKLQPTKGAKYTSLIVRKANVHVRCPDKEDVEKGMSRGVHVPIFYLITVFTEKSTKKQNDGISLVVGSENQAGIIMPGLNMRSG-KYIR------------------------------------------------------------------------------------NENYGENLYNDRAGLVFAIEEIIEPARIGKLVEDPGLKREQKMDRVYAVELESYITKAIDLADLQILHEALFIVEHNVMSSDAIQSIIINDTFEYDNRVVQAEARTETL-GTTEHIVRLGDK----VQIGVPAIEKQFKQTYAVVTQEKSSQPRAIDVKCSMMTSITK-----KTIFDFLFSLRRMWTEIALALSTIPNTIAKSKTDIVEAIKRNVDILEEAEGDQQKAVLEKYIVKIFQAVISKEKRPEVDLREKSLDEPSAAIEAEDENIEALIIDSLTTTALRVIEYNKLIQVITPAFLEINTTNSTEASELEARIRLEAMRIDVKRLECIASPLLSIITEGDFLDVCIAPIIEKDVGKLHEQKAEFKKRFLNLSLLQGIEAGIASLIASSAPIIQMSTNFKRTFSIETKEIDTEIGSLFDNILNGAVRLTQRTKQGLYI--MAGGDCFIVENQKSALEFHSLTLGFVLKEDARMFVVFYPEVGSGTTILVLIVLIEERLEAGSTGERVPQDSYFDHVKMKLFELGGDMESKSNDIPRAEIKALEIRYTRERVDGVELITLNYTKGDDANEELVGTGTPPPQINARSFYPNCSRLIVIVALLKKLDAQDGLVSNAGLEPQCNRELTQVALLL-ACDFFLETHSIYWRTHLIGMIPGILSDLAYMSSFLNYISIDDYTSGDCGFNFTREQGLSKISFSL-KDKRILETGKLLSSISISGTLEAFYEKTLKGDDNKYLSPKLTPIALQVDLEQAIIREVKDFNVVTNFFGDSTLVSAFRVIMNSITAYPNIAPIPPNKACKALEKEQPGHFKRLEVDLEDAGVTSKVHTRACPGMEQKKKNKQAHSISLANQISSARSKNPYQMAQKYLVKPNESIETVCKGPITVNTVKVPLRAHLLNVYLLLYHNKVVKEDKLQIAKPIKSSIEAVIVAGSLSTASILQVGTAAFNLGPDSLLLIKAKLKVATITLFEHLGELSVSKGPLIGTIACYALARMVYHAIYVFGDFFLVEAVKYSLISPLVKYKVKSKAVDFEKTAKLVEVAREAYLLEV STRAIN: GC163 (SEQ ID NO:5)RSVRYTIDILETIVRSLLGKDVAGIHRASENKAGPMLKRAPFPILTIRAASINMICIDEYIMQKQIVYQGVLIDLKIKAAVMYWEAVADAKFSGVAIETKKLRGVDMVLRAVKTAEAVADDAICK-VKDAAQQLRRSAKVIPTLDMAYKVVTAAFPFMVVQGKIIHTVRPTVEMGRLWDVEGLLDRDTMDTDTCLDLEADPISLEVGPL-VAINYDDFAAMTDNVRAALLPMDKI--LDLVSMQKFVVLGV-LCDLHRLSAGVLDREALTRILWATTNSIVLLGRFCEFCKISEVRNTRPDEKNSAHLTNRNKELTAMLSHAVCRFKLEDGSKQNQTVGLLADEELTMGHEYATVNVRSNTINDVSTSIQAQIFNIIFPIKSKVQAAAQAHKTKKDAAIDNDTLSIDKAAKGIASRIMAAISVVDNAAELNYRDPLVIERAQALYGHPLVSLLHGGMREEALLVATAKNIWP--GFYIADCA------Q--TNSLLLGVGAELLKSMTLEITKDVSKMLDHTKRAITKVKLDEPNGARAAEMALELYITKYRVIVEKAVKFDLAIGEEGGEGTSAKVGKKLNIYARITYVGDIIKVQLSISVSPADTAGYMINASLVLQAAKAGLGLLTGTIAQRRKIMEVAGTVIGLPKMQNSFISHAKGLEPIWADDVTVNRAREIAII-KDRLGLTLDVTLDAKVYVSMDILRAERADGYSMAKVTRVNIGEYPIPEEALESIMPQGVYQMIISGGYPSFRAQYCIKKLNVPVATTVMTATEQACVPSRAIFKASLIVKAVSEIPIRFELETKLAGVNKDVEVFNRHSLQQLGPYFKRGCAARDKSRTMCSNLIFLGRTVIDEDYLTGALSVLPGVYELEWEEKETRRYAKKAQVRLKSTVLTDVIATSQVLDYSPSVEVLYSNIFAYEHLNAFIDWTFSQNHIVDAEKKSSTLAAVNKRAAGIDNLIGLAKRRARRLSQEASIVDGRVSQLIGVFCVDGELAKCAPISLPTLQW------------------------------------------MAAEGCEKELLAYAANAALMEDNFTVGVNNDAVKIFFFVQEEDYNITEGKFLAVVAAFGIVKPLLRFYVFKAEEFLSALVLGAGKQIDEHEVSYRFPKAADVEAAAAKAEGTGGLHTVAAGDKAYFAMITAALDEAAVFKLIGIIEWGRRADTVNFTPFELDIMLIAEREVSAEAGKIVGEKAKKVVRNITLNKLAGKFAVLAEKTSILKPVEIVAKAVVMTTHVLLISAGIPKGPVSALAVRDLSDVDSAYKFKIAHLMRSIAGTDFIQRKVEAYDGLPDPVVINRITFYVTFADSLDRTFLILVVAEIIEAVGPMWRTAADLSGFRILTVIEYLFTVILRKSTKQIVQCGGSGCECTLNVESLFAAVQCYQADVRFSVLIIIFDMSCCKFTIFGLSGFHTEAHQMETGTANREMIEVLQYYIDGITVLYTLQQFFHVPLFVEHLMITEFPGKRALVESKSQDIGSDKQGAIDDIVQNIDKSDTVFLLIELGNVTFDIEKTSTMPLDMEA-KIDVFKEVKFEHITM-GFFYKDE-FPIYNQTIWAWVRSRINVEGDLVFIAKSVGTKVWLPCPYLLQTAMEDIVQKGITSTVAAVIALYQLVFNPQFLKFTLGVYFNLGGAMAAKAYTFFKALKAKEKAPVVGALANMGTLELSIERIQMMFCCLIFNSVMVSSGGRIVVSTAVADMEAVNKEKLNEIMLLGFSLVVLLLVIAVAQYCRKAPFIKFIRDKR-EVGKQILEKIEQFQFGLYTQVTDVIDPDVLGSTVSQNLRTGLLMVNLGTEKAYIECAQMAGEALETEEPVIVKAIIVVASDDKPEASLLCMDRGLGTDNAIRVWLALVIRPVLVGKAIIYKDEPMTLAGYTPALIVVEFRLIMADELVCLMSPEDDFERCIIGFVDLETKG-VTLGVMVAVGSLLDGGDK-------------------------------------------IGDLEIFAGGDQLRFLIHYNTFTFDHKLDLTSDDDVFQVLAP------------------------------------------THPKLAVTFPTSILVLKWDVEETTHATELIRTSPVIEVEGTAMVAPEKVAELAETIFIERDMLKVDDTMGKLGTVDLIDFYNNLKIVGVTIIDIAGLCYRMFIKLFARMRYILVHLNYEPSRADEEQKMADTAMLSNTAPNDLLRSKQMNMKVVISPMLQVGVIKKGFSEVVDYAQAASARWRSMVITINFNEESGDVDAMEVKYIDAKALEPFSRIPLTNSDLSNYAFLIGIKEGFGGYPMGR--------SLEGDGVCSKRDYVRKKSQRVELAEPEDAVGCRLRSRRDVERKLTAHPVAALILKIRPESKLPFMWDARFGRSGETLEVEEEYLAFKRGTAHHRTVCVEPVFEYHVTVLAYLKRVRASVSEYRLS-VGRQTTEISMNRNDYAGYVAYAFVIFPVKHTVEISTTIEAAAAIVTKSTNINYVEQRGPDDDESEYQKATMGAPLVASLRTDGIKQDILTLANGTLEDIKSILTLLELLQGVDALLLLNLAGVLCYLSGIDFQSYRLPMNALLTLALVTIGVKAAVMALQFTDATHLHNVSVLLMIIGFPMIYSQKTAKENMGFDFIIRT-NFVIFNTSLAGIFRSAVVAGQE-KVTEKRVISKVIVDSNPVTLV-SADRL-AIGPAVLAAIVLENVASPVIDARSSCVFVDFARAAAEDFIQA----ILASLVLTQTGQLSGAIGNNATPADLIAVFFVVAIACFYHNAEICDKEMVEKLNWRGPPLT-MSDAGDVPEFVEAEVLPQRAVNMYICDKLVAPRLWATDVDAFAKEQPRRFLNGVVEGVVPLAMIVTGQYDQ-PAIQIAKETVKAFGPMGAALIIIEPVKYKQAPEDRLQAAVQGSFRKANAEIESVGVAAIAISEGDEMRDFYVFFRDTKLKKVVWPSKQDVTVVLVVAIAVVMLLFVLLILFLFSFGSILIENQYLRIFQIESGNLGTVANFRPTKIVSFR-QNHVIWKNLTLTNAMELKYKIVAALCAPAKGAEGFYVIEVLKGKADGARYMRDMDQLMGPEEKKVKVKRVVTCDYVGAKMAAVK-PAKSKQAKFIGNYKENMCNFRLATVNYQIVSKLGKDEVLVK-NVSAIYGEIEKMGYGAAKPPTGEAIKAMRSPVVAFGVSAGVGKDLPMRLVKVQKIVEFNFEIKTVNVLEPRLGTRKTADATERAKTHKMYGKSMKQQSYARKRFCNARGMNTMGKLNKEINPKAL------------------------------------------ILRYRIRVSVDIRKIYAACLKLAAENDVAEVCPMPRGLKRTSTILSELETKVDEKVFTTEAGGLDSARPMLYKLSGGWEETRRNDVVMIWIAPAIMIDQQDTIDVAKAVEKEDCRQSLTQQVKRAVAYLTSAEALLRKDYTPVCVIAKAQISKKQKEATAISNGLRLHLHAKANGTAKASAFMPRNIFIVNGDEAKGVKVLNEKVSKEKAHGISGHVPAGVVEGNMKHVPREQGIKEYPAG-VKDVVCKCGEIALVVEAYSVISAADIELVLGQDYAVRHVLFYAVAKSLDLAVVALNTGLAMDCIFADIQEGHLAAAAVGEGLDLTQARAAALYFAGSFRRVIACNALKKGLMAENALGSMAFNCKQQMLYLAQLAL------------------------------------------LRVRGRMGQVAAIKGKWKPAETSSEYVVVKVLADVDETRLHPGVKSKYDLLTLRHADANVRAGPAADVEKGTDRGAHAALVTIITTYSEKKHRRTQTDISVVVSKKNRANLVLPSMSHRAVHLLVRSSIQIEAMRGTLIDNGVVSEYDIIEPISDILMKWQDLGYAPLTIERHPFCGSKCLIAAFKMFRVLKFMACAVEVSTEVPAEQARNDTKGKNIYHDRVNLIYVVEQLIDPADVSKIVDDPGNKKEQKLERCYAVELEDFISKAVLVAAMQLVRENLLVIYTEDTSSGCVLDLVVNSPFECNINVVGAKARAEQLPGTTSYLVKAGDPVAVEVQIAVPAVAKEFRKTVAITTLKNTSKPKALAVEAACMTSVTERAEFLEALHVFLLYDDELWMELPLALFENKGAVTKGEQGVADSIAIIARVWYESEGDHEQAVAERYYVRVLKSVVEKPRPDQLDLAEKALQDSSGLLEVEDNNVECLVADSMTTVAIRAVEYGRLIVVIKDKYLDNNTPKETDAEDVDSGVSLESIRVDCRPLPVVTSRLLSVITKDNILEHAMAELVGADTGSLHKKTEDKEKRLVGFKILGGVKHGI--LMASDTQVLEFGTNFKMDYDLKTRDLADEVGEIYKNLLNSILPLISEAQEDLLERGVAAGEAFIFEDQNEAFA-HKLLVQYALQEGARALRFYFDLAGDGRPAIVMFVFLEPGPP------------------------------------------RETRYTGDRADGVELVTKARGKSKDAREKIVGTSKPLSGVDARQFYVNCIKMITIVALLIKLDARDKAVAAIALAGRAHSELASLALLLGAVDFELGE-AGYAQIHLAGAIPGYLSEEAWVETRHSIIVVDDLTKANLGVHFTKMEGLSKVSFSLEIERQGVGTMPL-ADVTVSPGREEVHFNTLKGKDNRFTTPHLTEIALKKQIEALVVRTCHEIRVVTKFLDEHTLTSRFAVFSQEYLIDPNTTKFSPRKEVKALEVAKAGHFKKLAIDFAAGDVVSKVFEVAIPGMVQKKREKQAHSTTITDNVCSSRSRSPFQSAEKIMVEPAESLETKCRGPITVHAVKYPVRSHLNAVMNLMFHQECIDTDKVQYAEPIREAVARTKVAGAVNAASKLRIGTAAFAAGPNALVLALAKLEIAQVGLYEHLMTINLAKELCAPTAAGVCLARAVFHRVFLVGDLDHITAVVFTPWAPWAKYHVKRANVKFDKALGLVTFAGAVYLIVL STRAIN: GC1987 (SEQ ID NO:6)RSVYVTIDILETIVRQTTAKDVAGIHRADDYKAGPMLKRAPFPIMTIRAATVKMIAIAEYVYEIKLIYGNVLVELKLKAKLIFWQVVNEEKLSVVDLETAKLRGVDKVMHAIQTEEAFAEDAINKAVQAAADKQRRTKMILTNLERVFKVKTFSFPLHVELKKVIHMKEPIIAKGELVDLEGLYDKDGVNIDDCLELEKDPIALEVSPID-----ARMDAVALQDRAKIKATEEVTADLIIIFQKMTVIHP-LCTVHLLCAEFIDQFYVGEVIRAETGAIVLLARFCQFCRISEIKNVREDETNGAGFARRSKELSVLVSCAVCKLKYAAGSRQDQ--KLLIDEKLTMGHNFAEVNIRSDDTEDTATSTQAAIFGIISAIKSKKVINKTLRKSKKIVAVNGEVLSIDRAIKGYVARKLTVISVVDNEREINFRDPLIIERAQAEYGHSLASLLHPEEFRQEA-LIIAKQVFGESGFKVSDIY---L-----GDGIVLGIAPIFAKTLTLYITKEVRKLLNE-EVAVAKAKMDEPNGAKGAMEVLELYITKYKVIIEKAYKFDLVLAKEGGEGATASVGKKVVVYHKIKFVHDEISVDLIIEIKPADRKNTLINAHLVLQATKAQIGLQDEAISQLRQIMSISGTVVGKPLTREAVITHASGLEPIFTNDVTIRRNKESQIIEKDRIGTIVETTLKCKVYVSLKMLNALRTESYKLAEVTSPFMGDYYFPDFCLDSIVPKKFALFVAGNDYLEFQARSYLRRENISTLVTYFKAAEQEMVPSEAILSKPTVIKATAEVTIKFEIQAALMKCSKEIEIFNRHAWHEAGPYFDYAADANDRQKTMISNYVFMQEVVITEDFLTGAIAVSPGVFELEFMENEIRKLEKLGEIKLDGSNIADVIAKNQLMNQFLHSEILFGNLFEFDHVNAFIAYSFSKNHIIDREKKESFLAAVSAEAAGVDRLIHLEQRRAKNIDRETNIIDESFSAIIGVFTLDGTLRGLKAYGL-PMETSEYIFDEVVQLVADKEEGFLAALLGAAMYKMDASAEKGMRAMMAAEGCEKELLSLKANVAFFFKQFEIGINNTVIILELYVQPEEWNITREKFLVIVTAFGIPCPLLRFEVYHADEFLVALIAGAGLQVGDINASYKLPKVATLQKEKAQKEDTGGLFTVVKRDKLHVNAVLPALDEGAVVQLEAIVDWGRKAKSFTFEAAEIEILLIRDREVSIDRKKIIGDKARKVVRSITVKELKGKFKIMAKKSVMFKAVEVTAVVIVLSTHVLIITAGVPKSAVSAMAVEDISDASSAYEFKICHIHRSVAKAGFIERKTERYDDMRDPVLIPSIVFYIRFGDKVDPFWTIRCLVQILDCVKELWRSAERLVGNQVIVHIQYL------------------------------------------SVLIIKFDITS-DFTKIGLSGFAADKHEMETGMAQKELLGNIEFWIQPIVVLYTLQQFFYIPLFLENLTLTEYVGKKKCLPTSHQDANDDKQNAIDDIVQNIEKKSDLYLFVEFADVEFEIEETSINVEDIEIEEESFYKSA-KYVIEVGAYLVRLCFFPALNYTAYFWDRGKTDVEGDLVFLEEAVKDKTWVPCPYLMLYSIDNVLTKGITSCVAAVITLYQLVFNPEFLKFAIGVYFNVGGRMTCKAFT-FRTKAQKTAEKVVGALAGMGLNAQSIERIQNMFGCLVFNTVMQTSGARIVVTSDTVDFEAQNREGLGSIYFVKTELIVLMYVMAVANYVR-ASCVDFIGVRK-KIEKQMLEKIAQFRKTIFIWVTEINYEDVVHTTVTIDLTTGIRMVNLGEAKAYIRCACMTGLALDTEEPVVIRAMMVEDKDNKEEVSLICLDRPLHVDNSMVIFLRWVIRPVLIGKAIICKVEPEITKGVTPSYIVIMMRIIMADQLILVTRPETDTENFIIGVLSARYQCPFVLNFTV-VEGIGEEGGDLVPQQFSLFFGAICGYKLLQLVTGAF--TIPGVSSTKFALVG-PLAIQIVLKSEGYWEFVFLDLATFYQFPEEKKVEFGFLVLAPKCNMVSVNDYQIIMRMFSAKADDKVMLEWRYDLIALLSAIVETHPGLPVILPKEILILERKIKDNADATEWIRLAKVLEQRADRLLSAERIKELEETCFVEANELRMDDTVGKMGVMDLIEFYNDLYIIGVVIVEIADFCYKIFITVFDRMKYISSLLLYVKGQASTAKNMADTKILANTVPDNRVKSKQIGMKIVLTPMLQVGVVRKGFKDIVEYTNNTPPRWAENLIVIVFTEEKAAIDALETKYIEKKTLEVFTQMVTSNANLTNQAWVILIIDGFGSYLMGRIAEVSFRGELDREGAFCKRDFVSKKQQQVELSEPQPRVTCRLRNNKDIDRPLTGHPFSLLVVKFRQ-DAIRFLYEARFGRSGETLGIEDELLGLAGSQAKKSTVMVEPMYEFHVHILAYLKKVRANVDESRLERVGKQTTEIGMNRGDFIGYTEFSLFLFPVRSTVEISTTVTQAAAIITQGTDIYRLEDKDADEPEGEASKLEFAPLLIALFETDGMSEDVLTLSNDNLEDIKSLLTLVNLLVGLEARLTMGLSNEVVYLSRMEFSQYRFPMNAMFELALITVGVKQTIMALKTSDVLHLKKVTIFLIVVGFPMIFAQKTSKEQVGFNLILRS-DVLIFSESLTGVVREAIVVGQERRLVKKKVLSSLVVDSNAVVEVKEENKA-ALNLCSLAAVILQNLKTPIVEAKGSIVMIKFARLMCEEFLTKMLTVIMLAVAIIQKSALGAVSDYWSNSVELIGLFMILALINVYHNKEIFESQDVEKVNWRGPPLT-INDEGDVPASIQENLVPQ------------------------------------------LAMIVNPQYKQEVAVHIAEGQLKSYGPMGVELDLIAPVKFKQGPKDRVNAAVQGDFKKQNPEPESIGVSAVEISEGDEMNEIYS-FADYKFKKIVWPTRIEVTTVIVSFIGVIICMFGYAIIYLGGFGSILIEQRYL-VLTVENYSVG-TSNIRPVRVLAQRHQNHVIWENLKLTSAIALKTQAIAALATGAKGAEGFYVIEVL-GCIEGARYLRALKDLMGPEEKKIDVKRVVTCDYVGAKVAAVK----QKMGKFIGGYQENLMNYRIKTVDYQIVIDVAADPVLVKDNVSAVCAEIKMIGYGSSMPETGEAIRTLGSKVVSIGTAAGVGKELPLKLIKVEKIVGFRFEIKAVTVMEPRLGTRKTADAMEKAKLRKVRGRSVKQSAFAKTRYVNAREISKIGKINKEVSPATL------------------------------------------TAKYGIPAKVDIKKMYLAAGKVVAENDVEEADPIPRALKRSCTIMGELTTLVDHSPFTTVSGGIDESRPKLLELANIRDQSKINDVVIVFICEAVIIDNQESNVIRKAIAEEDCTKSLEEEAKTGVAYVETSEVILRKQYAPAMIVVKLQRSGERKTVEAVKNGFKLHLRPESRATAKQSCFMPRCRNAVDDDDNVGISVLEDRVSQEAAKGIAGKIKKNVVEGNMKHTPAQQGIKEHYAGMIDGVVAKTGVIAVIIEAKAIIAIAPFDFVLKPIQLVDHVVFKVVAKSLALALAALNSCIAERCTIPDIDAIHVAAAMILAGLHLTAARKAAMFYAEPLKRLSKLETLAVGLIVHGAYGRDRFHVIKEIILVSGVLI------------------------------------------MRVKGKMGYMATINGDWKPIGTSAEYVVVKVIGGVEEKRLHPGSKSMYDILTARHADAHVRAGAKADVDKETDKTIHVSLLVLVYTFTERKTKKINDGVTIVLGPKKKGGTVLPGMVHRAIRMYVRQSVQIAAMRGTLLDNGVVSEYDIIEPISDMLMKWQDMGYASLRIEQHSYCHETAMASAFGMFQLIKLMVAAADVLAPVPGANEEHTRQGENVYNNEINLVYVIEELIDPVKVQRIVMDPGESKEQKLERTYAVELEEFISRAVNVSDLQLVRNNLFIVRNDDTSSQCVMDLVVNPSFETHINVVGAEARNSPLDKTADALVKAGDAIFIEVQIAVPAVGKEFKATVQVTTLKEASTPKALAVMAAYMTSIVERARFYQVKFDFEVVADMAWPAMNLAKYETPGAVAKSEAGVI-NIKVSAKCVEPPVGDQEIAKIDAYYVQILKALIEKEQPDHLDLDEKALAEPSSLVEAKDDNIETMVIDSLSCTSMKVADYKRIVVVIRDKYLEINTPKETDAEDFESGINIEALQVDVRPLPVVTSRLLSVIVKSDILEHAMADLVGIDSGSLHVKSEDKEKRLVGLSLLGIIAMGVD-LMYADATMLKFAMHFFSDIDIDNFEINEEIGEIYSDLLNAMMPLLCESEKGVLESGIAGGEVYIFEDQNEEHEFHRVPPRFILTKEAELYKILIPLEDDGVTAVVLIICIQDRLEAGSTNERIP-NNYFNHRKMKLFDLGGSLDRKKNDIATAEIETHETRYTGDRADEVELVTRDRRKNSNTRENRVDTTNPLNGVDARQFYTNCVKIIVIVALLPKLTAHDGMAAELQIESELETEVEKLALLLAAIDFFLGVGGEYAAIHLCGLVE-ILDEEDWRAEKLRRIVIDDMTPGDVGVHFTRREGLSNVKFSVEVKRQATETNLE-SGVSISEYHEDLWENTPRGNEQKYVLPNLTKIAMELTVETMIVRTVREIVVVTSFLGDLLMISKYAVVTRDILIYSNTVRFSPHKEVKAVDAEKPGHFTKVNEDFAAGDAVSKTYMSHSPGMAQRK-DRQAHSTTITDNLASARSRSPYQMADKSLIEPSEALDTKCRGPVEVNTVKLAVRAHLLHIYKLLYHPAISGKDKVQFAEPIKVAVTKVMIGGALAAAAKIEIGTAAYDAGPDALVIVKAKLAIGAIGLAEHILDIAAAKDPIVATAA-IPMARNVYGHAVVLGDFILIEVVVYTPYSPWVKYKVKRAKLELSKKLKLVGVARPVYLVKI STRAIN: GC203 (SEQ ID NO:7)RAIFSTIDLSTIVVKQIAEKDISQLLRANEDREGPSQPRRFFPIYTLRAAVVNLITIEKYIYKVQIVYDKALKDLKVKEEILYYDSIEQATVHFVDMASARCFGIKMVLHALELEDAIMTA-LKDALEEIEEKLRRTKLLIPDFERTVEVEIFQLTYHICQNKVLHKVEEWLEKDFLVEVDDIEDHAGVWIEDCIELREEED-LEVGAI-LAVECDKAAVASNHERAAFEACEEFEEELIYYVEKEAMIGLKLSRVHRLGADFLDRLAITEIFRAAIELIVMLMRYADFQ-VSELRTVKADEVNGAGFATKNKELTALIGNGLCRPKYKDGSKQDK--KLVLVDDLNMDNSMAKIFVKSDSINRTSVSTTADIFNIIKAHKSLRQEETRLHGKRRRAT--TAAYKLDKLKVNIANNKLAIIAYCSDKLEVNYLDDSFIDTVNAQFGASVIGLLDPGIEAEKLLLILARELFESPGFLMEDFYKSAIKKSIAAKGMFMGVMKDLIHALCIKIAKALKPLKTNSRRSLQDAELKEVPGNLNAEMCIELYVIQFKAKLHHNVEFELLVDKDGGEGKICQVVKDVLVKRLITLIKDEIKVALVIEVKPADVANAIIGAPLVLQATKGKIGLQREKVLQLDIIMRIADTVIGANRMGDATVTIGEMMNEIWADTITLRKSKESEIFQKAHGTVSVRISMSARVYLSFEVIDNERIDSY-IAALTPPKLGDCLIAEKVYDSIYEVQFVLIVAGNHYIEFIAEEYLELPAVSTYCIYERADQREIIGSEVILKTKTLIKATMPVPNKEDYTATILKASVDCEVNNRSKLRENGPFINLAAEKKDRDRTMISDIVFTDSIIRTEDYLTGAAAIVPGVADLAYNDKQERLLKKKGKIIADNDTICKVICNSQVIDEKPAVDVMYADLFAFEHLNAFINVPISKNNIVNREKQETFLSVV-KEAAGLARLYKYEAG-----DFENNVLYGTATSIIGISVTDKEPLNLKELHFEP-RSTALTLEAMIVDYGEIVDDQASRLELVLLLYITQEKMDFVVLAMAMKGCEKEIQATDANIKVKTQDYMNNVVNDEMILFLDVEE-DWNRKENHVLAMLTGFGIPFPFLKVEVFHAEQFFVIKIIGFLKEINDVNVKYRIPGVASKLKRDAEAEGTSGIFGIAKGDKVHINVILPVLSVQEVFKLQAIENWGKKAKQLEFNPVKLERILFKDR-YPLEKEEIVSQKQKVVVRQTDLKGLEGKFELLANQRTIQKAVEVLLKIVVIT-HTVFVTCAVPASAASALCEQTMSDVESAYAFKINYIKNIQINDQGR--KLDQFKDMPNPALIKTIVFFITFARKIDTMLIVT-IIKIVEMLDPYVRTAHRMAGKQLVTIIQYLYTAILRNNTKRIFLASHPSCKVALNVESLLITVQCYAAEVLYSVMTLHFDIDSVDYVMFKIMGFNV-AHEIETGLENKQFLANLNYWFAPINVLYQLQQFFHIAIFLHGLTVTDFPTSRRAHSAKQENTNDESRHVLDNIVQNIEKHTIKFLILRLEGITFDIEKLSESSLKMDVAKTDYYKSATAIVVKMGKYCMELSSYPPYNYTMYMWNLGKQRVEGQILFLADSVGEKVALPAPYGMQKSVNDESTKKVTLVVPVVIKSTSLPY-EDHLTFCVDAFENVDGGLGAKEFSFQESQARGEAQVVIGALAKQNILEITKDRLEHLLSVLYLN-A-VSSGIIDVVGSDEVDIERFNKEQLAQVLLLQYTLVVVSMVLV------------------------------------------VFNPKVIGATVTFYLTTHVEACDAGEEKADIECASLVGLC--DELPVVVKMILVESKDNQPIAGLIDMNDTLHANNALLLWLKWVVNPVLVGRSIIIKLDVNILESWTPNLVVVEFE-IAAEEFIT-------------------------------------------NEDICLLLMIMWGYKGLGIFNAGLMIELIGIVNGKFAFTTITFQLNLTAKNACWYKLVYFDVMDIYQSSDEKKTKFGFLVIAPFCRDVRVNDYQQIMRMFMAEVGDMTQLEWRLDLLAVLALIIQTYPGIYVLLPKAQLVWQWDIHDNMEVVEWVRLTKVVSQPTDRMVAAEKAKDNGDTIFIEADMLRIESRFAKFTIMDLIKYYNDLEVVGVVAVEVYILCYKVFVPVIHRISYVLSPLLYDKKEADTKVTMSDTAVIANAQDEDRIQRIRIGFQIVLSPMTEAGVIKKNCMAIVDSSSATPARWKEILIIIGITEEKGTADDAELKYIDMKTLEIFSQFLLSNTDLNNEEWLALIIEGFGSYPNTRIRWTPILG-HQQIGIFTKDDFVSKKEQKVEMSNPQETVAAKLQNEKELARIRTAHPLAELVIAFRTGNMLEFLYRAAFGRSAESVEFSEEML-FKRTMLKKKSICVEIVVQYHVQIVTYIRKLVARVEEGRIV-TGPQTTEVGNDRGDYAGFTYFAMFIYPCNSTVHASDTRAKAAAIITKESDVHYTEEASQSEPRVKITKVKFKVLILAMYESTELKEDVLTLSNGTLPDIKSILTLNILLVGIEAQLIIKIAGGVEYISRAGIFRHRFPVNCMIALVLITIGVKDEQMSLRITDELSLQKIAILSTLLQFAGIFADRNVKLKVGYDLILRDIDQMIFNARLDGVIHAAIIVGKKQNLIAQKVLTSVLIDAHKVAAVQQFDKLPKLKATVLVEVVSEEIVSQFIEAKGSVIFITKTRLRSEEFLTKLFVILVAALCIVQSGGLASGFAIMGRKTTLGLFMVIMSITAVYRAKKVSQLEKVQIYVAPGPPLRLVNPVGEVPSFIEEELVPQIEFDKYIQNLILAPEVFVANNLSMIFGEPNRFIKKLLAQTT-IILVVKRKYERSVALAISKERLKSFGPMGAELIIISPVKFKMADNDRLRQAVQVDRTKDTI-EATIEVSTVAISESGEMNAIYVYIKESYLHKVSWPTYSELAVVLYSLLALVVGMFFMKIIIIGAFGSVLVQKRYLKTLMIEGVRVINGANIKKIRPVQHRHQNILIWGSLKLTTAIQLKTKQIAAVATGAENAECHVVIEVFGGKAKAASYLAKMATILGSQAKKISIKNVFTSDFVAAECCAMLRPKKQKTGKYTGNFKEVLGNIRLKTVNYAIVLNSAHPNILVKENVTAIWGEIVKLAFGGEKPHTGEVITAKGSPLVKIARMAGVAKVLPKKFLKTYEIFALKWKVKSVTVTEPKISIRKSADAMERPVVKKIFGRKVKNTGYARKRFQNARGMSKMGHINKDMNPEKVEHALNPMIDGEKVNEVRFSATAATTRDPVEKQKRREMSKVTMKLQNPTRMRVDIRMVFEAAEKLIAEQEVTKVDAMPAGRKRSNIIKGTMATWVDESHYTTARAKLKDATPQLLELSGAWEYSRENDVVLVFMAEEVMIDSKTSNVIRISMEAENMTETMENDMKTVIAVITTAKVLLRKNFTPVCIIVNWDLTGETRNLKVVKNGLNLYLKPESTGTSKSSIFMPRNINALEKGNEAGISVLNTNVSTAAAHGNAGKVVKGAVEGNMKSTPAPQGIKEHPAGKKSEVYSKSGEVLVRAEFNAILALSPTRLVTGQIPNISINVFKVFARTFDIYLIFVHSNILKRAIISDIQPVHSAAISILEALALHKAYLACLFYDGPMHQVANLHSVKEGLIASGITPTQEFDNIPTLLMAMSLLVVSRISAALSIREKFNANKLEGLVGTLVQLEYIEAILQALSA-QKTRGRQGFKAKIRQQWKPADVKAEGVPVTIAEGVSYIKLQPTKEAKYSALIIRKANVHVRCPDAEDVEKGMSRAVHVAIFYLITIFTEKSSKRKNDGVSLVLGEENQAGVILPGQNMRAG-KYIREDADIERQEKVLIKEGMAAHFTTVDPLASVKATRDFQSYKTLLIDKHPCCNINIFICAFGIHSVEKCTVAAINMLSDIPGTDIENQNYGENLYHDRAGLVFAIEELIEPLKIGKLVEDPGLKREQKMERVYSVELESYITKAIDLAELQILNEAIFIVEHNVMSSEAVYSIIINETFDYDDRIVCAEARTETL-GTTECVVRLNDK----VQIGVPAIEKQFRQTYAVITQEKSSEPRALEIRCAMMTSIAK-----KTIFDFLFTLRLTWLDIAVALSNIPSSVAKSKSDIVQSIRRSVDILTPAEGKQEIAILEKYVVKIFQAVISKEKKPEVDLQEKSMQEPSAVLEAANDDIEALIIDNLTTTALKVVEYNKL-PVITPAFLEINTTNSTEAEDLESRIGLEAVRIDVRRLAVIASPLLSIISEGDFLEVCIAYIIEKDVGKLHEQKVDFKKRFLNLSLLQGIEHGIANLIASSAPIINMSTNFKRTFHIECKEVDTEIG-LFRNLLNAAVRLTQRTKEGLYS-SMAGGECFMRNNQKQEIEYHQFFFGFALKEGARMFTVYFPAEGFGEAVLVLVQFIGQKLEAGSTGERVPQDSYFDHVQMKLFELGAGLDAKSNQIARAEIKALEIRYTRERVDGVELITLNIVKSDDATEDLVGTTTAPPQISARSFYPNCSVLIVIVALLKKLDAMDGLVANSSLQPPCNKELTQIALLAEACNFLYNTHSIYWKIHLIGLIPGILNEIQYVSEKLNYITCDDYTSGDCGYHFTREEGLSKISFSL-RDKRILASGKILSSISISGTLEEFYERTLKGQDNKYLSPCLTPIALQVDLEKAVIRESRDFRVVTNFLGDSTLSSAFRVILNSVEAYPNITPVPPNKACKALDKEKPGHFKRLETEFNDANVTSKVHTRACPGLDQKKKNKQLHSISLANQISSARSKNPYQMAQKFLVKPNESIETICRGPITVNTVKVPLEAHLLHVYIILYHNAVVKEDKLQVSKPIKSAIEAVVVAGSLSAASILNVGTAAIDLGPDSLLLVKAKLKIATITAFVHLGELSVSKNPLIATVSALPIARMVYAAIYVFGNFFLVEAVKFSIGSPLVKYKVKTQAVDFEKATKLVEVAREAYLLEI STRAIN: GC2120 (SEQ ID NO:8)RSVYVTIDILETVVRQTTDKDVAGIHRADDYKAGPMLKRAPFPIMTIRAATVKMIAINEYIYDEFIIYGNVIVELQVKEKVLFWLPVQAEDLSAVNLATEKLRGVIKVMKAFETDAAIAEDAICDAKKDIADKTRRTKMVIPNFERSFDMDIMGFPFHVEQRSVVHMKNPIVEHGDLWDVEGLYDKPGIMVDDCLSLEKDFIALEVSPL-LAIKVPEMVAVTDQTRENIRKTEKLD-EKLAVYQKKVVIHP-------------------------------------------LRQVKEEEENAAAYVSRNKEMSIMISCAVSKLKYKSGSKQDA----LIDEQLTLGHNYAQVNVKSDDIEDTSTSTQALILGLINAIKSKLVTETTARKSKKETAVEKEVLSINKASKGYCARILTVVELTMNERQMNFRDPLVIERAQAEYGHSLASLLHDEVEKQELVIFLARYIAEKEGFGVTDIF-----KNVTNDSMLMGLVRPLVKALTLQIAKEIKGLSDFEEVAVAKAKLTEPNGQKAAMEVLELYITKYKVIIEKAYTFDLAV-SGDGEGTEASVGKKVIVYHKIEYLHDSIQVQLGEHIGPADKAKAILNAYVVLQAAKAGITLQDEAIAQLKAVMRIAGTVVSKPLPKETLITHGKTLSEIFMDDITIKRNRESTILGKDRVATVVEVALKCKAYISLKLLSAERTQSYDLKAVADPYLKDLCVADIALGSVYAEQFPLLVLGNDYVEFKIKSYLALEDVSAMVTYLKLNDLSVIPAEAVISAPTLIKATAEVTIKFDYEAALMKCSKEIEIFNRHSLGKEGPYFSLGADAKDKERTMVSNYVYLQDVVLTYDYLTGPMAVSPGVAELEWHPNEIRWLCKKGEIRIDGSVLADIIATNQVLDEGVQREVLFGDIFVFERINAFINYTFSKNNIIDRERRESNLYAVSKEAEGLEKLISLEKRRARPVDRETNMIGDTFSAIIGVFTLDMKLYDLEKLAFSEFQ-------------------------------------------MAAEGCEAELEAVDANVTFMANEFEIGVVNSAVIIEMYVKTEEWNITEEKFLVIITAFGIPFPILRFSITHADEFLVSLVVSAGLEVGEVNVSYRFKNLANLKQEAAQKEAEGGTFSIKEGDRPHLSAVVAKLEDAEIVKVTGIVEWGKRAKYFHFETTEIEIILVKE-EMSLQAEKIIGEKAKRVVRNITMNKISGKFQILAEKSSMVKAVEIPAKTLVISTHVLLITAGVPKAAVSATAVEDIGDADSAYEFKICHIRRQIVNEGFIERKVERYRDMGSPVLIDSVAFFIRFGTKVDPLITVRTIAEFIEALGEMWRTAERLSGRNYVVFIQYLYTVILRTNTKRIIQVGHPDCDAELSVNSVLIAVQCYDNDVHLSVLIIKFDISCCHFTVFGLSGFKVDKHEMETSLANSELLNNLFFWIRPHTVLYTLQQFFHVPLFLERYRMTEFVGRRACMQSDE------------------------------------------TVEDMKVEEKDFFKAV-KYYYCKGDYVIALCFFPALNYTAYEWDRGKTNKEGDLVFLEESVNAEVWLPCPYLMLKSMDEAI-KKITTEVLAVIEIYQLVFHPEFLKFTYGVFFNVGGGMCAKDFT-FKEKAKREAEKVVGALADMGMLEKSIERIQNLFGCLVFNSVMFQEKAPIVVGSQELDMEQLTRERLNEVFMLGFALVAIMKVLVVAKYVQSAPFVYFVDARE-DISKQTMQEIEQFEENLFIWVTDVNYEDVLKTTVTLDLVTGVEMLNLGEEKAHIRCKCMVELSL-TEEPVVIKMIMIEKKDDKEEVSLIKMDRDLHVDNALDIFLRWVIRPVLIGKAIIIKVEPQATEGITPAHIVIEMR-IMAEELVLVMEPEDEFDRCIIDFVDAADKGMMIVAVTISIGSLLKK----VPQKISLIYVIVGGYKLIGWITSAF--GIPGVSVTGFAFVA-SGEIEIAAKSRGLRKTVDYDLDLPYQFGEENKVDFGFLKIAPKCSNVSVNEFQVVLRMFTAKAADKVQLEWRFDYIAILAQIVPTHPGMFVIYPKECLILKWEVEETSETEKWIRWAKVLSQPADRLVAPERIKIRKETEFVEKDELRMDDTSGKFATVDLIEFYNDLQIVGVVAVEIAHFCYKIYIKMFDRMKYISSLFAYVKGEAATAIKITDTASLANTIPKERVKESQIGLKVVLNPMLQAGVIKKGFKELVEYTQNSPARWKELIIVIVFTEEKGAIDGLEIKYVDAKTLEVFSRMLMTNSDLTNQEWLVLIIMGYGCYIVKRNENISKYG-LNRDDSYSR-DYIMKKQQEVELSDPQDRVASRLRNHKDIARPLTAHPISRLVVRFRK-DIVYFLYDARFGRSGETIRIEEMLLSLRASGARRKTIMVESLYKYHVRLMTYIKKVRASVDELRLETKGQQTTAIGMDRGDFAGYVSYSKFLFPVKSTVEISDTVAKAAAIETKDTDIHYLEQYGDEEPQDRLKLLAFSPTLIAIYMTDELKEDVFTLANGNLEDIKSLLTLVELLVGLEARLVLQLAGGVVYLERALIRNYRLPMSAMIEYVLINVGIRDEIMKFKISDFLSFKKVTIIMLVIEFPVIFADNTSKEGVGYNLLIRKSEILIFVDALNGIIYAASAKDQEPRLLAKQVLSDFLV-ANAVTAV-SVNKL-NLHLATLAAVILDNIKTPILDVKGSLVAITFSRLAGEEFLTITLLILADCITIVQGSALGTIASYWGRSMELFLLFIVLAALN-YHNKEILERQEVEKMNWRGPPLTGKVDEGDVAETIQTALIPERAINMYICDKLVAPRLWMTDVDTFQKEQARRFLNGVVEGDVKLDLVVNQKYKQNAAVHIAEEKIKAYGPMGAQLMDIQPVKFK-------------------------------------------FFKGLKFNKIIWPDKTTLTAVVVSVIGAIIICVGVLL------------------------------------------QNHVIWEYLKLAIAVSLKTKIIAALCTGALGAEGFYVIEVLPGSAKGARYLRALKEIMGPEEKKIDVKRVITCDYVGAKMAAVN-PS-QKMGKFIGNFKENLSNFRIKLVNYLIISDIEEDPVMVKEKVTAVAAEIKMLGFGSSKKETGEAIKTLGSKVVLIGKDAGVGKDLPVKLIKVQKIVGFKFEIKAITVIEARLATRKTADSMERAKMKRTRGRSIKQSASAKKRMANARGLSKMGKMNKEVNAVTV------------------------------------------KLSYRVQACVDIRKIYYASKKLIAENSIEEANPIPRAEKRMS------------------------------------------DVVIVFIKEEVMVENQDTIVIKKSIVEDSVTENMEQEMKTCVDYVETAEVVLRKEFTPITIIIKLQYSDETEKVEAVKGGIKLHLRPDSKGTAKASPFMPRCRNGVDDSEEAGVKVLNEKVSVEAVKGIADKVQKGVVEGNMKHAPAPEGIHEDYAGKLGDVVAKTGVILVNAEAQALVSIADFNFILKPISKVEHLVFKVIAATLELALVALFSTVMKVGLIPSVEEIHVAAAMVVEGLYLTEAVLAAMFYNGPFRRLTNLETIKKGLIANQCYMTDDFELYKELLMVAGVFL------------------------------------------MRVKGSMGNVACINGKWKPAETSTEYVVVKVLAGVPEVKLHPGVKRTYDILSARHADAHVRADAKADVEKETDKTIHAELLTLVYTFTESKTKKRKDGISIDVGPRAKGGTLLPGMVHKTIRLLIREDGDIEEEKRTLIKEAAVAHFTTIDPIASMKAFRDFQTYKSVRIDKHRYCGEKQLISDFNMMNLLRFMAAAAEVTAPTEYEAEAKTKKGENIYHDLINLLYVITELLDPLKIERQAVDEGERKEQKLERTYAVELEDFISSAVNVSDLALVRNNLFIIQNDETASEAVLDLIVNKPFETDLNVVGAQARAEQLPETTNYLVRAGDEVSIEVQIAVPAVEKQFKATVSVTTLKKSSVPKAIAVKATMMTSVTV------------------------------------------TIRINAKLVEKPEGSNEFGYSDEFYVKILKAVIDKDRPDYLDLDEKALHEPSSLVEAKDDEIETMVIDTLSCVSMRVVDYNKIVVVIKDKYIEMNSPKETDAEEVDSGVEIEALQVDIRPLPVVTSRLMSIISKADIMEVAMSEIVGIDTGSLHKKSDERSKRLVGLELLKGVQVGVE-LMYSDTAFVEFATHYLADYDIEILELNENNGEIYKDLVNALLPLLCEAFDELLEAGIAGGAAFIYNDQGEEIALHKVPPGLVIKKGIEKYRLLVSLEDDGYTAVVLLICIDERLDAGTTTERVA-DNYFNRKTMKFFDLSGDMERKSNDIPTQEVGELESRYTGDRADEVELVTKERGKESDSRENTVNTNNPLRGIDA------------------------------------------VALFLGAVKFLKEIRSERIAIHFAGLIPGYLGEEDYCAERNHRIVVDDLTEADENVHFTKKEGLSQVGFSMEVMRQALDTGLY-SGMSISVVKEALYRNTPKGKEKKYLLPDLTAIASKLDLEAMIIKTVKDIRMVVNFLGDIIMGSRYTVVARNIMIIANVVKMSSKTEVKAVDKDKAGHFDKVEEDFEAGDAISKAHMFHAPGMKQRKKVKQAHSTTLTDNLASARSRSPYQMAEKLLVDPSEALDTRCRGPVTVNTVKLVVRSHLLNVYKLLYHPEITGKSKVQYAEPIKVAVKKVVIGGALAAAALIEIGTAAFDLGPDALIITHVNLSIGAIGVAEHLLEIASAKKPLIHTGARIPMARNVYDQALVLGDHDLIELVVQAPWAPWVTYKERREKVEIDKDLSLVDAARAVYLAKI STRAIN: GC2270 (SEQ ID NO:9)RAVFSTIDLSTIVVKQLVEKDISQLLRANEDREGPSQPRRFFPIYTLRAAVVNLITIEKYIYKVQIVYDKALQDLKVKEEILYYDTIAHDTVHFVDMASERCFGIKMLLHALELEDAIM-VALKDALEEIEDKLRRTKLLIPDLERTVEVEIFQLTYHICQNKVLHKVEEWLEKDFLVEVDDIEDHAGVWIEDCIELREEED-LEVGAI-LAVECEKSAIASNHERDAFDARDEFEEELIYYVEKEAMIGLKLSCVHRLGADFLDRLAVTEIFRAAIELIVMLMRYTDFQ-VSELRTVKADEENGAGFVSKNKEMTALIGNGLCRPKYKDGSKQDK--KLVLVEDLNMGNSMAKIYVKSDSINRTSVSTTADIFNIIKAHKSLRQEETRLHGKRRRST--TAAYKLDKLKVNIASNKLAIIAYCSDKLEVNYLDDSFIDTVNSQFKTTTIGLLDPGIEAER-LLILARELFESPGFLMEDFYQVAV-EEITGKGMFMGVIKDLIHALCIKIAKALKPLKTNSRRSLQDAELKEVPGHLNAEMCIELYVIQFKAKLHHNVEFDLLVDKDGGEGKVCQIVKDELVKRLITLIKDEIKVALVIEIKPADVSNAVIGAPLVLQATKGKIGLQREKVLQLELIMKTADTIIGSNSDDDSKVTIGEMMDRKFADDITLRKSKESEIFQKATGVVSVRISMSARVYLSFDVINNERIDSY-IAALTPPKLGDCLVAEKVYNSIYDVQFVLIVAGNHYIEFIAEEYIELPALSTYCIYERADQRELIGSEVILKTKTVIKATMPVANKEDYTATIMKASVDCEVNNRNKLRGEGPFVNLAAEKKDRDRTMISDIVFTDTIIRTEDYLTGAAAIVPGVADLAYNDKQERLLTKKGKIVADNDTICKVICNSQVIDDKPGVDVMYSDLFNFENLNAFINVPISKNNIVNRDKQETFLSVVGKEAAGLARLYKFEAGRYKRPDFENNVLYGTATSIIGISVTDKGPLNLKELHFEP-RSTALLLEKMIVDYGEIVDEQASRLELMLLLYVTQENMDFIALAMAMKGCEGKIQSVGANIKVKTADYMNKVVNDDMIIFYYVED-DWNRKENHVLAMLTGFGIPFPFLKVEVFHAEQFFVIKIIGFLKEVNDVTVKYRIPGIASKLKRDAEAEGTSGIFSIAKGDKVHINVILPVLSVQEVFKLQAIENWGKKAKQLEFNPVKLERILFKDREYPMEKGEIISQKQKVVVRQTDLKGLEGKFELLANQRTIQKAVEVLLKIVVIT-HTVFITCAVPASAASALCEQTMSDVESAYAFKINYIKSIQINDQGL--KLEQFKDMTTPALLKSIVFFITFARKVDAMIIVT-IVKIVEMLEPFVRTAHRMAGKQLVTIIQYLYTAILRKNTKRIFL-SHESCNVALNVQSLLITVQCYAAEVLYSVMTLHFSIDSVDYVMFKIMGFDV-EHEIETGLDNKQFLHDLNYWFVPFNVLYQLQQFFHIAMFLHGLTVSDFTTSRRAYSAKEENTNDESRHVLDNIVQNIEKHTIKFLILRLEGVTFNIEKLSESSLQMEVAKTDYYKSATAIVVKMGKYCIELSSYPPYNYTMYMWNLGKQRVEGQVLFLADSVGEKVALPTPYGMQKSVNDASTKKVTLVVPVVIKSTSLPY-EDHLTFCVDAFENVDSGLGAKTFSFQENQARGVTEVVIGALAKQNILEITKDRLEHLLSVLYLN-A-VSSGITDVVGSDSVDIERFNKEQLAQVLLLQYTLVVVSMVLV------------------------------------------VFNPKVIKATVTFYLTTHVEVCDAGEEKPDLECASLVGLC--DELPVVVKMILVESKDNQPIAGLIDMNDTLHANNALLLWLKWVVNPVLVGRSIIIKLDVNILASWTPNLVVVEFE-IAADEFITPTEPSEDFDRCAMGVINAEKKN-SILMIAISTGSFVEANGEL-KEDICLLLMIMWGYKGLGIFNAGLMIELIGIVNGKFTFTTIQFQLNLEHKNMCWYKLVYYDVMDIYQSSDEKKTKFGFLVIAPFCRDVRVNDYQQIMRMFMAEVGDMTQLEWRLDLLAVLALILPTYPGIYVLLPKAQLVWQWDIHDNMEVREWIRLTKIVTQPTDRMVAAEKAKEN-CTIFIEADMLRIESRFAKFTIMDLIKYYNDLEVVGVVAVEVYILCYKVFVPVIHRISYVLSTLLYDKKEADTKVTMSDTAVIANAQDSERIQRIRIGFQIVLSPMTEAGVIKKNTMAIVDSSSATPARWKEILIIIGITEEKGTADEAELKYIDMKTLEILSQFMLTNTELTNEEWLALIIDGFGSYPNQRIRWIPLEG-HQQIG-FTKDDFVSKKEQKVEMSNPQEAIAAKLQNEKELARIRTAHPLAKLVIAFRTGNMLEFLYRAAFGRSAESVEFSEEML-FKRTMLKKRSICVEIVVQFHVQIVTYIRKLVARIEEGRIV-TGPQTTEVGNDRGDYAGFTYFAMFIYPCNSTVHASNTREKAAAIITKESDVHYLEESAQSEPRVRIARVKFKALILAMYESTELKEDVLTLSNGTLPDIKSILTLNVLLVGIDATLIIKIAGGVEYISRAGVFSHRFPVNCMIALVLITIGVKDGQMSLRITDELSLQKIAILSTLLQFAGIFADRNVKLKVGYDLILRDIDQMIFNARLDGVIHAAIIVGKKQNLIAQKVLTSVLIDAHKVAAVQQFDKLPKLKATVLVGVVSEEIVSQFIEAKGSVIFITKTRLRSEEFLTSLFVILVAAICIVQSGGLASGFAIMGRKTTLGLFMVVMSITAVYRAKKVSQLEKVQIYVSPGPPLRLVNPVGEVPSFIEEELVPQVEFDKYIQNQILAPEVFAANNLSMIFGEPNRFIKKLLAQTT-IILVVKQKYERSVALAISKDRLKSFGPMGAELIIISPVKFKMTDNDRLRQAVQVD--KDTI-EATIEVSTVAISESGEMNAIYV-------------------------------------IIIGAFGSVLVQKRYLKTLMIEGIRVI-GANIKKIRPVQHRHQNILIWGSLKLTTAIQLKTKQIAAVATGAENAECHVVIEVFGGKAKAASYLAKMATILGSQAKKISIKNVFTSDFVAAECCAMLRPKKQKTGKYTGNFKEILGNIRLRTVNYAIVLNSAHPNILVKENVTAIWGEIVKLAFGGEKPHTGEVVTAKGSPLVKIARMAGVAKVLPKKFLKTYEIFALKWKVKSVTVTEPKISIRKSADAMERPVVKKIFGRKVKNTGYARKRFQNARGMSKMGHINKDMNPEKVEHALNPMIDGEKVNEVRFSATAATTRDPVEKQRRREMSKVTIKLQNPTRMRVDIRMVFEAAEKLIAEQEVTKVDAMPAGRKRSNIIKGTMSTWVKESHYTTARAKLKDATAQLLELSGAWEYSRENDVVLVFMAEEVMIDSKTSNVIRIAIEAGNMTETMENDMKTVIAVITTAKVLLRKNFTPVCIIVNWDLTGETRNLRVVKNGLNMYLKPESTGTSKSSIFMPRNINALEKGNEAGISVLNTTVSTAAIHGIASKVVKQVVEGNMKSTPAPQGIKEHLPAKVEDVIAKSGEVLVRAEFNAILALSPTRLVTGQIPTVSINVFKIFARTFDIYLIFVHSNILKRAIISDIQPVHSAAISILEALALHKAYLACLFYDGPMYQVANLNSVKEGLIATGITPTQEFDNIPTLLMAMALLVVSRISAALSVREKFNANKFEGIVKQLVQL-YIEVILQALGA-QKTRGRAGFKAKIRQQWKPADVKAEGVPVTIAEGVSYIKLQPTKGAKYSALIIRKANVHVRCPDAEDVEKGMSRAVHVAIFYLITIFTEKSSKRKNDGVSLVLGEENQAGVILPGQNMRAG-KYIR------------------------------------------LIDKHPCCNINIFISAFGMHSVEKCTVASINILSDIPGTDIENQTYGENLYHDRAGLVFAIEELIEPLKIGKIVEDSGLKREQKMERVYSVELESYITKAIDLAELQILNEAIFIVEHNVMSSEAVYSVIINETFEYNERIVCAQARTETL-GTTECVVRLNDE----VQIGVPAIEKQFRQTYAVITQEKSSEPRAIEVRCAMMTSIAK-----KTIFDFLFTLRLTWLDVAVALSNIPSSVAKSKSDIVQSIRRSVDILTPAEGKQEIAILEKYVVKIFQAVISKERRPEVDLQEKSMQDPSGALEAADDNIEALIIDNLTTTALKVVEYNKLIPVITPAFLEINTTNSTEAEDLESRIGLEAVRIDVRRLEVIASPLLSIISEGDFLEVCIAYIIEKDIGKLHEQKVDFKKRFLNLSLLKGIEHGIAGLMASSAPIIAMSTNFKRTFNIECKEVDTKIG-LFRNLLNAAVRLTQRTKQGLYS-SMAGGECFLRRNQKQEIEYHSFFFGFALKEGARMFTVYFPASGFGESVLVLVQFIGKRLESGSTGERVPQDSYFDHVQMKLFELGAGLDAKSNQIARAEIKALEIRYTRERVDGVELITLNIVKSDDANEDLVGTTTAPPQISARSFYPNCSVLIVIVALLKKLDALDGLVANSSLQPPCNKELAQIALLLEACDFLMKTKSIYWKIHLIGLIPGILDEIDYVSQKLNYITVDDYTSGDCGYHFTREEGLSKISFSL-RDKRILDSGKILSSISISGELDSFYERTLKGQDNKYLSPRLTSIALKVDLEKAVIRESRDFRVVTNFLGDSTLESAFRVILNTIEAYPNITPVPPNKACKALDKEKPGHFKRLEAEFEGADVTSKVHTRACPGMDQKKKNKQLHSISLANQISSARSKNPYQMAQKYLVKPNESIETICRGPITVNTVKVPLEAHLLHVYIILYHNSVVKEDKLQVSKPIKSAIEAVVVAGSLSAASILTVGTAAIDLGPDSLLLVKANLKIATITVFVHLGELSVSKNPLIGTVCALPIARMVYAAIYVFGNFFLVEAVKFSIGSPLVQYKVKTQALDFEKATKLIEVARKAYLLEI STRAIN: GC2386 (SEQ ID NO:10)RAVRVTITLSKLEVNSLLGKDAAGILRADDAKAGSVLHRAPFPIMTLRATTMKFIAIREYIFTKGLVYGGSIRSLSLKEDIVYWEAVAQEQFAVTELPSEELG-TSTVARAAKAGEAITGDETRDA--GAADAQRRAQFLLPDIDRHMDFKVIKFPKHIVEGRVIARV------------------------------------------LRIEAEDLEALIELPRDRIHEKEHVTDEELAFLQRQIVIDI-LCDVHIAGAGPLDALQVEEIFRARS-AIVLLTRYADMDALSEAEAVQPEEADAAGLLKRNKDLSAFLSSAVMKIRLQALSREDAEVSAAVDEQMTLGRQLCKVYTRAATDDDTSTSTQAVALGIIEAIKSKLTNEKHKRKSKRREAIAGAAYQLDKAGAGIAANKMAILTIVDPPAELHWMDPLVIWVAQAAAGHSLIGLLHPEQFGQQ-------------------------------------------RPLTFQIPKRLPRLFDHSRRRIRNVVLTQEEAPKSTPAAIELYVAHEKVVINRKVEFPLVV-DGAGAASKGEVAKPINIYTRITWVGDNLKVEMATAVRPAEKEGAVIN--LVLQAIKSGVGLADGTVASLKQVERAAGTIVGRPLVKSTYIALARKLSPIWADDVTIRRARVASSMQHDRLAVTVRVTLQAKVYWTLGKLQALRTEVE-VAKVMDPVLGDVVFYFGMIESVHAVEFMIPYGASDYVQFKVRSTVSVASVADLTTSLSLSAKRMIPSRAVLSKPGIIAGVSTVAIRLDYEATLERASAEVELNNRHQLRQAGPYFKRAAQREQKERSYFSDLLFPSELIPDEDYLNGASAITPGFIELEWRPKDTRIIAMKAAIEFDDLAITDMVAMNQVVEKKPSREVLYGDIMEYERLNEFIPVTFSENNIVDDQKREHALAVV-APAEGLDQIISFEERHFKAPDREASHLVDRVTALIGVALADANLDGIGGTREPPWHWTERGVELPVELLGDSEDGLHATLLRKLIKEVTASNFSGF---AAAQGVEREIIQVSATVNLLTKEFAAKVTGSEIVLFYFVKGKREGPRSIRIAVAVSGFGIVMPFLRWEVIRSEKFVTALLVGAGTQVGDVAVRYRIPGFWTEKRRDAVAEGESGLFTISD-NKTHF-MIAPELDRGKTYLVTGVTIWGRKAGVVNYTPVELDLVKLRDREIALKANEVLGNRARSAIRKIDKGRLNGKLILLAASNIMTKAVEIRAGLLAIASHLNFVSAGVPESAASAIAVEDLSDAESAYGFRTYFVLRIILRDGLVGRKMDRYDELNDAAVLKSVSFYIYF-DALDPETFIAAVIDIVKALHPLLRTAHRLAQGRVVVVIQALHTVLLRHNTQAIVQCQRPNCEVDLNVNACLLAVQAYDGDTHFSILTVKFDMG-PVYELMGLMGFRLKKWEMEVGKALRRMVEDLPDWLEGATVLYTLQLFFHVAFFLSGTSLKTFFGARKAMVTTTEHASDDEQNTIDDIIEGISDHDVAFLFVELAGVAFEITGTSI-PLDVHLDATDRYQAV-EKFYKWGQYILEMNFFPALNFTLWKWDLGHQAKENHIVFVWKAVGDKVWIPLPYLLEKAIDDIVTKPVNVFVPAVIEDNQCPF--TRVEFSIKVYENVG-DIIKDAFA-FRSL-QKEAAGVVGAMAKEGILLLSKDSVQMVRTTLEINSAMVSGGAPFVVASSAATIEDTTREPLDEVLFLSLVLVLAARVLV------------------------------------------LVDPDIAHATVTIELSTGVETINAGDQKASFGCAVLVGV---SSRAVIRQYMLIVVSGDKPDASLIYMKPSGQQNNAVDIFLPWIVRPVLIGQAIILLNPAKIQEGVSRAELVVDIPKIHLPNVALIFERSTEFERAIPGAVNYRDKETLLVAVSVSASSVAEAGGAV-HQKISALYAMVSGFKGGGIFTSFYYVDLIGFAVTHFAFVM-PLELEIALGWENLAIGVYINAFRAYHMINIDTDDSVWVRLKP-ATLVSVHKYQQVVRMFTFKAGGESRTKPKWWKFSMLAAIIDTFPGLPVLLSPTALVLHRDTRETGEYPNFVRLAKILEKQAARSLPVDRFEEEEETEFVEADMLYIDDTVAKMATLDGIEFSGDSYVVGVVAIEVHGFCYHPYIKILDAIDVIVTLVNAETGTASTEVVMTDTALLANTMDDKHMRAKQFSVDVIITPLTECGAVRQGFKNIVDYAKSGPPRFVERLVVITMTSEKADIKDLLLQVLDLKEVEVFTMLITDTSPLTSEDWVALVTDGWGSWP-----------ETATAGSFTATDFIAKKEEEIELADPLDTVGCELKNQKDIVRPFTANPVAMLVVKFVATGKALVMYDAKYGRSAESIAVEEELLDFGPGQVKRDCVCVEPVIEYHVNILAYLRKVRASVDEGRLTRKGNVVTEVGRARGDIVGYATFSMFVYPVESTVYIADTIDDAAGILTEGPTIHWLNERAGSSVDPEVQRAALGPQMGALFATCALRADILTLANESLAEVKSLLPLTELLVGIDVRLLVNLMGEVVW--------NTFPMQVLIRLVAITIGFRQQVMDLQVTDQFSLAKIAILYITTGYPAVVSRRTSSDDTGFDLIIRAVDLIVFAEKLDGVVKYIILPGQEKNYLEVRVLSDVVVDSDVVVEIREVDRA-SVGVESILGVIVHRITTPILDAKGSVLGATFARLHAHEFLAAILEIIVASITLIHGGGLSDMFTAGTGVAELFIVWVAIIILGMYHKKTIFQEEEVKKRDREGPPLSAKESAGDVPAMVSDTLVPQMEFGKYVENAFIAPEVYVARWQALIF-APNRLLGSHPPHTTGLAIVVNPSQTQGVATGIAKEGVKSFSPMDAEML-IRPVQFKRGDKDYITKQVQARLTKDNPSPENIEVSAVEVSENGESRAAYIFIKQIILRKVVTPTAKELSGVFIVVLMLLVGMLLVWVIFLGGFGSVLVFEEYVQVMGIESWSIASWSNIRAVRVVQQ--QNFLTHSFVKLTDAIALKTKQIAALAAGAKGAEGFYVIDMTEGKVTGARYLRSLKELMVTEDKKISVKSVVTTDYPAAEMAAV---AKETEARAQGSYKNALVNITFRLVDYRIVMIAERPQVYVRENVSAVVREIQKMGDAATRPPTGEAITTMGSAMVRVAEEAGLGKQLPVQLIKIEDIVSLQLKIRSVTVVEPALSTRKTADSTERAKVHVVRGRSKKEQSYNKRGFQNARGITRIGHLDREVSPEKIPYALSSFLNKQQVNEMQFSTTAATTRDPVAKQKRQEYPEIGEIARHRVRARMDIRKIFAAARKVIARVRVKTVDVFARANKRTSTIVGTVDTWVDVSPFTTEAANLDQSRPQLMTVATGWEESRLNDVVLVFIWEQVQLVKNQTNVIRRAVEAENVLDSLEQVMFRVIAYITVTQVLLRKTYAPASIIINMGYSGRSENIKAVKNSLRLRMKPPAKGTSKK-PFLPRSPFVVPGTDAKGVRVLDDVVSKAAAKGIRGKVPNDLVEGQIKHVAQQQSISEHLPGNVQEVVAKSGEIHVRIEARSLVAIADLGYVTG-DPAIMHLVFCVVARSFEIVVVAG-SPIAQRATMADCERVHATAALVLGAWAADAAGYAAQFYRASLVAVLDCASILKE-VAEAFDDTLNFRIAGTLIALLNLCILSEISSAVHKEDPLDSSRTRGLYAGLVQLSYRELMISLLSSLIRTKPGRGFQAAVRGRWRPLGASTEFINIHVIGGVSEVRRDPSRERNYTILMARKADTHAKAGPKADVDKGTDRTISLELVTIVTSFTESKTRKRDDGVTLQIGEKNGAGQLMPGMTHRTG--MVRDDADIDAQKHVLIQEGAVANFTTVDPCASIKAKRDFQAYRPLRLDPHPWCHEEQFCANFGTRTIQKVTAAAARITAGTDNQYTKLPTFGTGVYHDRVGLVYTLTALAQPVAIDHGVEDKGLRREMSMDKTYAVELEGYIAEATIVSDLTVTRTSMFVVINDDMASESVLDVVVNAPFHLHFDVVGCDAKQEGL-ETADHIVKAGDDVMLEVQIALPAVDKQYQQTVEILTLKQKTNPTGVALRAAMITSITISAKLNSLLRLYIVVDDMSWVRMARAIFDVPRALAKSDASIC-HILRLARVTE-PEGNQESGDHERYYVEILRAKVAVSKHDDLGLDEKSLNEPSALLNARDDSVEALIVDSLATTALKVVSYDQLVPVIGDAFIDVNTPKETDGEDVVSGIKLDALQVDVRPLAMVVSPLLSVITVGDVADHAIADIVERDIPALLPPPEEHEDRFVGLSLFVGIPVGVQQLMAQDTQVIKFGAMYMNTFALRSRDREEEIG-----LLYALLTLMSEAAKHVLEEGISGGEAVVLDDHLSKIKLQTVIPDVWIKEGSEAANLYGELEDDGRSQLILVVLVDEGPGAGATSEIVV-ENYFDHKKIKLFELSGDKDRRSNDIATEEANERETRFTGERAGEVELVTRDRVKDEEAREEYYDTKPTPSGEDARDFYPNCSKIAAIAGVFPKRVMRGDLFLQLAVDGGTSIELLRVRLAVGAVESRLGV-GVYAAVHLLGLIEVFLTDTGWWPD---RVAKNNASMGDLGQALNGEEALAKVRYSIEVERRLDESHNA-AGESVSPGLQEFTTATPLGVDRKAVYPRLTPVALETDVDALVVRTATEIAVGTDFLGERVLKSQWALILADWAMLPNQT-LGPQREVKAIQIPKPGHFARLEEDFAEGSVTTKTWRNECPGMVQSK-DKQAHSTSITDAVASGKSRSPYGMAERMVVDPSETLEGTVRGPVEVQSAKIELAAHLIAVYGIFYHTEIFNKDKVQVANPIKAAVAACLIAGCLSAAAKVIIGTACFDHGPDAAIVARCKLRVALIYVE-HLQRIGLVKGRLIGIPAHTCNARKLNADPVVVGHVLL-QLVVQTPWAPWVQYRMKANRVFGDSALTTVREVRPVYVFKF STRAIN:GC2786 (SEQ ID NO:11)RSVYVTIDILETIVRQTNDKDVAGIHRADDYKAGPMLKRAPFPIMTIRAATIKMIAINEYIYEDFIVYGNIIVELQIKEKVLFWLPVQEDQISVVDLSTQKLRGVSKVMNAFKTDEAIAEDAIAKA---IEERRRRTKMVIPNFERAFEMEIMEFPLHVEQRSVVHMKLPIMEMHELVDVEGLYDKEGITVNDCMNLEEDFISFEVSPL-------EMEAVTVQVRENIRATEKLENEVLAVYQKKTVIQP-------------------------------------------TRSVKEEEENAAAYVSKEKYLSIMCSCAVCKLKYKDGSKQDA-LKKLMDEQITLGHSYAEVNVKSEDVEDTSTSTQALIMNIINAIKSKLVAQTTERRSKKEAAVANEALSISKASKGYASRILAVVNLVDERHEINTRDPLVISRVQAEYGHSLTSLLHPELEAQELIILLAKNLIGEDGFAVYDIF------Q---NSLLMGLARECIKSITLHIAKEVKGLAN-EEVAVARSKLTEPNGLKGAMEVLELYITKYKVIIEKAVTFDLAV-NDGGENTEASVGRKVIVYHKIEYIHNSIEVQLGENVGPGDKAKAVLNAYVVLQAAKAGISLQDQAIGQLKAVMKIAGTVVAKPLPKETLITHATSLNDIFKDDITIKRNRESTIIEKDRIHTSVQVALKCKVYISLKILNACRTESYALGKITDPAFGDLCFPAEVLGSIYSLEIPLLVAGNDYIEFKIKSYLEIEDISMLITYLKPSDLEMIPSDAIISKPTLIKAVAELDVKFEYEAHVMKCSKEIEAFNRHYLGKEGPYIKLGAQAKDRERTMVSDWCYLQEIVLTYDYLTGPMAISPGVGELEWNQKEQRNLCKKAEVQIDESVIADVIAANQLMDEYCQKEIMYKDIFLFERINAFIKYSFSKNNIVDREKRETDLAAVNAEAEGLEKLINLEKGRARPIDRETNILDGVFSGILGVFTFDGYLHSITELEPEKFVV------------------------------------------MAAEGCEAELQAMDANVAFMSKEFQIGVVASAIILELYVKDEEKNITEEKFLIILTAFGLPFPILRFEVAHAEQYLVCLVVSGGLQVGEVNVSYRFAKLATLNKAAAQKEDEGGTFSIKEGDKFHLNAIVAKIEDAAVAKITGVVDWGKKAKYFQFDAVELEILLVRDRTMSLQAEKIIGEKARKVIRNISINKITGKFQILAEKSTMVKAVEVPAKTVVMSTHVLIITAGVPKAAVSATAVKDISDADSAYDFKICHVQRQIANDGFVARRVERYRDMDAPVLIDSIAFYIRFGSKVDPLLTVRTIKEILECLGELWRTADRMVGRNYVIFIQYLYTVILRKNTKRIIQAGHEDCKAKLQVNSLLIAIQCYANDIHLSILIIKFDIACCKFTMFGLSGFEVTKHEMETSLAVSELLENLEFWLKPYTVLYTLQQFFHIPLFLEGVNLTQFMSSRNCMESKA------------------------------------------TVEDMKVDEKDFFKSV-KYYYEKGDYVVRLCFFPALNYTAYEWDRGKVNKEGDLVFLEESVNKETWLPCPYLLLKSIDDVLVEGMTTEILAVIEIDQLVFHPEFLKFTYGVFFNVGGGMCAKAYTFFKTQAQREAEKVVGALADMGMIEKSIERIQNLFGCLVFNTAMFQTRRPIVVGSDSFRMQQLTRERLNEVYMLGFALVAMLRVLVVAKYCKDAPFVKFVCDRE-DVSKQVFEEITQFQYGLYVWVTDINYEDVMGTTVTLDLETGIRMLNLGTEKAYIRCKCMAALALDTEEPVVVKMIMIAAKDDKDEVSLIVLDRDLHTDNSLKIFLRWVIRPVLIGKAIIIKVEPQTTKGVTPAHIVIEMRIIMAEELVLVMEPAEEFDRCIIGFIEAAEKG-MIVTLTISVGSLIYNG---APN-VSLFYIIVGGYKCLSWLTSAF--GIPGVAITGFAFVG-SADLELYAKSRGLRKTVDFDLTDPYQFGEENKIDFGFMVIRPKCSDVSINEYQVVLRMFSVPAEDKVELEWRYDKIALLVAIVETHPGMFVIYPREILILKWEVEETSHATQWIRLAKVLEQEADRLVSPERIKELKETEFVEANELRMDDTSGKFAVVDLIKFYNDLQVVGVVAVEIAGFCYKIYIKMFDRMKYISSLFAYVKGEAATAVKLTDKDALASAIPTERVKESQIGLKIVLNPMIQVGQIKKGFKELVDYAQNSPARWAEMIICIVFTEEKGAIDGLEVKFIDAKTLEVFTALIVTNSDLNNQKWLVLIITGYGCYLVHRLEAISRKQELDRDEAFTKKDYVMKKQQEVELSDPQERVASRLKNTKDLNRPLTAHPVAMLVVRFRNN-TLYFLYDARFGRSGETIEIEERLLSLSSSQARRKTIMVEPLYQYHVRLMTYIKKVRASVDELRLE-VGQETTAIGMDRGDFAGYVAYSKFLFPVKSTVEISDTVAKAAAIVSFDSDIHYCDEFEAEEEAKKRQLLAFDPLLIATFSSEELKSDVFTLSNGSLEDIKSLLSLIELLVGLEASLNIGLAGGVVILPSAEFYNNRFPLQALLAYVLINIGVKNAVMALNISDYLSFSKVTIIMLVVEFPVVFADNTSKEGVGYNFLIRS-FILIFVDALNGIIYAASTKDQEPRLLAKQVLSDYVI-ANAVTAV-AVDKL-ALHLETLAAVILDNIKTPIIDTKGSLVAITFSRLVGTEFLSATIQIVILSITIVQGNNLGALTTYWSRSMELVLLFLIISALT-YHNKEILERQDVEKMNWRGPPLTGEVDKGDVVKTIQSSVIPERAKNMYICDKLVAPRLWTTDVDTMQKEQARRFLNGVVEGDVPLALVVNQKYQQGVAVHIASEKIKAYGPMGAKLQMIGPVKFKQGRKDRVNKAVQSKLKKQNAEPESIEVSAVAISEGGEMNELYTWFAGLKFQKIVWLDKKSLTAVLVSVIGAIIVLIGIFLIYLGGFNSILIEERYLFVLTIENESVMGKSNIRPIYIVQRRNQNHVIWELLKLAIAVALKTKIIAALCSGIKGAEGFYVIEVLPGAVTGARYLRALKAIMGPEDKKIDVKRVITCDYVGAKMAAVK-PS-QKIGKFIGNYKTNLSNLRIKLVNYLIISDIEEDPVLVKEKVTAVAAEIKMLGHTGSKRETGEAIKTLGSKVVLIAKEAGVGKELPVKLIKVQKIVGFRFEVKAITVIEPRLGTRKTADSMERAKLKRTRGRSIKQSASAKKRFANARGLSKMGKINKEVNAEALSKALDGFIDDETINEMQFSAAAATNREPVEKQKKREYPKVTIKLSYRMQACVDIRKIYYASEKLIAENKVEEANPIPRAEKRMS------------------------------------------DVVIVFIKEEVMVENQDTIVIAKSIVADSTTETMEQDMKTVVDYVTTSEIILRKVFTPITIVIKLQYSDETEKVEAVKGGYKLFLRPESKGTAKASPFMPRCRNSVN-TDEAGVKVLNEKVSKEALKGIADKVAKNVVEGNMKHTPMQAGIQEDYAGKMGDVFAKTGVILVNAEAAALISIADFNFILKAIAGVRHAIFKIIARTFQLAIVALLSVVLKRGLIPTVEEIHAAAAMVLEGLKLTQAYNAAMFYTGPFRRVS-METIKKGLIVNQCYMEDEFELLKEVLMVAGVLIISMISSAVNDDDKIDHNKAKGLFDYLKMLKMTHVLLGLLVA-MRVKGTMGNVACINGKWKPAETSAEYVVVKVISGVSEIRLHPGVKRVYEILNLRHAEAHVRAGTKVDVEKETDKTIHAELLTMVYTFTESKNKKKNDGITIDVGPRNKGGTLLPGMVHKTIRLLVREDSDIEDEKRVLIKEGIVAHYTTIDPIASMKAFRDFQQYKSVRVDKHPYCGEKLLMSDFNMMNLMRIMAASAEVTAPARYEDEAKTKKGENIYHDQINLLYVVTELIDPASIERIALDEGERREQKLERTYAVELEDYISRAVNVSDLALARNNLFIIQCEETASQAVLDLVVNNPFDTHLNVVGAQARAEQVPKTTSYLTKAGDKLRVSVQIAVPAVEKQFKATVAVTTLKKSSVPKAIAIKASMMTSVTARQEFKQIAMEYKVIEDSSWTTMALAKYDIPSSVAKGQASL--TIKLTAKVVTPGGGDNEYGYSDEFYVKVLKAVIEKDNPDYLDLDEKSLNEPCSIVEAKDDNIETMVIDSLSCISLRIVDYNKIVVVIKDKYIEMNTPKETDAEDVDSGVRIEGLQVDIRPLPVVTSRLMSVISKADIMDVAMSEIVGIDTGSLHKKNDERPKRLVGLQLLKGVQVGVE-LMYSETSFNKFATHYLADYDVEIMEYNEDNGQIYQQLLNAILPLVCETFANLLEQGIAGGAAFIFNDQDEEIALHKVPVGLVIKKEVERFRLYVTLKDDGVTAVVLLICIDEMLPAGTTTERVA-ENYFDRKTMKFFDLSGEMERKSNDIPTQDVEALESRYTGDRADEVELVTHERGKEDDSREKTVNTNSPVNGVNA------------------------------------------VALLLGAVLFLLEAHSLYSCLHLSGLVKALLTEEKYRSDRSQSIVVDDLTEGDADVNYTKQEGLSQVGFSVEIKKQAFPSGLALSGMSISEGKEELHQNTPKHKEKKFLLPELTEIAAVLELDVVIVRTVHDIRMVVSFLGDLIMQSKYTVVARDIMILANVVKMSAKTAVKAVDKEKAGHFDRVEVDFAEGDAISKAFMFHCPGMVQRKKVKQAHSTTLTDNLASARSRSPYQMAEKLLVDPSEALETTCRGPITVNTVKLAVRSHLLHVYKLLYHPELADKDKVQYAEPIKVAVTKVVIGGALAASAIIEIGTAAFEAGPDALIITHANLSIGALGLGEHLLEIASAKDPLIHTAA-IPMARRTYGQAIVLGDHDLMELVVQAPWAPWVVYKEKREKLELEKKLNLVDIAAPVYLTKI STRAIN: GC2916 (SEQ ID NO:12)RSVYVTIDILETVVRQTTDKDVAGVHRADDYKAGPMLKRAPFPIMTIRAATVKMIAIKEFIYDDFIIYGNIIIDLQVKQEVLFWLPVAEELFGAVDLETQKLRGVTKVIRAAKTAEALAEDAIAEA---IEERKRRTKMIIPNFERTFEMDVLDFPFHVEQRSVVHMKTPVLEHQELVDVEVLYDKEGITVDDCLGLKEDFISLEVSPL--AIEVEEMEAVTEQKRENIRATERLD-EVLAVYQKKTVIHP-------------------------------------------LRGVKEEEENAASYVRNSKEMSAMISCAVSKLKYKNGSKQDASTKLLIDEQLTLGNSYATVNVKSEDLEDTSTSTQALIMNIISAIKSKLVAETAARRSKKEAAVAKAALSIDKASKGYASRVLSVVNVTNDEHRINFRDPLVIDKVQAKYGHSLASLLHDDVEKQE-LILLAKVLFEDKGL----GF--AIGVDTVSNAMLMGLMPPALKSLTLFIAKEVKGLLNETVKKARKNKLDEPNGQKGAMEVLELYITKYKVVIERAVTFDLAV-NNGGEGTSATVGKKVIVYHKIEYVHASIRVQLIEGIAPADKSNAVINAYVVLQAAKAGIKLQDDAIGQLKQVMRIAGTVVAKPLPKETLITHAKSLNDIFMDDITIKRNRESSIIEKDRIHTVVEVTLKCKAYISLEILSAQRTQSYEIYRVTEPTLGELYVPQVALGSIYEVHFPHLVLSNDYIEFKKRSYLEKKDMPVLVTHLRLSSLEMIPSDAVISRPTIIKAVAEVDVKFDFEAFIMKCSKEIQVFNRHLLSKEGPYFKLGADAKDKERTMVSDYVYLQEVALTYDYLTGPMCISPGVAELEFMDNQERRLVKKGEIRIDGSVLADVIASNQVMDEGCQIEIMYGDIFLFERINAFIGYSFSKNNIVNREKMESELWAVSAEAEGLEKLINLEKRRARTIDRETNMIDGTFSAIIGVFALDLKLYSLDEMACSEYE-------------------------------------------MAAEGCAKELLAVDANVAFLPASFAIGVVKNVIIIELYVQKEHWNITKEKFLVIVTAFGIPFPVLRFEIAHADEFFVSLVVSGGLEVGQVKVSYRLTKIATLKAEAAKKEDTGGAFSIKDNDKFHLNAVLAKLEEEAMVTITGVIEWGKRAKYFHFESCEVEIILVRD-EMSLKAEKIIGEKAKKIIRNIEMNKLEGKFSILAEKSVLFKAVEVPAKTIVLSTHVLLITAGVPKASVSATAVEDISDADSAYAFKICHIRRQIAQDGFVARKVERYNDMEEPVLIDSIAFYIRFGSKVDPLITIRTIIEILEVLNPMWRTAEQLSGRNVIVLIQYLFTVILRKSTRRIIQCSRPDCDAELNVESILAAVQCYEHDVHFSVLIIKFDIACCHFTLFGLSNFNIDKHEMETSLEIAELLDNLEFWLLPYTVLYTLQQFFYIPLFLEGYKLTEFPSKRKCMQTDE------------------------------------------AVEQIKVEEKKFFKSA-KTYYQKGSYVIRLCFFPALNYTAYEWDRGQVNCEGDLVFLEESVNAEVWLPCPYLLLKSLDDII-KGITTEVLAVIDIDKLVFHPEFLKFTYGVFFNVGGGMSAKDFTFFKAKAQREEDKVVGALADMGVVEKSIERIQNMFGCLVFNSVMFRSKRSFVVGSSTLDMEQLTRERLNEVFMLGFALVAMMKVMVVAKYVQSAPFVYFVQARE-DIAKQTMKEMEQFENDLFISITEVNYEDVLRTTVTLDLETGVRMLNLGEEAAYLQCKCMVDISLSSEEPVVIKMIMIVASDDKEEESLIKMDRDLQADNSLKIFLRWVIRPVLIGKAIIIKVEPRITDGVTPARIVIDMRIIMAEEMVLVMEPEDEFDRCIICYVDADEKG-LIVVLTISIGSLYANG---APQQISLLYIIVGGYKGLPWFTTAF---IPGVSVTGFAFV--SANTNIYEKSRGLRKTVDLDLADPYQFGEEKKIDFGFLKISPKCGNVSVNDYQVVLRMFSAEAGDKVQLEYRYDLIAMLVAIVPTHPGMMVIYPRAILILKWDVVETSEATSWIRFAKVLEQETARMVANDKADEQEETTFIEADMLKVDDTMGELCTVDLINFYSDLYVVGFVVIDLAGLCYYLFIKVFARIGYILAYLMYEKCEAPADLKVTDQASLANIIPKERVKDKQIGVKIVLNPMIQAGQIKKGFKEIVDYAQNSPPRWKELLIAVIFTEEKGGIDGGEIKMVDAATLEVISRLVMTNSELTNQEWLVLIITGYGCYLVGRLRGVRTRGENDRDDAFTKKDYLMKKQEEVELSDPQDRVVSRLRNARDIPRPLTAHPLARLVVRFKG-LGLYFMYDAAFGRSGETIEIEEKLLSLKSSQAKRKTIMVETLYKYHVRLMTYLKRVRASVDELRLDTVEQQTTEIGMDRGDYAGYIAYSLFLCPVKSTVEISETVEKAVAIVTSDTDLHYLEEFGEDEEAKRRELLEFDPVLVALFRTDALRSDVFTLSNGNLEDIKSLLTLVELLVGLEADLNISLAGGVMYLKYVSFRNYRFPLTALMLRVLINVGVKNAIMAMGISDYLSFKKVTIIMLIIDFPIIFSPNTSKEGLGYNFMIRSA-LLIFIDSLTGIIYAAVTKGQEPRILEMQVLSEFVI-ANAVTEV-SVNKL-ALHLATLSAVILDNIKTPIIDVKGSLVAITFSRLQGEQFLS-TLTIIIICVSVIQGSALSGSIDYWGRSMELYALWLILALLN-YHNKEILESQEVEKMNWRGPPLTLKVDEGDVAKTIESELIPERA-NMYICDKLVAPRLWMTDQDTFQKEQARRFLNGVVEGKIKLSLVVNEKYEQNVAVHIASDKIKAYGPMGAKLGEIRPVKFKQDPKDRVNEAVMSKMAKENPEPESIEVSAVEISEGNEMNEIYTFWKGLKYKRIIWPDKETVTAVIASVAGLIIALIGLFVLYFGGFSSILIEERYLFIMALENESVADLSNIRPIYIVAQRNQNHVIWENLTLAIAVAVKTKFIAALATGAKGAEGFYVIEVLPGSATGARYLRALKQIMGPEEKKIDVKRVITCDYVGAKMAAVK-----KMAKFIGNYKANLCNFRIKLVNYLIISDIEEDPVLVKEKVSAVAAEIKALGFGSNKKETGDAYKTLGSKVVLLGKEAGVGKDLPVKLIKVQKIVGFKFEIKAITVIEPRLATRKTADSMERAKLKRVRGRSVKQSASSKRRFANARGLSKMGKMNKDINAEALERALNGFVDGEMINAMRFSAAAATSREPVEKQKKREYPKVTVKLSYRVQACVDIRKIYYASKKLVAENNVAEANPVPRAEKRMS------------------------------------------DVVIVFIKEEILIENRDTIVIKKAILDDSITETMEPDMKTVIAYVTTSEVVLRKIFTPMCIVIKLQYSDETEKVEAVKGGIKLHLKPVSKATAKASPFMPRNRNGVN-TEEAGVKVLNEKVSKAAVKGITDKVVKNVVEGNMKHTPAQQGIHEDLAGKVDGVVAKTGVIMVSAEVRAMIAIAEFNFVLKPIEHVEHNIFKFIAQTFQIVLVGLLSTVIRHGTIPTVEPIHVAAAIVIEGLYLTQAAYAAQFFKGPFRRLSTLDTVKKGLATDMSYMTDKFKMLREILLAAGVLIISRISTAISEHQKIDHNKADSLFEYLQSLGFSRPMIGLLAA-MRVKGTMGYVACINGKWKPAETSAEYVVVKVIAGVPETRLHPGVKRSYEIIALRHADAHVRAGPKADVEKETDKTIHAELLTMVYTFTEKKNKRRADGITIVVGAKEKGGTLLPGMVHKTIRLLVRENGDIEEEKRTLIKEAVVAHYTTIDPIASLKAFRDFQSYKMVRIDKHPYCGEKQLISDFNMMNLMRMMAAAAQVTAPTRYEDEAKTKKGQNIYHDRINLLYVIAELIDPVSVERLALDEGEKREQKLDRTYAVELEDYISKAVNVSDLALARNNLFIVQSEETASQCIFDVVVNNPFETDINVVGMQARAEQIPETTNYLAKAGDPIQVEVQIAVPAVQKEFKATVAITTLKKSSTPKAIELQAAMMTSITARLEFKVYFPDYKVIDDAAWTRMGLAKHDVPKAVAKGDAAL--NIKLTAKIVEPSEGENEHGYSDEFYVRILKAVIDKDRPDYLDLDEKSLNEPSSIVEAKDDNIETMVIDSLSCISMRIVDYEKIVVVIKDKYIEMNSPKETDAEDVDSGVNIEGLQVDIRPLPVVTSRLMSVISKADILDVAMAELVGVDTGSLH-KNDERPKRLVGLQLLKGVTVGV--LMYSETSMNKFATHYLADYDIEIMEANEKNGEIYQDLMNAVLPMTCETFEDLLEAGVAGGAAFIFNDQHESLSLHKVPVGVVIKKECEPFRILITLPDDGLTAVILFICINEGIDAGTTTERVA-TNYFDHRAMKLFDLSGDMERKSNDILTQEVQDLESRYTGDRADEVELVTMERGKEADSREQTINTTTPVSGVDA------------------------------------------VALLLQAVDFLLEAKSVYLAIHLFGLIPGILQEQTWVSEWNESIVVDDLTQGDEGVHFTKQEGLSRVGFSVEVERQALRTGLHLSGMSISEGKEELYQNTPKGKEKKFVLPNLTPIASDIEVDVMLVMTCHDIRIVTNFLGDLLLGSKYTVVARTIMIRANVVKMSSKTEVKAVDKEKPGHFDRVEEDFAAGDAISKAHMFHAPGMVQKKKVKQAHSTTLTDNLASARSRSPYQMAEKLLVDPSEALETKCRGPVTVNTVKLVVRSHLLNIYKLLYHPEITGKSKVQYAEPIKVAVTKVMIAGALAAAAKIEVGTAAFDAGPDALILVEAKLSIGAISIAEHLLEISSAKKPLIHTAG-IPLARQVY-QILVLGDHDL-ELVVQAPWAPWVTYREKRNKVAMDKEMKLVEAARAVYLAKI STRAIN: GC3144 (SEQ ID NO: 13)RAVRVTITLAKLEVNSLLGKDAAGILRADDAKAGAVLHRAPFPIMTLRAATMKFIAIREYIFTKGLVYGGSIRALSLKEDIVFWEAVAQDKFAITELPSEELG-TSTVIRAAKAGEAVTGDETRDA--GAAEAQRRSQFLLPDIDRHMEFKVIKFPKHIVEGRVIARV------------------------------------------LRIEAADLEALIELPRDRIHEKEGVTDEEIAFLQRQIVIDI-LCRVHTSGAMPLDSLEIEFIFKARS-AIVLLTRYVDMPKLSEAEAVTPDEADAAGLMKRNKDLSAFLSSAVMKIRLEALSREDAQVSVAVDEQMTLGRQLAKVYTRAATDDETSTSTQAVALGIIEAIKSKLTNEKHKRKSKRREAIAGSAYQLDKAGAGIAANKLAILTIVDPPAQLHWMDPLVIWVAQAAAGHNLIGLLHPEQFGQQ-------------------------------------------RPLTFQIPKRLPRLLDHSRRRIRNVKLTEEEAPRAAPAAIELYVAHEKVVINRKVEFPLVV-DGSGANSKAEVAKPISIYARITWVGDKLKVELATAVRPAEKENAVIN--LVLQAIKSGVGLADGTIASLKQVERAAGTIVGRPLVKTTYIALARKLAPIWSDDVTIRRARVASSMQHDRLTVTVRVTLQAKVYWTLGQLQALRTEVE-IAKVLDPLIGDTVFYFGMIASVHPVEFELPYGASDYVQFIVKGMVFIAAVPDLVTSLSSSAKRMIPSRAVLAKPGIIKGMSDVNIKADYEATLERASAEIELNNRHALRQAGPYFKRAAQREQKERSYFSDLLFPSELIPDEDYLNGASAITPGFIELEWRDKDEKLIAMKATLVFDELAITDLVASNQVVEKKPSREVLYGDVMDFERLNEFIPVTFSENNIVDDQKREKELAVV-APAAGLDQTISFEERRFKAPDREASHLVDRVTALIGVALLDENLDELSSVREPPWRYTERGVELPVEMLGDSEDGLHAALLRKLIKEERVSNFSGF---AAAQGVEREIIQVQATVAVLTKEFAAAITGTEIVLFYYVDGKEEGPRGIRIAVAISGFGIVLPFLRWEVVRAEHFVTSLLVGAGTKVGDVSVKYRIPGFWSAKRREAVEEGESGLFSISS-NKTHF-MIAPELDRGKTYLVTGVIIWGRKAGVVNYSPTELDLIKLR-REIALKANEVLGNRARSAIRKIDKGRLNGKLILLASFNIMTKAVEVRAGLLAIASHLNFVSAGVPESAASAMAVEDLSDAESAYGFRTYFVLRIILRDGLVGRKLDRYDEL-DAAVLKSVSFYIYFGDALDPGTLIVAVIDVVKALRALVRTAHHLAQGKMVVVIQAIHTVLLRKNTQAIVQCQRPNCEVDLNVNACLLAVQAYDADTHFSILTVKFDIGGPVYELMGLMGFRLKKWEMEVGMALRRMVEDL--WLENTTVLYTLQLFFHVPFFL-GTSLKTFFGSRKVLNTTTENTGDDSQNAIDDIVEDIADRDVAFLFVELAGVTFEIRGTSV-PLDIHLDATDRYQAV-EKFYKWGQYILEMNFFPALNFTIWKWDLGHQAKENHIVFVWKAVGDKVWIPLPYLLEKAIDDIVEKPVNVFVPAVIDDNQCPF--TRVAFSIKVYENVG-DIIKDAFS-FRSL-EKEAAGVVGAMAEEGILLLSKDSVQMVRTTLEINSAMVSGGAPFVVASSAAAIEDTTRETLDEVLFLSLNLVLAGKVLT------------------------------------------LVDPDVVHATVTIDLRTGVEVINAGDEKAEFNCELLVGV---SSNAVIREYMLIVVSTDKDDASLIYMKPSGQQNNAVDVFLPWVVRPVLIGQAIIILNPGKIEEGITRAELVVDIPKIHLPNVALIFERSTEFERAIPGAVNYRDKEGLLVAVSVSASSVAEAGADV-RQKVSALYAVVSGFKGVVVFTAFYYVDLIGFATTHFAFV--PLELEIALGWENLAIGVYDDAFRAYHMIDIDSDNSVWVRLKP-ATLVSVHKYQQVVRMFTFKAGGTARTKPKWWTFSMLAAIIDTFPGLPVLISPTALVLQREARETAAYEEFVRLAKVLEKQAARSLPKDRFEEEAETEFVEADMLYIDDTVAKMATLDGLEFHGDSYVVGVVALEVHGYCYKPYIKILDAIDVIITLVNAETGTAATEVVMTDTALLANTMDDKHMRAKQFAVDVIITPLTECGTVRNGFKNIVDYAKTGPPRFAERLAVITMTEEKADIKDLLLQTLDLKEVEAFTALITNNSPLTSEDWVALITDGWGSWPYNMINELDLMDEQSTAGNFTATDFIAKKEEEVELADPLDTVGCELKNQKDIVRPFTANPIAMLVVKFRHKGKARVMYSAKYGRSAESIAVEEEMLDFHPGQVKRDCVCVEPVIEYHVNIIAFLQKVRASVDEGRLARKGNVVTEVGRARGDIVGYATFSMFVYPVESTVYIADTIDDAAGIITEGPTIHWMNARAGSTMDPDVQRAALEPQMPALYSTRALRADILTLANGSLAEVKSLLPLTELLIGIDVKLLVNLMGEVVW--------YTLPMQVLIRLAAITIGFRSQVMSLAVTDEFSLEKIAILYITTGYPAVVSRRTSADETGFNLIIRSVDLIVFAEKLDGVVKYIILPGQEKNYLEVRVLSDVVVDSDVVVEIREVDRA-SVGVESILGVIVGRVTTPLLDEKGSVLGVKFARLHAEEFLAALLQIIVFSLTLIHGGGLSDMFTAGSGVAELIILWVAIIILGMYHKKAIFQEEEVKKRDREGPPLSA-ESAGDVPTMVSDTLVPQ------------------------------------------LAIVVNPSQTQGVATGIAKEGVKSFSPMDAELL-IRPVQFKRGDQDYVTKQVQARLTKDNPNPENIEVSAVEVSENGESRLAYIFIKQIILRKVVTPTSKELAAVFIVLLMALVGMLLTWIIFLGGFGSVLVFEEYVRVMGIESWSIASWENIRAVRVVQQ--QNFLTHSFVKLTDAIALKTKQIAALAAGAKGAEGFYVIDMTEGKVTGARYLRSLKELMVTEDKKISVKAVVTAEYPAAEMAAV---AKETEARAQGAYKNALTAFTFRLVDYRIVMIAERPQVYVRENVSAVVREIQKMGDAATRPPTGEAITTMGSAVVRVAEEAGLGKQLPVQLIKIEDIVSLQLKIRSVTVVEPALSTRKTADSTERAKVHVVRGRSKKEQSYNKRGFQNARGITRIGHLDREISPEKIPYALSPFLNKQQVNEMQFSTTAATTRDPVAKQKKQEYPEIGEIARHRVRARMDIRKIFDASRKVIARVRVKEVDVFARANKRTSTVVGTVDTWTDVSPFTTEAANLDQSRPQLMTVATGWEESRLNAVVLVFIWEQVQLVKNQTNVIARAVESENVLDSLEQVMFRVIAYVTVSQALLRKTYAPASILINL-YSGRSKTIKAIKNALRLHMKPPAKGTSKK-PFLPRSPFVVPGTAAKGVRVLDEAISKSAAKGIRGKVKDDLVEGQIKHVAQQQAIAEHVPRVEEEVVAKSGEIHVRIEAASLVAIADLGYITGEDPDVIHLVFRVVARSFEIVI-EG-SPIAQQATMADCDEIHATAALALGAWAADEAGYVAQFYRASLRSILDVEAIRTEATADAFDDTRNFRIAGTLMALLNLS-LSEISSAVHKEDPLDSSRTRGLYAGLVQLSYAEVLISLLSSLIRTKPVRGFQAAVRGRWRPLGTSTEFINVHVIGGVSEVRRDPSRERNYTILMARKADSNAKAGPKADVDKGTDRTISLELVTIVTSFTESKTRKRDDGVSLQIGAKNGAGQLMPGMTHRTG--MVRDDADIDAQRHVLIKEGAVANFTTVEPCASIKAKRDFQAYRPLRLDPHPWCHEEQFCANFGTRTIQKATAAAARITAGADNEYTKLPTFGTGVYHDRVGLVYTLTALAQPVAIDHGVEDKGLRREMSMDKTYAVELEGYIAEAIIVSELTVTRTSMFVVVNDDMASESVLDVVVNAPFELERNIVGCKAKQEGL-DTAAHIVKAGDDVLL-VQIALPAVDKQYAQTVEILTLKQKTNPTGVAVRAAMITSITTSAKLNSLLRLYIVVEDTSWVKMGRAMFDVPMALAKCEASVS-HIPRLARVTENPTGDQESGVHERYYVEILRAKVAVSQHDDLGLDEKSLDEPSAMLNARDDSVEALIVDSLATTSMKVVSYGQLVPVIGDSFIEVNTPKETDGEDVASGIKLEALQVDVRPLAMVVSPLLSVITVGDVADHAIADIVERDIPALLPPPEEHEDRFVGLALFVGIPVGVQQLMAQDTQVIKFGAMYMNTFALRSRDREGEIG----ELLYALLNLMSESKKNALEDGISGGDAVVLEDHMSNLKLQTVIPDYWIKEGSEAANLYGELADDGRVQLILVVLVDEGPGAGATSEIVV-ENYFDHKKIKLFELSGDKDRRSNDIATEEANERETRFTGERAGEVEMVTRDRVKDAQAREAYYGTKPTPSGEDARDFYPNCSKIAAIAGVFPKRVMRGDLFLQLAVDGSTNIELLRIRLATGAIGARLGV-GVYACVHILGVSIVFLTETGWWP----RVAKNNASMGDVGQALNGEEALAKVRYSIEMERRLEESHNA-AGLSVSPGMQDFTDATPVNIDSKAMTPRLTPQALEVVVDALLVRTATEIAVGTDFMGERILKSQWALILADWAMLPNQT-LGPQKEVKALQVPKPGHFARLEEEFPEGTVTTKTWRNECPGMVLSK-DKQAHSTSITDAVASGKSRSPYGMAERMLVDPSETLEGTVRGPVEVQTAKIELPAHLIAVYGIFYHTEIFNKDKVQCANPIKAAVAACMIAGCLSAAAKVIIGTACFDHGPDAAIVARCKLQVALIYMETHLQTIGIVKGQLIGVVVHTANARKLLYEIVVVGHVLL-QLVVQTPWAPWVQYRMKANRVFGESALTTVREVRPVYVFK- STRAIN: GC466 (SEQ ID NO:14)RAVYNTISLLPTIVKQLVGQDIAELLRANEDRAGPERPKRFFPIFTIRAAVIKMMTIEKYIYKERIIYHKALRDLLVKEQVLYYDVIETEQVHLSDLVQARCFNIKVQLKALEATNAIMDTGLKEREDELIEKLRRTKLLIPNFERSLEVDIFQFTIHVCENKVMFKVETILQTDFLVDLDNIYDSLGINVDSCLDLR---DDLTVSAI-LDIACDKAAVAQDHLRKLFTEKEGYEEAMVYYVEKEAVIGLTLSDLHRLGADFLDRLTITEIFRVAS-LIVLLMRYVDFK-VAEFRTVDKEEENAAGFTSKSKEMTALISSAVCKLLYKDGSKQEK--RLVLAEDINMRNSYGKHYVKSDTITDTSVTRTAEIFNIIKAHQSERQTEKRLHAKRRRAMTE-EDLALDKLKKHIAANKLAVISFCNDYLDVNYLDDSFIDTVNAEFNTTVVSLLDDAERQEHLILMVAKEIFESPGFYVSDVF-DAVDLGIASRGLMMGVVKEFLHSLCILIAKALVPLKTHSRRSLRRVEMGDQPGNLNAEMCIELYVIQFKVKVHREVEFDLLVDNEGGEGKTAKVVKDVIVKCKIELIKEEIGVALVIEVKPADKANAVLNAPLVLQATKGKIKLQNE------------------------------------------RKGRDSEMFEKETAGLTVRVSMSARVYLSFNLLEKIRIDSY-IASISEPELGDLLFYDIILDSIYPVHFVLLVAGNDYIEFRQLEYLEAPAVSTYVIHQRFSERSLIASEAIIKSKTVIKAVMQLTNREEYTATIAKAGVDCEIYNRQKLRKEGPFLNFAAEKKDKERSLLSDIIYTDEMVRTEDYLTGPCAVVPGAADLAFNELQERLLINKGVIVIDRNCFCSVICTSHVLDDEPHVEVLYGNVFDYEDFNAFINVPISKNNIVDREKQVSLLNVVGKEAQGLNKLFKFEASRHKIDDFENNVLYDSVTSIYGVSLFDENPADLAPIHFSP-HSKDLLIESIILEIGEIEEEQASRVVTKMVL--KDEAVELFNIFMEAKGCEKDILKTKANIALLSAEYGINVAADEMLLFFFVED-EWNRKDAHVLALVTGFGIPFPFLKVGVAQVTEFFVVRILGFILTIDDVDVKYRIPGIATRLRREAEAAETSGIFNIKEGDKIHVNVITPVLSIQEVFKITGIEAWGRKAKHLQFEGLKLERILFR-R-YPMEAGEIISQKIKVVVRQTDLKGLQGRFDLLVNSKIVVKAVEMLVRIFVPFGHIVIITAAIPNSSASALCEKTMDDIESAYAFKINYVKKVVINDQFR--KLERFDEMERPAYLASIAFFITFAKKIDPCIIVSF-LEIVEMLDPMYRTAHKMGGKQIITIIQYMYTAILRKNTQRIVL-EHEGCKVELNVNSIFIAVQCYEADTHYSVMTLHFDIDPVDYVLFKIMGFKV-YHAIETAMNNKDFLNQIQFWFAPCTILYQLHQFFHISLFAHGITLTEFPETRRSYATKERSSDDDHRHVLDDIIQNIEKQTLKFLILRLENINFEIEKLSTKSLNLEVASTDYYKTAAEVIIKIGKYVIELSNFPPYNYTSFMWDLGKQRLLGQILFLEASVNAYIALP-PYGLFKPMETASEKKITLVVPVVIQSTSLPY-EEHLKFCIDAFENIANGLGIKGFSFFANQANEAASKVIGALAKQNIVAISKDRLQHLLSVLFLN-VMVQEGGKDVVGSQALKLERYTKEQLSQVLLLNYTLVVVMIVLV------------------------------------------VVDPDVVGATITM-FTTTLESVDAGEEKSRIECASLVGVGMDSELPVVVKMILIESRDNSPICSLIHMNDSLHNNNALLMWLKWVLNPVLVGKSIIIKLDVAILEGMTPTLVVVEFE-IAADEFVLPTEPSEDFDRCVVKVLNAEKKN-LVLLVAISTGSFVEASGEL-REEIVVLFIQMWGYKGIGWITTGLMIELVGIVNTKFSFVTITFKLNLYKKNKCWFKLIYLDVMEMYQSSDEKKMKFGFLVLLPYCRNVRVKEYQQVLKMFTAPVKGFTRLEWRFDLMAVLALIIPTHPGIEVILPRRQLVWDWEVHMTMGPKEWIRFTTVIEQSTERFVPADKAKNAS-TLFIEAEMLRLESRIAEFAIMDLIEFYNDLHVVGVVAVEVAQYCYEVFVKVLDRISYVLNQLLYEKKEADTKITFSDTAVIANAQEEEKMKRHRIGFQIVLSPMTEVGVIKKGYAEVVDYSSNSPPRWKEMLLIINITEEKMTADDAEAEYADYKTIEMFSRIFIVNSDISNQELVALLSEGFGSYPDHRILWMEKNT--DQIGVFTKSDYVSKKKDKIEMSNPVEKSCARLQNERDFDRIRTAHPIARLVIKLRTCDKVEFMYAAAFGRSAESKRFKEELLSFSRTLLKKQSICVEIILQYHVHILTYIKTVTAKIDEGRLV-TEPQVTEIGNERGEFADFTDYSFFIYPCQSTVTSSNTTYKAAAIITKDNDVHYLDQLEKSEPREKIEIMEFDEPLLAMFGSTEIKDDVLTLSNGTLPDIKSILTLNVLLTGIETTLMIKIASGVEYLTKAGIFKHRFPCNAIIIHVLITLGAKEEHMSLRTTDELSLNKIAILKTLLDYSGIFANRNVKLKVGFELYLRDVDIMIFNTRLEGVIHAAIIIGKKQNLIAQKVLTNVLIDAHKVAAVQQFDKLPRLNASVLLTIISEKISSQFIEAKGSVLFITFGRLRSSDFLCEIVSILFVCAIIVQSGGLSSSFQIMGRKTTLTLAMLVLCISA-YRKKAVSQLEKVQYLVPTGPPMRLVSPFGEVPNFIEEDLVPQVEFDKYIQNVILAPEVFVANNFALIFGEPNRLFKKIIASST-IILIVKNRYEKNVAVAIAKDRLKTFGPMGAELLIIEPVKFK-NDRDRLKKAVQVIRTKDQA-EATIEVSVVAISESGQMNEIYVYISDVYLNKVTWPTWSELAIVMISVIALCIAMFIV--ITLGGFGSVLVQRRYVKIMMVEGTRII-GANVKKIRPVQHRHQNILIWGKLKLTTAIQLKTKQIGALATGAENAEAQYVIEVYGDKARAANFLAKMTTIMGSQAKKIAVKYVFTSDFVAASVAAILRPKHQKIGKYTGIFREVLCNIRFRTCNCHVVLESRNPNILVKENVTAVYNEIVKLAYSGTRPSTGEAVKAKGSPLVKFARMAGLSKILPLRFLKIFRIFDIKWKIKSVTVMEPKISIRRNAAAIERPKVRKVFGRKVKNTGYAKKSFQNARGLSKMLHMNKDMNPEKIEYALDTLIDYEKVNEVKFSATAATSRDPVENQKRREMPRTTI-LRDPTQMRVDIRVMFEAAEKLIAEQDVQEVDGLPAARKRSNVIRGTLTTKEKETKYTTARAGLKAAQPQLWEIAGSWDRSRQNDVVVVMMADEIMIDNTTSNVIRKAIQAENMTETLENDMKTVIAVLEVAKVLLRKSYTPVCIIVNLDRTQITERIEAVKNGFNMHLKPASTGTSKSSIFMPRNINAVEDDDQAGMSLLDAAVSVAAVHGNAGKVPDQAVEGNLKHTPAPQGIKEHVPGRRAEVYAKSGEVKVRFIFNALLALSDVRLVTG--KYFRVAVFHLYARSFEIAFLYLHSDILRRALISRTEEVHAAALAVLEAWLLDDTYRACLFYTGPMRQVA-IPTVGSCIIANNLLPKLEFDNIPNLLLLAALLI------------------------------------------QRTRGRMGFKAMIRQQWKPAEVKSEGVPVTIADGVPYIKLQPTKAGKYSALIMRKANVHVRCPDKVDVEKGMSRGVHVPIFYLIVVFTESKTKKQDDNVTLVVGAEEQAGSILPSLVMRAG-KYIRQSIQIEEMRGTLIDNGVVSDYDIIDPISDMLMKWQDMGYAKLFIEKHPYCHISQIINAFAMLALEKCTVASINVISDVPGQDVENVHYGENLYNNEAGLEFTLEELIEPAKIGKIIEDSGLKREQKMDRVYAVELFSYITKAIELALLQILHESIFIIESDVMSSEAVEEIIVNAELDFDVNVVGCQARTEAMSSTTSFIVRFGNTV---VQIAVPAVDKQFRQQVGITQQEKSSEPRAIDVRAKMMTSITT--------MDFLFSLLLTWLDISKAKYSIPKTISKCKGDTV-AIRRNMDIFEPAEGDQEKGVVEKFVVYIFEVVINK-KNPEVDLQEKSLDAPSGRLEAEDNNIEALIIDSLTTCALRVVEYGKLIQVITNAFLEINTINSTDAEEVEARVGLEAIRIDVRRLSCVTSPLLSIITEGDFLEVCMAVIIEKDVGKLHEQKVEFKKRFLNLELLKGIEAGITNLIASSNPIMSISTNYKRTFDIETKEIDQEIG-WFGNLLYAALDMLSRSIKGLA--IIAGGDTFIYPNQ-ITIEVHIVTLGIYIKDFADRLVLLMDEELDGLYGVILLSYVDNKIEAGSTNERVPDENYFDHVKMKLFELGGDLESKSNDLPRAEIKTLEVRYTKDRVDGVELITKNKHKGDDATEELVGTTTSPANVAVRAFYPNCSKLIVIVALLKKLDAQDKLVTNGRLETECQVELTKFALLL-ACNFFYGTGSIYWRIHFCGLIPDILSEITYRSSKHMYIMSDNYTSGDLGTNFSREEGLSKISFHV-HDKRIL-TGKMLSSVSVSGEFDEFWECTLKGHDNKFLSPQLTMIAMKVNLDLAAIRESKDFNVVTNFLGESTLLSAFRVMLNDLSAYKNISPVPPQKACKALDKEKPGHFKRLEVNFEGTEVTSKVHARQCPGTDQKK--KQAHSISLTNQISSARSKNPYQTATKFMVKPNESIEAICRGPITVNVVKVAVRAHLLHVYVLLYHGNVVAEDKIQVAKPIKAALEAVVVAGSLSAAAILQIGTAAYDLGPDSLILVKAKLRVATITIALHLGDLSVSKGPLIATAAAYPIARMVYEAVFVFGNFFLVQAVKFSLKNPFVVYKLKRAAVDLEKQFKLVDVARQVYMFEL STRAIN: GC563 (SEQ ID NO:15)RSVYVTIDILETVVRQTTDKDVAGIHRADEYKAGPMLKRAPFPIMTIRAATIKIIAIDEFIYDDIIVYGNVIVELQIKEKVLFWLPVDEGVISVVDLATQKLRGVTKVVNAIQTEEAFAEDAIAKA---IEERKRRSKMVIPNFERAFTMDVMAFPFHVEQKSVVHMSQPILDMNELVDVEGLYDKEGITVDDCMNLREDYISFEVSPL--DIKVEQMEAVTEQKRENIRATEQLDNEVLAIYQKKTVIHP-------------------------------------------LHSVKEEEENAAAYVNRDKSLSCMISCAVSKIKYKDGAKQDS-KKMLIDEQITLGNAFATVNVKSEDLEDTSTSTQALILDIINAIKSKLVTETAARKSKKEAAVANAALSIASASKGFAARVLTVVNLTDNGHAINYRDPLIIDKVQAEYGHSLTSLLHADVEEQKLIIIWAKNLFGEDGFGIYDIY------Y--GNSWLMGLARPLVKSLTLVIAKEVKGLLNEEVTAVARKKLDEPNGQKGALEVLELYITKYKVIIEKAVTFDLVV-GGDGAGTEASVGRKVIVYHKIEYIHESIEVQIGENIGPGDKANAVLNAYVVLQAAKASVTLQDEAIGQLKAVMKIAGTVVAKPLPKETLITHAQSLNEIFKDDITIKRNRESNIIEKDRINTVVEVALKAKAYISLKLLSATRTQSYEFSNITDPSFGDLCVAAKVLDSIYPVAIVLLVMGNDYIEFKIIAYLEKIDVPYFVTYLRLSDLEIIPSDAIISKPTVIKANAEVDIKFEYEAALMKGSKEIELFNRHKLSKEGPYFKLAAAAKDKERTMISNVLYVQEIVLTYDYLTGPMAISPGVAELEWHEKEERRYVKKAEITLDESSIADIIANNQLMDEYQQVEIMYQDIFQFDRINAFIVYTFSKNNIVDREKRETVLAAVSKEAEGVDKLINLEKGRARPIDKETNVMDGYFSQILGVFTFDEKLTDIKDLAFDTYEV------------------------------------------MAAEGCEAELAAVNANVNIDGSEFAIGITNSDMFVQLYVKDEEKNITDEKFLCIVTAFGIPFPILRFEIAHADAYIVSLVVSAGLQVGEVNVSYRIPKVATLNQASALKENVGGTFSIKEGDKLHLNAVVAKIEDAAVAKITGVVEAGKRAHYFQFDGVEIEILLVRDREVSIDAGKIVGEKAKKVLRNIAMNKLAGKFNILAEKSGMVKAVEVPARAIVMSTHVLIITAGIPKAPVSATAVKDISDADSAYKFKICHVNRQVADDGFIERKVERYKDMEDPVLIDGIAFFIRYGSKVDELITVRTIIEILECLGEYWRTADRMTGRNFVIFIQYLYTVILRKNTKRIIQAGHEDCSAQLEVDSLFAAVQCYTHDVHLSVLIVKFDIACCHFTLFGISGFETDKHEMETGVAMSELIENLGFWIKPYTVLYTLQQFFQIPLFLENFNLTQFVSTRSCMDSKE------------------------------------------TVENMKVEEKDFFKAV-KYYYEKGDYVIRLCFFPALNYTAYEWDEGKHSKEGEITFLKQGVDKAVWLGRPYGLVRSVDQDI-KGMTTEILAVIEIDKLVFHPDFLKFTYDVFFNVDGGMCAKAFTFFKEQAEREPEKVVGALAGMGINEYSIERIQYLFGCLVFNSAMFQSKEPIVVGSDDLEMEQLTRERLNEVYMLGFNLVAMLKVLVVAKYVQSAPFVYFVSARE-DIEKQTMQRIEQFNEGIFVDLTGINYEDVLHTTVTLDLETGVYMLNLGVEKAFIKCRCMVALALSTDTPVVVKFIMVFAKENSKACSLIHFRSNLHDSNTLKIFLRWVIRPVLIGKAIIIKVEPQVTKGITPAHIVIDMRSIMAEELVLVMEPAEEFDRCIIGFIEAADKGGMIVTLTIAIGSLVANG---------------------------------------------SADLELAKKSKGLSKTVDFDLSEPYQFGEENKIDFGFLLISPHCSNVSVNDYQIVLRMFSVEANDKVELEWRFDKIALLLTIVPTHPGMYVIFPKAILILKWDVEETSSATEWIRLAKVLEQQTGRLVAPERVVALEETSFIEADMLKVDDTMGKLCTVDLINFYSDLLVVGYLVIDMAGLCYHIFIKVFARINYVLAYLCYEKCEAPEKVKMTDADSLANSIPDNRVKDKQIGMKIVLNPMIQVGQIKKGFKELVDYTQNSPPRWAENIILIVFTEEKGEIDELEAKFVDAKT------------------------------------------ELDRDGCFTRRDYILKKQEEVELSDPQDRVASRLRNEKDTARPLTAHPVSRLVVRFREEDMVYFLYDARFGRSGETIEIEDRMMSLQATQAKRKTIMVETLYKYHVRLMTYIKKVRASVDELRLQTHGQETTAIGMDRGDFAGYVAFSLFLFPVKSTVEISDTVAKAAAIVSPDSDIHYLEEFGEEEETNRLELLSFPPLLIALFSSTDLKDDVFTLANGNLEDIKSFLSLVELLVGLDASLNIALAGGVVFLPNIPFYNYRFPIQAIFEYVLINVGVRDEVMNFKISDYLSFKKVTIIMLVVEFPVIFADNTSKEGVGYNLLIR-SFIIIFVEALNGIIYAACTKNQEPRLLEQQVLSEFVVNANAVTAVDSVNKL-NLGLSTLCAVILDNIKTPIIDAKGSLVVIKFSRLAGEQFLSIILSVLIVSLTVIQGSALGTIATYWGRSKELVCLFFIISILN-YHNKEILEREDVEKMNWRGPPLTGT-DAGDIVKTITAHVIPDRAVNMYICDKLVAPRLWLTDVDTMQKEQARRFLNGVVEGKVPLDLVVNEKYEKKAAVHIAGEKIKAYGPMGAQLDEIRPVKFKQDRKDRVGEAVQSRIQKQNPEPESIEVSAVAISEGGQMNEIYIWFSGLKFQKIIWPEKQSVTAVLASVVGLIILLIGVFLIFFGGFNSILIEERYLFVLALENSQVAGKNNIRPIYIIQQ--QNHVIWEYLTLAIAVAVKTKVIAALCAGVKGADGFYVIEVLPGSATGARYLRALKAIMGPEEKKIDVKRIITCDYVGAKMAAVK----NKVGKFIGNYKLNLSNFRIKTVNYLIITDIEDDPVLVKEKVTAVAAEIKIMGYTGSKKETGEAIQTLGSKVVLIARDAGVGKDLPVKLIKVQKIVGFRFEVKAITVIEPRLGTRKTADSMERAKLKRTRGRSVKQSASSKRRFANARGLSQMGKLNKDVTAAAL------------------------------------------KLSYRVQACVDIRKIYYASKKLIAENKVAEANPIPRAEKRMS------------------------------------------DVVIVFIRDEVMIESLDTIVISKSIADDSTTVTMEPDMKSVVAYVETSEVVLRKIFTPITIVVKLQYSDETEKVEAVKGGYKLFLKAESVGTAKASPFMPRNRNPLN-SEEAGVKVLNEKVSKEALKGIANNVAKNLVEGNMKHTPMQQGIHEDLPGKMGDVFAKTGVIHISIEAAAIIAIAEFNFILKLIAGVAHLLFKVIAQSFDILLVILLSTVLRTGTIPTVEEIHVAAAMVLEGLELTEAYHAAMFYDGPFKRVA-LESIKAGLIATKCYMEDEFKLLKEILMVCGVFI------------------------------------------MRVKGSMGNVACINGKWKPMGVKAEYVVVKVISGVPEVKLHPGQKKEYDIINLRHAEAHVKAGTKVDVEKETDKTIHADLLTLVYTFTEKKNKRRKDGITIDVGARNKGGTLLPGMVHKAVRLMVREEADIEDEKKTLIKEGVVAHYTTIDPVASMKAFRDFQEYKTLRIDKHPYCGEKLLMSDFNMMHLKRLMAAAAEVTAPTRYQDEAKTTKGENIYHDRINLTYIVSELIDPLSVERIALDMGEKKEQKLDRTYAVEVEDFISKAVNVSDLALARNNLFIIQCEETASQAVLDLVVNSSFETHINVVGMKARAEQQPETSSYLVKAGDEFRIAVQIAVPAVEKQFKATVAITTLKQSSEPKAIAVQASMMTSVEV------------------------------------------NIKVTAKCVEPGQGENENGYSDEFYVKILKSVIEKDKPDYLDLDEKSLNEPSSIVEARDDNIETMVIDSLSCISLRVVDYEKIVVAIKDKYIEMNSPKETDAEEVDSGVAIEALEVDIRPLPVVTSRLMSVISKADILEEAMAELVGVDTGSLHVKNDERPKRLVGLELLHGVQVGVE-LMYSETNMNHFATHYLADYDLEILEYNEKNGQIYKNLLNAILPLLCETLPDLLEHGIAGGTAFVFTDQREAVALHKVPANLVIKKGVEKYKLFVTLENEGTTAVVLIICIDEGLA------------------------------------------RETRYTGDRADEVELVTREHGKEDDSRERTVNTTNPVPGVNA------------------------------------------VALLIAAVRFLLNVGGLYAVVHLLGLVVVYLTQEEFVADKHDRIVVDDITEGDEGVHYTKQEGLSQVGFSVEVKKQALASGLE-SGMSVSPGIEKLYKHTPKGKEKKFVLPDLTKCASKLKLDVVIIRTVYDIRIVVSFLGDLLMKSKYSVVARDILIIANVVKMSAKTAVKAVDKEKAGHFKRVEEDFAEGDVISKALMFHCPGMVQRKKVKQAHATTLTDNLASARSKSPYQMAEKLLVDPSEALETRCRGPITVNTVKLSVRSHLLHVYKLLYHPELSQKDKVQYAEPIKVAVTKVMIGGALAAAAIIEIGTAAFEVGPDALLVTNIDISIGALGVGEHLLEISSAKDQIVSTAA-VPMARQTYGQVIVLGDHELIELVLQAPWSPWVTYKEKRVKVELDKELNLVDVAAPVFLVKI STRAIN: GC623 (SEQ ID NO:16)RSVHFTVSILDTLVRQTNGKDVAGLHRASDNKAGPMLKRAPFPVMTIRAATVNMIAIDEYIFQVQIIYNKVLVELKVKKEVLFWEAVAEEKIAGVDIETARCRGVDAVLRAFNTGNSLAEDAVSDA--ELESQVRRTKLIFANLERTHKLEIYKFPKHVVQGKVIHIQAPAIAQGTLWDVEALLDKEGVDILDCVSLEADPISLEVGAAE------------------------------------------------------------------------------------LRAVQPEERNAAALTARNKELSALISHAVCRFRYKAGSKQEKEVKLLLDEKSTLGHQYTTINVRADDDEDVATSIQCEIFGLINPIKSKLIAEVNARKSKKEAAAAGTGYKVDQAAKGLAAHKMTLVDVTNDGHEINMRDPLVIEHVQAEYGHALVSLLHEGARAEALLLALAKNIWGEEGFGAEDVY------E--NDSFMMGIEKEALKTLTLDMAKEIPKMLDAAYRSITRVKLKEPNGVRAAETAIEL-ITKYKVVVEKAVKFDLAILDGDGEGSEGKIGKKIRIYRRIGFVKDILRVEFAIEVRPGDKAGVVLNAALVLQAAKAGVGLKDEVVAQQKRIMEIADTVVGKPKAEDSFIAHAAGLEPIFTDDVTIRRNREADQL-KDRVGVTVDTTLRARVYISLDLLSAERTDSHQLAAVTDPEVRQVVMWDVALGSIHPRGFILVVAANDYLEFRARYYVEIPYVTTLGTYLGATNLNSVPSSAILTAPIIIKAAVELSARFDYEAAIATLNKDCEVFNRHRLALQGPYFKRGCASRDKERTSVSNWTFLCEIFLDEDFLTGPMAVCPGVFELEWHEKKKRRFAKKGGIAIEETTLADVIANSQILGKKPRREVLYGCVFEFERLNAFIDYPFSKNNITDREKKDTCLLATEDQAEGVDRLIAMEKRRARRLDREGSALDGRVTQLIGVFTLDGEVHDINPIHLPAYTTTPYAFEAVAQLLTEKEPGFLVELLEQVAVKLRATAERGVQAIMAANGCAKELMAVSGNVALMDTEFAVGVANDVVRLFYFVQKEETNITEDLFALVVTAFGLPEPLLRFTVCHAEEFLVCLVLSAGQQVGQVEVSYRLPKIATIEKREAEEKEKGGLFTIRQGPKFGV-VIIPAQGENAVFKLAGAVEWGRKAYVLTFTPFELDIMLVC-REMPIDQGKILGEKARHVIRGIILKKIAGKFDLLAAKMSIFKAVELTARVVAMSTHVLLITAGVPKSAVSAVAVKAITDVNSAYKFKINHFCRRMARGGLLKAKRARFGAMPDPVVIVQITFYIRFADAIDPTLLIAVIAELLPSLGPLWRTAHQLSGNKVVSLIEYLFTVILRRSTGRIVQVSVPTCDVKLNVDSLLVAVQCYAGDVHFSILIIKFNIS-CEFTIFGLNGFKVGAHDLEVGVAMHEFLGDLEIWFDEYTVLYTLQQFFYVPLFVAGMDITEYEGQRRIMDSQKESQGDSGQKALDDVVQNIEKKGDLFILIRLEEVEFPIENIAVMPLDLEAPDVDVFKEVDVEYIEM-AFFVAEP-WPLYNQAMWTWIRPKINVEGDLVFIIASVGTTTWLVCPYLLKAAIDDSVQKNITTCVAAVIRLYQM-FNTDFLKFSIGVFFNVGGCMAAKTFSFFKAI-QREKEKVVGALADMGILAQSIERIQMLFCCLYFNTVMYTTGGPMVVGSKVIDLDQLNKEQLNEVMLLGANLVALILVLVAARYVRDAPLVRFVWDRG-DMRKQLLAALAQFQYEVYTAVTDIIDPDVVHGTVTANLVTGLEMVGLGVEKPYLECQCLAALALETEEPVVIECIIVFAKENSKAGSNLHFSSALHVGNTLAVFLKWICRPVLVGKAIIYAVEPQITQGTTPGLTVITFRVIMADEMVTLFDPEEDFERAIPGFINYAKKKDLVLFFTVSAESILEEGGECLPQTAVFIWFWVIGYKLINIFTAMF-I-QLGVATTHFALVG-PAQMELWEGGADIRYLIHWNTFVFNHKLDLSTEGDIFKVLKPNCRDVKVKAYSQVVRMITFHPGGGAACEIELKRGALMAEIVQTHPGLPVIYPKTTLILKWEVKEDAEQTEWIRLTKVLEQEAALLLSAERVSALEETKFVEKGWLRIDDTMGKMATMDLIEWFNDLTILGVVIVELAQLVYRIFIEVFDRQRYITILLAYEKKTASSQKCMSDTAILSNTIRENRLRAKQIGRKIVLNPMLQVGVIKRNFKDIVDYSQASPARWKEQLISISFTEEHANIDAAELDSLDLKALHVFSKLVLGNSDITNQEWLALLKEGFGSYPFGRIRALDPRREVSRLGASTRKDYVSKKSEEMELADPQWEIVCRLRNERDVDRRLTAHPYSKLFFAFKTGNALSFLWDAAFGRSGETLEVEEELLPFRGSQAKTPTICVAPVIEYHVAIVAYIRRVRAYVHDMRLERVGKQVTAIGLARNDYAGYTRFAYFVFPVRSTVEISDTVEASAAIITRTTNIHYLEERGGQIPEAELELVQFEDLIIAVFRTDRTKDDVLTLAQGTLEDIKSLLSLTELLVGIDADLIMGLTGVVCYISGLDFYQHRFPMNALLSTVLVTVGVKDAVMALRVTDQLHLQKVSALLTIVGYPMIFSTRTASEDIGFDLIIRTG-CLIFYASMNGVYKAAVVAKQERRVTEAQVISKCMVSSDQIMVVREVDKL-HLEPAPLAAVLLENVISPLFRASGSLLFIVFGRLASADFLSALITILLCGLIIVQGSALSGAIDFLSKTLDLWVIFLILTLLLLYHNKTILREETVEKVTWRGAPLTGKVRNGDVPAFVEEEVVPQRAIDMYICDELVAPRLWMTNADSMQREQARRFLNGHVETDIPLNMVVTGLYEKGVAMHMATEALKAFGPMGAQYMIIEPVKFQ-ARRDRVHAAVQGQFKKANPEFENIGVSAVAITEGDEMRAFYVWFREMKLKKVVWPDRKTVTTVLLSLAGVCIIFMAVMIIFLYGFSSILIERRYIRVFSVEGSSVWEVTNFRPVKFVAQRQQNHVIWDLIKLSFAMEVKIKRIAALAAGAKGREGFFVIEVLSGRSSGARYMRDLNQLMGPEAKKVGVKRIVTCDYVGAKMAAVK-PA-PKKGKFIGAYADNVRNFRLATVDYQIVSRLGRDPVLVKENVSAVYAEIIKMGAGARKPPTGEAIKTLRSPVVAFGREAGVGKELPLRLVKVQKVVGFKFNIKAVTVMEPRLGTRRTADAVERAKMRKIWGKSVNQASYARKRFTSAKGMNTMGKINKEVNAATL------------------------------------------YLRYRIRVQVDIRKIQAASMKLCAENDVSEATPMPRANKKTSTIKGELTTKENDSVFTMERGKLENNRPQLYKLAGKWEETKENEVVLVWICSQVMIEQRTSNVIKKALADDDCTVSLQQDALTVVAYIAPVRALLRKTFTPACIIAKGQRSGEPIEAKAVKNGLRLHLSPESVGTGKASVFMPRNIFILQGTHEKGLSYLSKKVSKEAANGLSGKVPGLVVEGNMCHVPKEEGIKEAVGAKIGGTVCKCGEVRVMIEARAILAIADINFVLKPNAGVHHLLFKAVAKSLRLCIVIADTPLAVECILPDIGEIHYAAAAVAEALALTQARTAARFFKGPMRTLFNLPYVTKVLITGPAYKTDDFNAIQTLIYAAKLLL------------------------------------------LRVRGRMGYQAAINGQWKPAETSSEFVVVKIIAGVSEVRLHPGKKKMYDMLTLKHADAHVRAGDKADVDKESDKAVHVPLLVAVTTFDEKKSRKRDIG-SIAIGPLNNAGQILPGMVHRAVRMFVRESVQIEEMRGTLLDNGVASEYDIIDPIADILMKWQDLGYAKLMIDRHPYCGDRMIASAFNIIRMPKIIAAATELCTEVPKDSERNSHQGENVYHDEINLQYVLISLIDPVKVDRKVEDTANKKESKMDRTYAVELEDFISKAVLVSDMQLLKEALFIIVSETMSSQCVLDVVVNAQFEVDLNVAGARARNDQIPETASHFARIHPAILVEIQIAVPAVAKEFRKTVAITTLKESSVPKAIAIQASMMTSVV-NAEIHELMRQYLVVDDYAWFAIPSALYDIPGSVAKEEKGFV-AIQTTAIMYVPAEGEQENGVSEALYVQVLKAIVEDDKPDDLDIDEKAFNDPSSVLEARQEDIETLVVDSLTCIAIRAVEIGRIIVVIKDKYLDNNTPKETEAEDIDSEVGLEALRVDVRPLPVVTSRLMSIITKGDVLDHAMAQIVGSDTGSLHVKTEDKEKRLVGLHILHGIELGVSGLMAADVAVIKFGTNYLNTYDIDSMDLKDEVGELYRNLLNSFLPLICESEKGLLEAGIAAGEALICDDQQEELEIHRVPPGVVLKPGALALKLYIRLEGEGCYAVVLIVFISDNVEAGATTERVP-TTYFNRCTVKLFNLGGGMDRKSNAIATQEVSARETRYTGDRADDVDLVTHNRAKDQDAREGRLTTKTPAAGLDARKFYTNCSVLVAIVALLLKLDSRDTLLADSTAAPTADSELCR-LLLWDAFDFWHDVGSLYFAIHLIGLQ-NILTEAAHVTDFLEKIVVDDMTDGDRGIHFTRLEGLSQVSFSLEVERQAHEAHVKLSSLSVSPGMEAFYENTPKGKEQCRVRPRLTPIAFTFTVEVLIIRTTRDIRLVTSFLGDHTLESKFLVVTADVLISTNQISFSPTKEVKALDIEKPGHLDKLEIDFQAGDVISKVHEVATMGMEQKKREKQVHSTTVTDNIASSRSKSPFQTAERMLVEPQEALETKCRGPITVNTVKLPVRSHLLHIYNLMFHQEIIANDKVQFAEPIKVVVAKLCVAGAVSAAAVIRIGTACFDLSGDAVALSEATIPIGQLAVCSHLMACAVSKDPCAATAAAVCMARSIFGDALLVGDLVLVEVVKHAPWAPWVKYVVKRAQISIDKKLGMVAIARPVYLVKI STRAIN: GC695((SEQ ID NO:17)RAVFSTIDLSTIIVKQLVEQDISEALRANEDREGPARPKRFFPIYTLRAAVVNLITIDKYIFKVQIIYDKALKELKVKEDILYYDLIGQEIVNFTDLESKRCFEIKVVLKALEVEDAVMQTALKETEQEYDESLRRTKLLLPDFERNVEVEIFHFATSVCQNKVIHKVEEKLASGYLVDVGNIEDNDGVCIDDCVELR--DVDLEVGAI-LDVECAKAAVASDHQREAFEAVEEYEEEMIYYVEKEAMIGLKLSQVHRLGADFLDRQAITELFRASI-LIVMLMRYADFR-VSELRTVKPEEENGAGYVMKSKELTALIGNGLCRPKYKDGSKQDK--KLVLVEDLNMQNSLAKVYVKSDTIKATSVSTTADIFNIIKAHKSIRQTNARLHAKRRRA---ENVFSLDKLKKHIAGNKLAVISYCSDKLEVNYLDDSFIDTVNSAFNTPTIGLLDPGIEAEK-LLLIARELFESPGFAMEDLFDAAIDYALHGSGKFMGVVKDLIHNLCIKIAKALKPLKTHSRRSLQDAELKEQPGNLNAAMCIELYVIQFKAKLHHSVEFELLVDNNGGEGKVCEVVKDVLIKRLVKLIKEEIKVALVIEVKPADKAGAVINAPLVLQATKGRIGLQNETVLLLKEVMKISGTVIGANRPREAEQTLGERIDTKWGDHITLRKEKESDIFQQAHGIISVRVSLSARAYLSFDLIANDRIDSY-IAEVTPPALGDCLLAEAVYGSIYPVKFVIIVAGYNYIDFIRDEYIELPAISTYGVYERAGDRELVPSEVILTSKTILKAVMAVAQKEDFTATILKASVDCEVNNRTKISANGPFINLAADKRDRERTMISNIVYTDSIIRTEDYLTGAAAVVPGAADLAYNDKGERLLVKKGKIVVDQGSICQIICSTQVLDDRPSIDIMYGTLFEFENLNAFINEPISKNNIVDREKQETFLDVV-KEAQGLARLFKYEASRYGRPDFENNVIHGDATSIFETALTDKPPLDLRDIHFSP-HSKALLVENIVLDYGEIVEAEVGRLELLLLLYIKNEGFRFVELAMAMKGCEKEIQAKEANIKVKTQDYNNKIENDEMILFLDVEE-DWNRKENHVLLMITGFGIPLPFLKVAVFHAEQFFVVRIIGFLKEVDDVTVKYRIPGVASKLKRDAQAEGTSGIFTVAKGDKVHVNVILPVLSAQEVFTLKAIENWGRKAKQLEFKPTTLERILFR-R-YPMEQGEIIQQKQKVVVRQTDLKGLEGKFELLANQRIIMKAVELLLKIVVLT-HLIIVTCAIPSSAASALCERSMSDVGSAYEFKFNYVKKEQINNQGT--KVEHFMDMPDPALMPSIVFFITFARKLDTLMIVS-LVRFVEMLDPYYRTAHKMGGKQLVVIIQYLYTVILRKNTRKIFLCEHESCDVRLNLDSLLLAVQCFDAEVLYSVMTLHFDIDPVDYVMFKIMGFNV-EHEMETAMENKQYIGKLIFWFKPYNIMYTLQQFFHIAMLLSGVTVSEYLTSRRAYSAKESRNSDETRHVLDDIIQNIEKRTVKFLILRLADITFEIEKLSHSSLDLEVARTDYYKSATAMAVKMGRYCIELSDYPPLNYTMFMWDLGKQRVEGQILFLEDSVNEAVALPQPYGLQKSTNDMSTKGITLVVPAVIKSTSLPY-EGHLTFCVDAGENVEGGLGAKAFSFVEGQERVAAQVKIGALAKQNILEITKDRLEHLLSVLYLN-A-VSSGGLDVVGSDHLDIEKYNKEQLAEVLLLQYTLVVVSLVLVVVKYPREARLVYTIDMKG-DIVKRLFEAIQQFRYGLFIHIADVYNPDLFKATVTFYLTTKVEVCDAGEEKSDMECASLIGLC--TEQPVVVHMILVESKDNQPIAGLIEMNESLHDNNALILWLKWVVNPVLVGRSIIIKLDVEITESLTPTLVVVEFELIAADEFVMPTEPSEDFDRCGIGVINAEKKN-MIILLAISTGSFVESKGEL-DEEITLLCVIMWGYKGYALFTAGLMIELVGIVNTKFAFVTMTFQLNLCNKNKCWWKLVYYDVMDIYQSSDEKKTKFGFLVLVPYCRDIRVNDYQQVMRMFMAEVGDMTQLEWRFDLLAVLALILDTYPHLAVLLPKAQLVWQWDAHDDMELREWVRIAKILSQAVTNMVAADKTKQT--TCFIESDMLRIESRFAKFAIMDLIKYYNDLEVVGVVAVEVAKLCYKVFVKVLHRVSYVLSELCYEKREADTKVTMSDTAVIANAQEEDRIQRMRIGFQIVLSPMTQVGVVKKGYFQVVMYATTTPARWKEMVIVIGITEEKATADTAEVKYVDLKTAELFSRFTLTNSELDNQEWLALIINGFGSYPNERLKWIRTRG-LKQI--FTKDDFVSKKEEKVEMSNPQPRIAARLQNEKELPRIRTAHPLAQLVLSFREDNMLEFLYEAAFGRSAESVEFNEELL-LSRTLLRKKCICVEIVIQFHVQIVTFIRKIVARIEEGRIV-SGPQTTEIGKERGDFADFTYYSMFIYPCNSTVHASDTSVKAAVIITKEPDIHYLAELGPSEPRVQIKLLSFQELVLALYRTNELKEDVLTLSNGTLKDIKSILTLNTLLVGIASCLILNIAGGVEYLSRGGVFKIRFPMNCMVKLALITIGVKEAEMSLRISNELSLQRISILATLLQYKGIFADRNVKLKVGYDFLLRDIDILIFNSRLDGVVHAAIIVGKKQNLIAQKVLTSVIIDAHKVAAVQQFDKLPKLQATVLLGVLSQELCSQFIEAKGSVLFIVKSRLRSPQFLT-VISILLASIIIVQSGGLASGFQIMGRKTTLTLTVVVLSIIT-YRNRKVSQLEKTTVYVAPGPPLRLVDQYGEVPNFIEEELVPQVEFDKYIQNGLVAPEVFVANNMALVFGEPNRMFKKLLGETT-IILVVKSKYERNVAVAISKERLKTFGPMGAEILIITPVKFK-ADNDRLKAAVQIE--KDAV-DATIEVSTVAISEAGEMNVLYVYIKESYLYKVSWPTRTELAVVMFSLIAALIVIFVMFFITLGAFGSVLVQKRYLSTLMIEGVRVVQGANVKSIRPVQHRHQNVLIWGTLKLTTSIQLKTKQIAALATGAENAEALVVIEVYGGKAKAASYLAKMATIMGSQAKKISVKHVFTSDYVAAEICAMLRPKKQKTGKYTGNFKEVLSNIRLRTVNYSIVLDASHPNILVKENVTAVWGEIVKLAFGGQKPHTGEVITAKGSPLVKIARMANVAKQLPKRFLKTFEIFSLKWKIKSVTVTEPKISIRKTSDAMERPVVRRIYGRKVKNTGYARKRFQNARGMSRMAHINKDMNPEKIDHAMNPMIDGEKVNQIRFSATAATTRDPVEKQRRREMSRVTMKLRNPTRMRVDIRMVFEAAEKLIAEQEVSSVDTMPAGRKRSNTIVGTLTTKEKESQYTTARAKLKDAQAQLFELSGQWDQARENDVVLVFMAADIMIDSKSSNVIAISIEDENMTESLENTMKTVIAVIETAKVLLRKNFTPVCIIINWDLTGATDKLRVVKNGLNLYLKPESTGTSKSSIFMPRNINALEQGNEAGISVLKNAVSEAAVHGNAGKVVKNAVEGNMKHTPAPQGIKEHVPGKLEKVYSKSGEILVKAEFNAILALSDTRLVTGRIETVKVNVFHILAKTFDIFVIFVHSDILKRATISAIQPIHSASIAILEALALDEAYLACLFYDGPMYQLA-VMSVADGMIANKLIPTLEFDNIPSLLLVMTLLLISQISATLSTREKFSANKLEHLLEHLTQLNYIEPQLLLLTA-QKTRGRMGFKAKIRQQWKPAEVKNEGVPVTLIEGVPFIKLQPTKGAKYTSLIVRKANVHVRCPDKEDVEKGMSRGVHISIFYLITVFTEKSTKKQNDGITLVVGSENQAGIIMPGLNMRAG-KYIRQSIQIDEMRETLMDNGVVSDYDIIDPISDMLMKWQDMGYAKM------------------------------------------NENYGENLYNDRAGLVFAIEEIIEPARIGKIVEDPGLKREQKMDRVYAVELESYITRAIDLADLQILHEALFIVEHNVMSSDAIESIIINDTFEYDERVVSAQARTESL-GTTEHIVRLGDK----VQIGVPAIEKQFRQTYAVVTQEKSSEPRAIDVKCSMMTSITK-------IFDFLFSMRRMWTEIALAMTTIPNTIAKSKTDVVEAIKRNVDILEEAEGDQQKAVLEKYIVKIFQAVISKEHRPEVDLREKSLNEPSAALEAEDENIEALIIDSLTTTALRVVEYNKLIQVITPAFLEINTTNSTEASELEARIRLEAMRIDVKRLECIASPLLSIITEGDFLEVCIAPIIEKDVGKLHEQKSEFKKRFLNLSLLQGIEAGIASLIASSAPIIQMSTNFKRTFSIETKEIDTEIGYLFDNLFNAAVRLTQRTREGLYL--MAGGECFIVKNQKSGLEFHALTFGFILKKNAREFSVFYSDVGSGISILILLALISEKIEAGSTGERVPQDSYFDHVKMKLFELGGDMEAKSNDIPRAEIKALEIRYTRERVDGVELITLNYKKGDDANEDLVGTGTPPPQINARSFYPNCSKLIVIVALLKKLDAQDGLVANASLESGCNRELTQVALLSSACLFYLDTHSIYWRVHLVGMIPGVLSDLEYVSSFLRYISIDDYTSGDCGFHFTREQGLSKISFSL-KDKRILETGKLLSSISISGTLDAFYEKTLKGDDNKYLSPSLTPIALKIKLEQAVIREAKDFNVVTNFFGDSTLQSAFRVILNSITAYPNIAPIPPNKACKALEKEQPGHFKRLEVDLEDAGVTSKVHTRLCPGMEQKKKNKQAHSISLANQISSARSKNPYQMAQKYLVKPNESIETVCKGPITVNTVKVPLRAHLLNVYLLLYHNKVVKEDKLQIAKPIKSSIEAVIVAGSLSAASILQVGTAAFNLGPDSLLLIRAKLKVATITLFAHLGELSVSKGPLIGTIAQVALARMVYKAIYVFGNFFLVEAVKYSLISPLVKYKVKGKAVDFEKTAKLVEVAREAYLLEI STRAIN: GC957 ((SEQ ID NO:18)RAVYNTISLLPTIVKQLVGQDIAELLRANEDRAGPERPKRFFPIFTIRAAVIKMMTIEKYIYKERIIYHKALRDLLVKEQVLYYDVIETEQVHLSDLVQARCFNIKVQLKALEATNAIMDTGLKEREDELIEKLRRTKLLIPNFERSLEVDIFQFTIHVCENKVMFKVETILQTDFLVDLDNIYDSLGINVDSCLDLR---DDLTVSAI-LDIACDKAAVAQDHLRKLFTEKEGYEEAMVYYVEKEAVIGLTLSDLHRLGADFLDRLTITEIFRVAS-LIVLLMRYVDFK-VAEFRTVDKEEENAAGFTSKSKEMTALISSAVCKLLYKDGSKQEK--RLVLAEDINMRNSYGKHYVKSDTITDTSVTRTAEIFNIIKAHQSERQTEKRLHAKRRRAMTE-EDLALDKLKKHIAANKLAVISFCNDYLDVNYLDDSFIDTVNAEFNTTVVSLLDDAERQEHLILMVAKEIFESPGFYVSDVF-DAVDLGIASRGLMMGVVKEFLHSLCILIAKALVPLKTHSRRSLRRVEMGDQPGNLNAEMCIELYVIQFKVKVHREVEFDLLVDNEGGEGKTAKVVKDVIVKCKIELIKEEIGVALVIEVKPADKANAVLNAPLVLQATKGKIKLQNE------------------------------------------RKGRDSEMFEKETAGLTVRVSMSARVYLSFNLLEKIRIDSY-IAAISEPELGDLLFYDIILDSIYPVHFVLLVAGNDYIEFRQLEYLEAPAVSTYVIHQRFSERSLIASEAIIKSKTVIKAVMQLTNREEYTATIAKAGVDCEIYNRQKLRKEGPFLNFAAEKKDKERSLLSDIIYTDEMVRTEDYLTGPCAVVPGAADLAFNELQERLLINKGVIVIDRNCFCSVICTSHVLDDEPHVEVLYGNIFDYEDFNAFINVPISRNNIVDREKQVSLLNVVGKEAQGLNKLFKFEASRHKIDDFENNVLYDSITSIYGISLFDENPADLAPIHFSP-HSKDLLIESIILEIGEIEEEQASRVVTKMVL--KDEVVEGFNIFMEAKGCEKDILKTKANIALLSAEYGINVAADEMLLFFFVED-EWNRKDAHVLALVTGFGIPFPFLKVGVAQVTEFFVVKILGFILTIDDVDVKYRIPGIATRLRREAEAAETSGIFNIKEGDKIHVNVITPVLSIQEVFKITGIEAWGRKAKHLQFEGLKLERILFR-R-YPMEAGEIISQKIKVVVRQTDLKGLQGRFDLLVNSKIVVKAVEMLVRIFVPFGHIVIITAAIPNSSASALCEKTMDDIESAYAFKINYVKKVVINDQFRDLKLERFDEMERPAYLASIAFFITFAKKIDPCIIVS-LCKIVEMLDPMYRTAHKMGGKQIITIIQYMYTAILRKNTQRIVL-EHEGCKVELNVNSIFIAVQCYEADTHYSVMTLHFDIDPVDYVLFKIMGFKV-YHAIETAMNNKDFLNQIQFWFAPCTILYQLHQFFHISLFAHGITLTEFPETRRSYATKERSSDDDHRHVLDDIIQNIEKQTLKFLILRLENINFEIEKLSTKSLNLEVASTDYYKTAAEVIIKIGKYVIELSNFPPYNYTSFMWDLGKQRLLGQLLFLEASVNAYIALP-PYGLFKPMETASEKKITLVVPVVIQSTSLPY-EEHLKFCIDAFENIANGLGIKGFSFFANQANEAASKVIGALAKQNIVAISKDRLQHLLSVLFLN-VMVQEGGKDVVGSQALKLERYTKEQLSQVLLLNYTLVVVMIVLV------------------------------------------VVDPDVVGATITM-FTTTLESVDAGEEKSRIECVSLVGVGMDSELPVVVKMILIESRDNSPICSLIHMNDSLHNNNALLMWLKWVLNPVLVGKSIIIKLDVAILEGMTPTLVVVEFE-IAADEFVLPTEPSEDFDRCVVKVLNAEKKN-LVLLIAISTGSFVEASGEL-REEIVILFIQMWGYKGIGWITTGLMIELVGIVNTKFSFVTITFKLNLYKKNKCWFKLIYLDVMEMYQSSDEKKMKFGFLVLLPYCRNVRVKEYQQVLKMFTAPVKGFTRLEWRFDLMAVLALIIPTHPGIEVILPRRQLVWDWEVHMTMGPKEWIRFTTVIEQSTERFVPADKAKNAS-TLFIEAEMLRLESRIAEFAIMDLIEFYNDLHVVGVVAVEVAQYCYEVFVKVLDRISYVLNQLLYEKKEADTKITFSDTAVIANAQEEEKMKRHRIGFQIVLSPMTEVGVIKKGYAEVVDYSSNSPPRWKEMLLIINITEEKMTADDAEAEYADYKTIEMFSRIFIVNSDISNQALVALLSEGFGSYPDHRILWMEKEA--DQIGVFTKSDYVSKKKDKIEMSNPVEKSCARLQNERDFDRIRTAHPIARLVIKLRTCDKVEFMHAAAFGRSAESKRFKEELLSFSRTLLKKQSICVEIILQYHVHILTYIKTITAKIDEGRLV-TEPQVTEIGNERGEFADFTDYSFFIYPCQSTVTSSDTTYKAAAIITKDNDVHYLDQLEKSEPREKIEIMEFDEPLLAMFGSTEIKDDVLTLSNGTLPDIKSILTLNVLLTGIETTLMIKIASGVEYLTKAGIFKYRFPCNAIIIHVLITLGAKEEHMSLRTTDELSLNKIAILKTLLDYSGIFANRNVKLKVGFELYLRDVDIMIFNTRLEGVIHAAIIIGKKQNLIAQKVLTNVLIDAHKVAAVQQFDKLPRLNASVLLTIISEKISSQFIEAKGSVLFIIFGRLRSSDFLCEIVSILFVCAIIVQSGGLSSSFQIMGRKTTLTLAMLVLCISA-YRKKAVSQLEKVQYLVPTGPPMRLVSPFGEVPNFIEEDLVPQVEFDKYIQNVILAPEVFVANNFALIFGEPNRLFKKIIASST-IILIVKNRYEKNVAVAIAKDRLKTFGPMGAELLIIEPVKFK-NDRDRLKKAVQVIRTKDQA-EATIEVSVVAISESGQMNEIYVYISDVYLNKVTWPTWSELAIVMISVIALCIAMFIV--ITLGGFGSVLVQRRYVKIMMVEGTRII-GANVKKIRPVQHRHQNILIWGKLKLTTAIQLKTKQIGALATGAENAEAQYVIEVYGDKARAANFLAKMTTIMGSQAKKIAVKYVFTSDFVAASVAAILRPKHQKIGKYTGIFKEVLCNIRFRTCNCHVVLESRNPNILVKENVTAVYNEIVKLAYSGTRPSTGEAVKAKGSPLVKFARMAGLSKILPLRFLKIFRIFDIKWKIKSVTVMEPKISIRRNAAAIERPKVRKVFGRKVKNTGYAKKSFQNARGLSKMLHMNKDMNPEKIEYALDTLIDYEKVNEVKFSATAATSRDPVENQKRREMPRATI-LRDPTQMRVDIRVMFEAAEKLIAEQDVQEVDGLPAARKRSNVIRGTLTTKEKETKYTTARAGLKAAQPQLWEIAGSWDRSRQNDVVVVMMADEIMIDNTTSNVIRKAIQAENMTETLENDMKTVIAVLEVAKVLLRKSYTPVCIIVNLDRTQITERIEAVKNGFNMHLKPASTGTSKSSIFMPRNINAVEDDDQAGMSLLDAAVSVAAVHGNAGKVPDQAVEGNLKHTPAPQGIKEHVPGRRAEVYAKSGEVKVRFIFNALLALSDVRLVTG-LKYFRVAVFHLYARSFEIAFLYLHSDILRRALISRTEVVHTAALAVLEAWLLDDTYRACLFYTGPMRQVA-IPTVGSCIIANNLLPKLEFDNIPNLLLLAALLILSQISASLSSRPQFNLLKLEVFIMLLTQLDYIECLISLLLN-QRTRGRMGFKAMIRQQWKPAEVKSEGVPVTIADGVPYIKLQPTKAGKYSALIMRKANVHVRCPDKVDVEKGMSRGVHVPIFYLIVVFTESKTKKQDDNVTLVVGAEEQAGSILPSLVMRAG-KYIRQSIQIEEMRGTLIDNGVVSDYDIIDPISDMLMKWQDMGYAKL------------------------------------------NVHYGENLYNNEAGLEFTLEELIEPAKIGKIIEDSGLKREQKMDRVYAVELFSYITKAIELALLQILHESIFIIESDVMSSEAVEEIIVNAELDFDVNVVGCQARTEAMSSTTSFIVRFGNTV---VQIAVPAVDKQFRQQVGITQQEKSSEPRAIDVRAKMMTSITT--------MDFLFSLLLTWLDISKAKYSIPKTISKCKGDTV-AIRRNMDIFEPAEGDQEKGVVEKFVVYIFEVVINK-KNPEVDLQEKSLDAPSGRLEAEDNNIEALIIDSLTTCALRVVEYGKLIQVITNAFLEINTINSTDAEEVEARVGLEAIRIDVRRLSCVTSPLLSIITEGDFLEVCMAAIIEKDVGKLHEQKVEFKKRFLNLELLKGIEAGITNLIASSNPIMSISTNYKRTFDIETKEIDQEIG-WFGNLLYAALDMLSRSIKGLA--IIAGGDTFIYPNQ-LTIEVHVVTLGIYIKDFADRLVLLMEEKLDGLYGVILLSYVDDKIEAGSTNERVPDENYFDHVKMKLFELGGDLESKSNDLPRAEIKTLEVRYTKDRVDGVELITKNKHKGDDATEELVGTTTSPANVSVRAFYPNCSKLIVIVALLKKLDAQDKLVTNGRLETECQVELTKFALLL-ACNFFYGTGSIYWRIHFCGLIPDILSEIAYRSSKHMYIMSDNYTSGDLGTNFSREEGLSKISFHV-HDKRIL-TGKMLSSVSVSGEFDEFWECTLKGHDNKFLSPQLTMIAMKVNLDLAAIRESKDFNVVTNFLGESTLISAFRVMLNDLSAYKNISPVPPQKACKALDKEKPGHFKRLEVNFEGTEVTSKVHARQCPGTDQKK--KQAHSISLTNQISSARSKNPYQTATKFMVKPNESIEAICRGPITVNVVKVGVRAHLLHVYVLLYHGNVVAEDKIQVAKPIKAALEAVIVAGSLSAAAILQIGTAAYDLGPDSLILVKAKLRVATITIALHLGDLSVSKGPLIATAAEFPIARMVYEAVFVFGNFFLVQAVKFSLKNPFVVYKLKRAAVDLEKQFKLVDVARQVYMFEL  References: 1. Sheehan, D.V., et al., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry, 1998. 59 Suppl 20: p. 22-33;quiz 34-57.2. Yatham, L.N., et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord, 2018. 20(2): p. 97-170.3. Montgomery, S.A., et al., A new depression scale designed to be sensitive to change. Br J Psychiatry, 1979. 134(4): p. 382-9.4. Young, R.C., et al., A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry, 1978. 133(11): p. 429-35.5. Bell, C.C., DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. JAMA: The Journal of the American Medical Association, 1994. 272(10): p. 828-829.6. Hota, S.S., et al., Challenges establishing a multi-purpose fecal microbiota transplantation stool donor program in Toronto, Canada. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 2019. 4(4): p. 218-226.7. Spielberger, C.D., State-Trait Anxiety Inventory: Bibliography. 2nd Edition ed. 1989, Palo Alto, CA: Consulting Psychologists Press.8. Busner, J., et al., The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont), 2007. 4(7): p. 28-37.9. Sheehan, D.V., et al., The measurement of disability. Int Clin Psychopharmacol, 1996. 11 Suppl 3: p. 89-95.10. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med, 1998. 28(3): p. 551-8.11. Kwan, M.L., et al., A practical method for collecting food record data in a prospective cohort study of breast cancer survivors. Am J Epidemiol, 2010. 172(11): p. 1315-23.12. Vanderkooy, J.D., et al., Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry, 2002. 47(2): p. 174-80.13. Sibley, C.D., et al., A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A, 2008. 105(39): p. 15070-5.14. Whelan, F.J., et al., The loss of topography in the microbial communities of the upper respiratory tract in the elderly. Ann Am Thorac Soc, 2014. 11(4): p. 513-21.15. Nadkarni, M.A., et al., Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology (Reading), 2002. 148(Pt 1): p. 257-266.16. Relman, D.A., et al., The agent of bacillary angiomatosis. An approach to the identification of uncultured pathogens. N Engl J Med, 1990. 323(23): p. 1573-80.17. Psychogios, N., et al., The human serum metabolome. PLoS One, 2011. 6(2): p. e16957.18. Thabane, L., et al., A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol, 2010. 10(1): p. 1.19. Hertzog, M.A., Considerations in determining sample size for pilot studies. Res Nurs Health, 2008. 31(2): p. 180-91.20. Nagata, N., et al., Effects of bowel preparation on the human gut microbiome and metabolome. Scientific Reports, 2019. 9(1): p. 4042.21. Drago, L., et al., Persisting changes of intestinal microbiota after bowel lavage and colonoscopy. Eur J Gastroenterol Hepatol, 2016. 28(5): p. 532-7.22. Inserra, A., et al., The Microbiota-Inflammasome Hypothesis of Major Depression. BioEssays, 2018. 40(9): p. 1800027.23. Derakhshani, H., Bernier, S. P., Marko, V. A. & Surette, M. G. Completion of draft bacterial genomes by long-read sequencing of synthetic genomic pools. BMC Genomics 21, 519, doi:10.1186 / s12864-020-06910-6 (2020).24. Lau, J. T. et al. Capturing the diversity of the human gut microbiota through culture-enriched molecular profiling. Genome Med 8, 72, doi:10.1186 / s13073-016-0327-7 (2016),25. Shifu Chen, Yanqing Zhou, Yaru Chen, Jia Gu, fastp: an ultra-fast all-in-one FASTQ preprocessor, Bioinformatics, Volume 34, Issue 17, September 2018, Pages i884–i890, https: / / doi.org / 10.1093 / bioinformatics / bty560,26 Francesco Beghini1 ,Lauren J McIver2 ,Aitor Blanco-Mìguez1 ,Leonard Dubois1 ,Francesco Asnicar1 ,Sagun Maharjan2,3 ,Ana Mailyan2,3 ,Andrew Maltez Thomas1 ,Paolo Manghi1 ,Mireia Valles-Colomer1 ,George Weingart2,3 ,Yancong Zhang2,3 ,Moreno Zolfo1 ,Curtis Huttenhower2,3 ,Eric A Franzosa2,3 ,Nicola Segata1,4 Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3 eLife 2021;10:e6508827. lanco-Míguez, A., Beghini, F., Cumbo, F. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat Biotechnol 41, 1633–1644 (2023). https: / / doi.org / 10.1038 / s41587-023-01688-w,28. Nurk S, Meleshko D, Korobeynikov A, Pevzner PA. metaSPAdes: a new versatile metagenomic assembler. Genome Res. 2017 May;27(5):824-834. doi: 10.1101 / gr.213959.116. Epub 2017 Mar 15. PMID: 28298430; PMCID: PMC5411777,29. Kang DD, Li F, Kirton E, Thomas A, Egan R, An H, Wang Z. MetaBAT 2: an adaptive binning algorithm for robust and efficient genome reconstruction from metagenome assemblies. PeerJ. 2019 Jul 26;7:e7359. doi: 10.7717 / peerj.7359. PMID: 31388474; PMCID: PMC6662567.30. Schwengers O, Jelonek L, Dieckmann MA, Beyvers S, Blom J, Goesmann A. Bakta: rapid and standardized annotation of bacterial genomes via alignment-free sequence identification. Microb Genom. 2021 Nov;7(11):000685. doi: 10.1099 / mgen.0.000685. PMID: 34739369; PMCID: PMC8743544.31. Parks, D.H., et al. (2021). GTDB: an ongoing census of bacterial and archaeal diversity through a phylogenetically consistent, rank normalized and complete genome-based taxonomy. Nucleic Acids Research, 50: D785–D794.32. Rinke, C, et al. (2021). A standardized archaeal taxonomy for the Genome Taxonomy Database. Nature Microbiology, 6: 946–959.33. Chaumeil PA, et al. 2022. GTDB-Tk v2: memory friendly classification with the Genome Taxonomy Database. Bioinformatics, btac672.34. Chaumeil PA, et al. 2019. GTDB-Tk: A toolkit to classify genomes with the Genome Taxonomy Database. Bioinformatics, btz848.35. Shaw J. and Yu Y.W. 2023. Fast and robust metagenomic sequence comparison through sparse chaining with skani. Nature Methods, 20, pages1661–1665 (2023).  Although the invention has been described with reference to certain specific embodiments, various modifications thereof will be apparent to those skilled in the art without departing from the spirit and scope of the invention. All such modifications as would be apparent to one skilled in the art are intended to be included within the scope of the following claims. 

Claims

1. A method of treating bipolar disorder or a symptom associated with bipolar disorder in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides.

2. The method of claim 1, wherein the community of fecal bacteria comprise Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides salyersiea, Bifidobacterium bifidum,Butyricimonasparavirosa,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis.

3. The method of claim 2, wherein the community of fecal bacteria further comprises Alistipes communis.

4. The method of claim 2 or 3, wherein the community of fecal bacteria further comprises Otooleafessa.

5. The method of any one of claim 2 to 4, wherein the community of fecal bacteria further comprises one or more of Bacteroides caccae, Bifidobacterium pseudocatenulatum,Butyricimonasvirosa,Bariatricus comes,and Parabaceroidesmerdae.

6. The method of claim 1, wherein the community of fecal bacteria comprise Agathobacterrectalis, Alistipes communis,Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa, Bariatricus comes,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Faecalibacteriumprausnitzii, Odoribactersplanchnicus,Parabaceroidesmerdae, Parabacteroides distasonis, and Sutterellamerdavium (S. parvirubra).

7. The method of claim 1, wherein the community of fecal bacteria consist of Agathobacterrectalis, Alistipes communis,Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa, Bariatricus comes,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Faecalibacteriumprausnitzii, Odoribactersplanchnicus,Parabaceroidesmerdae, Parabacteroides distasonis, and Sutterellamerdavium (S. parvirubra).

8. The method of claim 1, wherein the community of fecal bacteria consist of Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa, Bariatricus comes,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus, Odoribactersplanchnicus,Parabaceroidesmerdae, and Parabacteroides distasonis.

9. The method of claim 1, wherein the community of fecal bacteria consist of Agathobacterrectalis, Alistipes communis,Anaerotignumfaecicola, Bacteroides salyersiea,Bifidobacterium bifidum,Butyricimonasparavirosa,Otooleafessa, Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis.

10. The method of claim 1, wherein the community of fecal bacteria consist of Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides salyersiea, Bifidobacterium bifidum,Butyricimonasparavirosa,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis,11. The method of claim 1, wherein the community of fecal bacteria consists of Agathobacterrectalis, Alistipes communis, Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiae, Bariatricus comes, Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum, Butyricimonasparavirosa, Butyricimonasvirosa, Dysosmobacterwelbionis, Eubacterium_Iramulus, Faecalibacteriumprausnitzii, Odoribactersplanchnicus, Otooleafessa, Parabacteroides distasonis, and Parabacteroides merdae.

12. The method of any one of claims 1 to 11, wherein the composition is for oral administration.

13. The method of claim 12, wherein the composition is formulated as a geltab, pill, microcapsule, capsule, or tablet.

14. The method of any one of claims 1, wherein the method further comprises pretreating the subject with an antibiotic.

15. The method of any one of claims 1 to 14, wherein the method further comprises a pretreatment bowel cleansing.

16. The method of any one of claims 1 to 15, comprising a single administration of the composition.

17. The method of any one of claims 1 to 15, comprising multiple administrations of the composition.

18. The method of any one of claims 1 to 17, wherein the method decreases MADRS score.

19. The method of any one of claims 1 to 18, wherein the method increases World Health Organization Quality of Life score.

20. The method of any one of claims 1 to 19, wherein the method decreases Sheehan Disability Scale score.

21. The method of any one of claims 1 to 20, wherein the method decreases State-Trait Anxiety Inventory score.

22. A composition comprising a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides.

23. The composition of claim 22, wherein the community of fecal bacteria comprise Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides salyersiea, Bifidobacterium bifidum,Butyricimonasparavirosa,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis.

24. The composition of claim 23, wherein the community of fecal bacteria further comprises Alistipes communis.

25. The composition of claim 22 or 23, wherein the community of fecal bacteria further comprises Otooleafessa.

26. The composition of any one of claims 22 to 25, wherein the community of fecal bacteria further comprises one or more of Bacteroides caccae, Bifidobacterium pseudocatenulatum,Butyricimonasvirosa,Bariatricus comes,and Parabaceroidesmerdae.

27. The composition of claim 22, wherein the community of fecal bacteria comprise Agathobacterrectalis, Alistipes communis,Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa, Bariatricus comes,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Faecalibacteriumprausnitzii, Odoribactersplanchnicus,Parabaceroidesmerdae, Parabacteroides distasonis, and Sutterellamerdavium (S. parvirubra).

28. The composition of claim 22, wherein the community of fecal bacteria consist of Agathobacterrectalis, Alistipes communis,Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa, Bariatricus comes,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Faecalibacteriumprausnitzii, Odoribactersplanchnicus,Parabaceroidesmerdae, Parabacteroides distasonis, and Sutterellamerdavium (S. parvirubra).

29. The composition of claim 22, wherein the community of fecal bacteria consist of Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiea,Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum,Butyricimonasparavirosa,Butyricimonasvirosa,Otooleafessa, Bariatricus comes,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus, Odoribactersplanchnicus,Parabaceroidesmerdae, and Parabacteroides distasonis.

30. The composition of claim 22, wherein the community of fecal bacteria consists of Agathobacterrectalis, Alistipes communis,Anaerotignumfaecicola, Bacteroides salyersiea,Bifidobacterium bifidum,Butyricimonasparavirosa,Otooleafessa, Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis.

31. The composition of claim 22, wherein the community of fecal bacteria consists of Agathobacterrectalis, Anaerotignumfaecicola, Bacteroides salyersiea, Bifidobacterium bifidum,Butyricimonasparavirosa,Dialistersuccinatiphilus, Dysosmobacterwelbionas, Eubacterium ramulus,Odoribactersplanchnicus,and Parabacteroides distasonis,32. The composition of claim 22, wherein the community of fecal bacteria consists of Agathobacterrectalis, Alistipes communis, Alistipesputredinis, Anaerotignumfaecicola, Bacteroides caccae, Bacteroides salyersiae, Bariatricus comes, Bifidobacterium bifidum, Bifidobacterium pseudocatenulatum, Butyricimonasparavirosa, Butyricimonasvirosa, Dysosmobacterwelbionis, Eubacterium_Iramulus, Faecalibacteriumprausnitzii, Odoribactersplanchnicus, Otooleafessa, Parabacteroides distasonis, and Parabacteroides merdae.

33. The composition of any one of claims 22 to 32 wherein the composition is for oral administration.

34. The composition of claim 33, wherein the composition is formulated as a geltab, pill, microcapsule, capsule, or tablet.

35. The composition of any one of claims 22 to 34 for use in a method of treating bipolar disorder or a symptom associated with bipolar disorder in a subject.

36. Use of the composition of any one of claims 22 to 34 to treat bipolar disorder or a symptom associated with bipolar disorder in a subject.

37. A method of treating the depressive phase of bipolar disorder in a subject, the method comprising administering to the subject a composition comprising a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides.  

Images